- en: <!--yml
  id: totrans-0
  prefs: []
  type: TYPE_NORMAL
  zh: <!--yml
- en: 'category: 未分类'
  id: totrans-1
  prefs: []
  type: TYPE_NORMAL
  zh: 类别：未分类
- en: 'date: 2024-09-06 19:38:45'
  id: totrans-2
  prefs: []
  type: TYPE_NORMAL
  zh: 日期：2024-09-06 19:38:45
- en: -->
  id: totrans-3
  prefs: []
  type: TYPE_NORMAL
  zh: -->
- en: '[2306.11768] Geometric Deep Learning for Structure-Based Drug Design: A Survey'
  id: totrans-4
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: '[2306.11768] 结构基础药物设计的几何深度学习：一项综述'
- en: 来源：[https://ar5iv.labs.arxiv.org/html/2306.11768](https://ar5iv.labs.arxiv.org/html/2306.11768)
  id: totrans-5
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
  zh: 来源：[https://ar5iv.labs.arxiv.org/html/2306.11768](https://ar5iv.labs.arxiv.org/html/2306.11768)
- en: 'Geometric Deep Learning for Structure-Based Drug Design: A Survey'
  id: totrans-6
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 结构基础药物设计的几何深度学习：一项综述
- en: 'Zaixi Zhang, Jiaxian Yan, Qi Liu, Enhong Chen, and Marinka Zitnik Zaixi Zhang,
    Jiaxian Yan, Qi Liu, and Enhong Chen are with the Anhui Province Key Laboratory
    of Big Data Analysis and Application (BDAA), School of Computer Science and Technology,
    University of Science and Technology of China, Hefei, Anhui 230027, China, and
    State Key Laboratory of Cognitive Intelligence, Hefei, Anhui, 230088, China. E-mail:
    $\{$zaixi, jiaxianyan$\}$@mail.ustc.edu.cn, $\{$qiliuql, cheneh$\}$@ustc.edu.cn
    Marinka Zitnik is with the Department of Biomedical Informatics, Harvard Medical
    School; Kempner Institute for the Study of Natural and Artificial Intelligence,
    Harvard University; Harvard Data Science Initiative; and Broad Institute of MIT
    and Harvard. E-mail: marinka@hms.harvard.edu. Correspondence to Qi Liu and Marinka
    Zitnik. Manuscript received xx xxx. 201x; accepted xx xxx. 201x. Date of Publication
    xx xxx. 201x; date of current version xx xxx. 201x. This research was partially
    supported by a grant from the National Natural Science Foundation of China (Grant
    No. 61922073).'
  id: totrans-7
  prefs: []
  type: TYPE_NORMAL
  zh: 'Zaixi Zhang、Jiaxian Yan、Qi Liu、Enhong Chen 和 Marinka Zitnik Zaixi Zhang、Jiaxian
    Yan、Qi Liu 和 Enhong Chen 就职于中国科学技术大学计算机科学与技术学院大数据分析与应用安徽省重点实验室（BDAA），中国安徽合肥 230027，国家认知智能重点实验室，中国安徽合肥
    230088。电子邮件：$\{$zaixi, jiaxianyan$\}$@mail.ustc.edu.cn，$\{$qiliuql, cheneh$\}$@ustc.edu.cn。Marinka
    Zitnik 就职于哈佛医学院生物医学信息学系；哈佛大学自然与人工智能研究中心；哈佛数据科学计划；以及麻省理工学院与哈佛大学布罗德研究所。电子邮件：marinka@hms.harvard.edu。通讯联系人：Qi
    Liu 和 Marinka Zitnik。手稿收到日期：xx xxx. 201x；接受日期：xx xxx. 201x。出版日期：xx xxx. 201x；当前版本日期：xx
    xxx. 201x。本研究部分由中国国家自然科学基金资助（资助号 61922073）。 '
- en: Abstract
  id: totrans-8
  prefs:
  - PREF_H6
  type: TYPE_NORMAL
  zh: 摘要
- en: 'Structure-based drug design (SBDD) utilizes the three-dimensional geometry
    of proteins to identify potential drug candidates. Traditional methods, grounded
    in physicochemical modeling and informed by domain expertise, are resource-intensive.
    Recent developments in geometric deep learning, focusing on the integration and
    processing of 3D geometric data, coupled with the availability of accurate protein
    3D structure predictions from tools like AlphaFold, have greatly advanced the
    field of structure-based drug design. This paper systematically reviews the current
    state of geometric deep learning in SBDD. We first outline foundational tasks
    in SBDD, detail prevalent 3D protein representations, and highlight representative
    predictive and generative models. We then offer in-depth reviews of each key task,
    including binding site prediction, binding pose generation, *de novo* molecule
    generation, linker design, and binding affinity prediction. We provide formal
    problem definitions and outline each task’s representative methods, datasets,
    evaluation metrics, and performance benchmarks. Finally, we summarize the current
    challenges and future opportunities: current challenges in SBDD include oversimplified
    problem formulations, inadequate out-of-distribution generalization, a lack of
    reliable evaluation metrics and large-scale benchmarks, and the need for experimental
    verification and enhanced model understanding; opportunities include leveraging
    multimodal datasets, integrating domain knowledge, building comprehensive benchmarks,
    designing criteria based on clinical endpoints, and developing foundation models
    that broaden the range of design tasks. We also curate [https://github.com/zaixizhang/Awesome-SBDD](https://github.com/zaixizhang/Awesome-SBDD),
    reflecting ongoing contributions and new datasets in SBDD.'
  id: totrans-9
  prefs: []
  type: TYPE_NORMAL
  zh: 基于结构的药物设计（SBDD）利用蛋白质的三维几何信息来识别潜在的药物候选物。传统方法基于物理化学建模并依赖领域专家知识，资源消耗大。近期在几何深度学习方面的进展，专注于三维几何数据的整合和处理，加上如AlphaFold等工具提供的准确蛋白质三维结构预测，极大推动了基于结构的药物设计领域的发展。本文系统回顾了几何深度学习在SBDD中的现状。我们首先概述了SBDD中的基础任务，详细介绍了常见的三维蛋白质表示方法，并突出了具有代表性的预测和生成模型。接着，我们对每个关键任务进行了深入评审，包括结合位点预测、结合姿势生成、*de
    novo*分子生成、连接子设计和结合亲和力预测。我们提供了正式的问题定义，并概述了每个任务的代表性方法、数据集、评估指标和性能基准。最后，我们总结了当前的挑战和未来的机遇：SBDD中的当前挑战包括问题表述过于简化、分布外泛化不足、缺乏可靠的评估指标和大规模基准测试，以及需要实验验证和增强模型理解；机遇包括利用多模态数据集、整合领域知识、建立全面的基准、设计基于临床终点的标准，以及开发扩展设计任务范围的基础模型。我们还整理了[https://github.com/zaixizhang/Awesome-SBDD](https://github.com/zaixizhang/Awesome-SBDD)，以反映SBDD领域的持续贡献和新数据集。
- en: 'Index Terms:'
  id: totrans-10
  prefs:
  - PREF_H6
  type: TYPE_NORMAL
  zh: 索引术语：
- en: Geometric Deep Learning, Generative Models, Molecular Design, Structure-based
    Drug Design, Therapeutic Science
  id: totrans-11
  prefs: []
  type: TYPE_NORMAL
  zh: 几何深度学习、生成模型、分子设计、基于结构的药物设计、治疗科学
- en: 1 Introduction
  id: totrans-12
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 1 引言
- en: Structure-based drug design (SBDD) [[1](#bib.bib1), [2](#bib.bib2), [3](#bib.bib3)]
    is becoming an essential tool for designing and optimizing drug candidates by
    effectively leveraging the three-dimensional geometric information of target proteins.
    Traditionally, the 3D structures of the target protein are obtained with techniques
    like X-ray crystallography [[4](#bib.bib4)], nuclear magnetic resonance (NMR)
    spectroscopy [[5](#bib.bib5)], or cryo-electron microscopy (cryo-EM) [[6](#bib.bib6)].
    Recently, the progress on high-accurate protein structure prediction such as AlphaFold
    [[7](#bib.bib7)] and ESMFold [[8](#bib.bib8)] further boosts the availability
    of structural data and lays the foundation for its broad applications. SBDD has
    emerged as an instrumental approach in the development of new kinds of therapies.
    Several drugs available in the market today owe their genesis to SBDD. For instance,
    HIV-1 protease inhibitors were identified using this approach [[9](#bib.bib9)].
    Similarly, raltitrexed, a thymidylate synthase inhibitor [[10](#bib.bib10)], and
    the antibiotic norfloxacin [[11](#bib.bib11)] are other exemplars of successful
    SBDD applications. Nevertheless, conventional SBDD methodologies, which are grounded
    in physical modeling, the application of hand-engineered scoring functions, and
    exhaustive search across vast biochemical space, present substantial challenges.
    In response to these limitations, there has been a burgeoning interest in geometric
    deep learning [[12](#bib.bib12)] to accelerate and refine SBDD.
  id: totrans-13
  prefs: []
  type: TYPE_NORMAL
  zh: 基于结构的药物设计（SBDD）[[1](#bib.bib1), [2](#bib.bib2), [3](#bib.bib3)] 正成为设计和优化药物候选物的关键工具，通过有效利用靶蛋白的三维几何信息。传统上，靶蛋白的3D结构是通过X射线晶体学[[4](#bib.bib4)]、核磁共振（NMR）光谱[[5](#bib.bib5)]或冷冻电子显微镜（cryo-EM）[[6](#bib.bib6)]等技术获得的。近期，AlphaFold
    [[7](#bib.bib7)] 和ESMFold [[8](#bib.bib8)] 等高精度蛋白质结构预测的进展进一步推动了结构数据的可用性，为其广泛应用奠定了基础。SBDD
    已成为开发新型疗法的重要方法。市场上许多药物的诞生都归功于SBDD。例如，HIV-1蛋白酶抑制剂就是通过这种方法识别的[[9](#bib.bib9)]。类似地，ralitrexed（一个胸苷酸合成酶抑制剂）[[10](#bib.bib10]]和抗生素诺氟沙星[[11](#bib.bib11)]也是成功的SBDD应用实例。然而，基于物理建模、手工设计的评分函数以及在广阔生化空间中进行的穷尽搜索的传统SBDD方法存在显著挑战。为了应对这些限制，对几何深度学习[[12](#bib.bib12)]的兴趣日益增长，以加速和完善SBDD。
- en: 'Geometric deep learning (GDL) [[12](#bib.bib12), [13](#bib.bib13)] refers to
    neural network architectures designed to capture and encode 3D geometric data.
    Unlike traditional methods that rely on hand-crafted feature engineering, GDL
    can autonomously extract salient 3D structural features. Additionally, certain
    GDL techniques, such as TFN [[14](#bib.bib14)], EGNN [[15](#bib.bib15)], and GMN
    [[16](#bib.bib16)] that integrate symmetry properties directly into the network
    design, which serves as an effective inductive bias and potentially leads to enhanced
    performance. In the realm of 3D Euclidean space, ”symmetry” encompasses transformations
    like rotations, translations, and reflections. It’s imperative to understand how
    protein and molecular properties vary under these transformations (Section [2.2](#S2.SS2
    "2.2 Symmetries ‣ 2 Preliminaries ‣ Geometric Deep Learning for Structure-Based
    Drug Design: A Survey")). With the rapid development of geometric deep learning,
    a series of SBDD tasks including binding site prediction [[17](#bib.bib17)], binding
    pose generation [[18](#bib.bib18)], *de novo* ligand generation [[19](#bib.bib19)],
    linker design [[20](#bib.bib20)], binding affinity prediction [[21](#bib.bib21)],
    and more [[22](#bib.bib22), [23](#bib.bib23)] have benefited. Geometric deep learning
    for SBDD has advanced rapidly, drawing more attention from broad communities.
    Therefore, writing a survey summarizing the recent progress and envisioning the
    future directions is necessary.'
  id: totrans-14
  prefs: []
  type: TYPE_NORMAL
  zh: '几何深度学习（GDL）[[12](#bib.bib12), [13](#bib.bib13)] 指的是旨在捕捉和编码三维几何数据的神经网络架构。与依赖于手工特征工程的传统方法不同，GDL
    可以自动提取显著的三维结构特征。此外，某些 GDL 技术，如 TFN [[14](#bib.bib14)], EGNN [[15](#bib.bib15)]
    和 GMN [[16](#bib.bib16)]，将对称性特性直接集成到网络设计中，这作为一种有效的归纳偏置，可能会带来性能的提升。在三维欧几里得空间中，“对称性”涵盖了诸如旋转、平移和反射等变换。理解蛋白质和分子特性在这些变换下的变化至关重要（第[2.2](#S2.SS2
    "2.2 Symmetries ‣ 2 Preliminaries ‣ Geometric Deep Learning for Structure-Based
    Drug Design: A Survey")节）。随着几何深度学习的快速发展，一系列结构基础药物设计（SBDD）任务，包括结合位点预测 [[17](#bib.bib17)],
    结合姿势生成 [[18](#bib.bib18)], *de novo* 配体生成 [[19](#bib.bib19)], 连接体设计 [[20](#bib.bib20)],
    结合亲和力预测 [[21](#bib.bib21)] 等 [[22](#bib.bib22), [23](#bib.bib23)] 都受益匪浅。SBDD 的几何深度学习已经快速进展，吸引了广泛社区的更多关注。因此，有必要编写一份综述，总结近期进展并展望未来方向。'
- en: 'Geometric deep learning for SBDD has two main categories of tasks: predictive
    [[24](#bib.bib24)] and generative tasks [[2](#bib.bib2)]. Predictive tasks are
    concerned with predicting outcomes based on given input protein/molecule data
    (e.g., binding affinity prediction), demanding high accuracy and reliability due
    to their applications in drug discovery. On the other hand, generative tasks are
    centered around the design of new drug molecule data, such as *de novo* ligand
    generation. In this paper, we discuss both tasks with an emphasis on exploring
    the potential and capabilities of the new emerging generative models for SBDD.'
  id: totrans-15
  prefs: []
  type: TYPE_NORMAL
  zh: SBDD 的几何深度学习主要分为两类任务：预测性任务 [[24](#bib.bib24)] 和生成性任务 [[2](#bib.bib2)]。预测性任务关注于根据给定的蛋白质/分子数据预测结果（例如，结合亲和力预测），由于其在药物发现中的应用，需要高精度和可靠性。另一方面，生成性任务则集中于新药物分子数据的设计，例如
    *de novo* 配体生成。在本文中，我们讨论了这两类任务，重点探索新兴生成模型在 SBDD 中的潜力和能力。
- en: 1.1 Distinctive Contributions of the Survey
  id: totrans-16
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 1.1 调查的独特贡献
- en: 'Artificial intelligence is increasingly used to augment all stages of scientific
    research [[25](#bib.bib25), [26](#bib.bib26)], including designing and developing
    new therapeutics. We here focus on SBDD, a critical element of therapeutic science
    underscored by a plethora of surveys detailing its advancements [[27](#bib.bib27),
    [28](#bib.bib28), [29](#bib.bib29), [30](#bib.bib30), [10](#bib.bib10), [31](#bib.bib31),
    [32](#bib.bib32)]. However, a common thread among these surveys is their vantage
    point rooted firmly in biochemistry, which may only partially cater to the machine
    learning research community. Marking a departure from these extant surveys, our
    review endeavors to bridge this gap. We overview geometric deep-learning methods
    explicitly tailored for SBDD, elucidated through the lens of machine learning
    and deep learning paradigms. A standout feature of our review is its meticulous
    organization, deeply anchored in SBDD task-specific frameworks. More explicitly,
    we have curated our sections based on distinct SBDD task categories. We have framed
    each task within a machine learning challenge, ensuring a seamless marriage between
    domain-specific intricacies and computational methodologies. This entails clearly
    presenting algorithms, benchmark datasets, evaluation metrics, and model performances
    for each task. Through this approach, our aim is two-fold: firstly, to enable
    researchers from the machine learning and deep learning fraternities to gain insights
    into SBDD tasks without being burdened by intricate domain-specific prerequisites,
    and secondly, to lay the groundwork that could motivate the development of more
    sophisticated geometric deep learning algorithms optimally suited for structure-based
    drug design.'
  id: totrans-17
  prefs: []
  type: TYPE_NORMAL
  zh: 人工智能在科学研究的所有阶段中越来越多地被用来增强，包括设计和开发新疗法。在这里，我们专注于SBDD，这是治疗科学中的关键元素，通过大量调查突出了其进展[[27](#bib.bib27),
    [28](#bib.bib28), [29](#bib.bib29), [30](#bib.bib30), [10](#bib.bib10), [31](#bib.bib31),
    [32](#bib.bib32)]。然而，这些调查的共同点在于它们的视角根植于生物化学，这可能仅部分满足机器学习研究社区的需求。与这些现有调查不同，我们的综述努力弥合这一差距。我们概述了明确为SBDD量身定制的几何深度学习方法，通过机器学习和深度学习范式进行阐述。我们综述的一个突出特点是其精心组织，深深植根于SBDD任务特定的框架中。更具体来说，我们根据不同的SBDD任务类别组织了章节。我们将每个任务框定在一个机器学习挑战中，确保领域特定的复杂性与计算方法的无缝结合。这包括清晰地展示每个任务的算法、基准数据集、评估指标和模型性能。通过这种方法，我们的目标有两个：首先，让机器学习和深度学习领域的研究人员在不被复杂领域特定前提条件困扰的情况下深入了解SBDD任务；其次，为开发更复杂的几何深度学习算法奠定基础，以便更好地适应基于结构的药物设计。
- en: 1.2 Organization of the Survey
  id: totrans-18
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 1.2 调查组织结构
- en: 'In this survey, we delve into the interdisciplinary domain bridging geometric
    deep learning and SBDD. To ensure comprehensive coverage, we curated papers from
    machine learning conferences and journals, including NeurIPS, ICLR, ICML, KDD,
    TKDE, and TPAMI. Concurrently, we retrieved publications from natural science
    journals. Guided by SBDD tasks highlighted in this survey, our search strategy
    was anchored by key terms, including ”structure-based drug design,” ”protein-ligand
    docking,” ”protein-ligand affinity prediction,” ”linker design,” and ”protein
    binding site prediction,” among others, ensuring we amassed a broad spectrum of
    relevant studies. Given that the majority of FDA-approved drugs fall into the
    category of small molecules [[33](#bib.bib33)], our focus in this survey primarily
    centers on papers and methodologies that discuss these small molecules. Following
    our exhaustive search, we meticulously categorized the gathered papers, aligning
    them with their respective tasks and methodologies. Table [I](#S2.T1 "Table I
    ‣ 2.5 Other Methods ‣ 2 Preliminaries ‣ Geometric Deep Learning for Structure-Based
    Drug Design: A Survey") provides a detailed breakdown.'
  id: totrans-19
  prefs: []
  type: TYPE_NORMAL
  zh: '在本次调查中，我们深入探讨了将几何深度学习与SBDD（基于结构的药物设计）结合的跨学科领域。为了确保全面覆盖，我们从机器学习会议和期刊中筛选了论文，包括NeurIPS、ICLR、ICML、KDD、TKDE和TPAMI。同时，我们还检索了自然科学期刊的出版物。根据本次调查中强调的SBDD任务，我们的搜索策略围绕关键术语展开，包括“基于结构的药物设计”、“蛋白质-配体对接”、“蛋白质-配体亲和力预测”、“连接体设计”和“蛋白质结合位点预测”等，确保我们收集了广泛相关的研究。鉴于大多数FDA批准的药物属于小分子类别[[33](#bib.bib33)]，我们在本次调查中主要集中在讨论这些小分子的论文和方法论上。在我们的详尽搜索之后，我们仔细分类了收集到的论文，将它们与各自的任务和方法论对齐。表格[I](#S2.T1
    "Table I ‣ 2.5 Other Methods ‣ 2 Preliminaries ‣ Geometric Deep Learning for Structure-Based
    Drug Design: A Survey")提供了详细的分解。'
- en: 'In Section [2.1](#S2.SS1 "2.1 Protein and Ligand Representations ‣ 2 Preliminaries
    ‣ Geometric Deep Learning for Structure-Based Drug Design: A Survey"), we introduce
    3D representations of proteins, the SBDD tasks reviewed in this paper, and popular
    predictive and generative models. The following sections are organized based on
    the logical order of SBDD tasks as shown in Figure [1](#S2.F1 "Figure 1 ‣ 2.1
    Protein and Ligand Representations ‣ 2 Preliminaries ‣ Geometric Deep Learning
    for Structure-Based Drug Design: A Survey"): as for the target protein structure,
    we first need to identify the binding site; then we can conduct binding pose generation,
    *de novo* molecule generation, and linker design; with the protein-ligand complex
    structure, we can use binding affinity prediction and other filtering criteria
    to filter drug candidates. Admittedly, the order and the category of SBDD tasks
    are not fixed since SBDD is an iterative process that proceeds through multiple
    cycles, leading optimized drug candidates to clinical trials [[34](#bib.bib34)].
    Some methods may also be capable of accomplishing multiple tasks. For example,
    EquiBind [[35](#bib.bib35)] can predict the binding pose of ligands without prior
    knowledge of the binding site, i.e., blinding docking, to ease readers’ understanding.
    Finally, Section [4](#S4 "4 Challenges and Opportunities ‣ Geometric Deep Learning
    for Structure-Based Drug Design: A Survey") identifies the open challenges and
    opportunities, paving the way for the future of designing geometric deep learning
    methods for structure-based drug design.'
  id: totrans-20
  prefs: []
  type: TYPE_NORMAL
  zh: '在第[2.1节](#S2.SS1 "2.1 Protein and Ligand Representations ‣ 2 Preliminaries
    ‣ Geometric Deep Learning for Structure-Based Drug Design: A Survey")中，我们介绍了蛋白质的3D表示、本文回顾的SBDD任务以及流行的预测和生成模型。接下来的章节根据SBDD任务的逻辑顺序进行组织，如图[1](#S2.F1
    "Figure 1 ‣ 2.1 Protein and Ligand Representations ‣ 2 Preliminaries ‣ Geometric
    Deep Learning for Structure-Based Drug Design: A Survey")所示：对于目标蛋白质结构，我们首先需要识别结合位点；然后可以进行结合姿态生成、*de
    novo*分子生成和链接设计；有了蛋白质-配体复合物结构后，我们可以使用结合亲和力预测和其他筛选标准来筛选药物候选物。确实，SBDD任务的顺序和类别并不是固定的，因为SBDD是一个通过多个循环进行的迭代过程，最终将优化的药物候选物带入临床试验[[34](#bib.bib34)]。一些方法也可能能够完成多个任务。例如，EquiBind
    [[35](#bib.bib35)]可以在没有结合位点先验知识的情况下预测配体的结合姿态，即盲法对接，以便读者理解。最后，第[4节](#S4 "4 Challenges
    and Opportunities ‣ Geometric Deep Learning for Structure-Based Drug Design: A
    Survey")确定了开放的挑战和机遇，为未来设计几何深度学习方法用于结构基础药物设计铺平道路。'
- en: 2 Preliminaries
  id: totrans-21
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 2 初步介绍
- en: 'Figure [1](#S2.F1 "Figure 1 ‣ 2.1 Protein and Ligand Representations ‣ 2 Preliminaries
    ‣ Geometric Deep Learning for Structure-Based Drug Design: A Survey") provides
    an overview of the SBDD tasks encompassing binding site prediction, binding pose
    generation, *de novo* molecule generation, linker design, and binding affinity
    prediction. Binding site and affinity prediction are typically formulated as predictive
    tasks, whereas binding pose generation, *de novo* molecule generation, and linker
    design are addressed as generative tasks.'
  id: totrans-22
  prefs: []
  type: TYPE_NORMAL
  zh: '图[1](#S2.F1 "Figure 1 ‣ 2.1 Protein and Ligand Representations ‣ 2 Preliminaries
    ‣ Geometric Deep Learning for Structure-Based Drug Design: A Survey")提供了SBDD任务的概述，包括结合位点预测、结合姿态生成、*de
    novo*分子生成、链接设计和结合亲和力预测。结合位点和亲和力预测通常被表述为预测任务，而结合姿态生成、*de novo*分子生成和链接设计则被视为生成任务。'
- en: 2.1 Protein and Ligand Representations
  id: totrans-23
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 2.1 蛋白质和配体的表示
- en: 'Protein and ligand molecule representations depend on the SBDD tasks and specific
    geometric deep learning methods. In SBDD, proteins are usually characterized by
    3D representations that capture critical 3D structural information in the form
    of grids, surfaces, and spatial graphs (Figure [2](#S2.F2 "Figure 2 ‣ 2.1 Protein
    and Ligand Representations ‣ 2 Preliminaries ‣ Geometric Deep Learning for Structure-Based
    Drug Design: A Survey")):'
  id: totrans-24
  prefs: []
  type: TYPE_NORMAL
  zh: '蛋白质和配体分子的表示依赖于SBDD任务和特定的几何深度学习方法。在SBDD中，蛋白质通常通过3D表示来表征，这些表示以网格、表面和空间图的形式捕捉关键的3D结构信息（见图[2](#S2.F2
    "Figure 2 ‣ 2.1 Protein and Ligand Representations ‣ 2 Preliminaries ‣ Geometric
    Deep Learning for Structure-Based Drug Design: A Survey")）：'
- en: •
  id: totrans-25
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: '3D grids are Euclidean data structures comprised of uniformly spaced 3D elements,
    termed voxels. These grids have distinct geometric properties: each voxel has
    a consistent neighborhood structure, making it indistinguishable from other voxels
    in terms of structure, and the vertices maintain a fixed order determined by their
    spatial dimensions. Owing to the Euclidean nature of the 3D grid input, 3D CNNs
    are conventionally employed to encode such data and to handle subsequent tasks.'
  id: totrans-26
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 3D 网格是欧几里得数据结构，由均匀间隔的 3D 元素（称为体素）组成。这些网格具有独特的几何属性：每个体素具有一致的邻域结构，使其在结构上无法与其他体素区分，并且顶点保持由空间维度决定的固定顺序。由于
    3D 网格输入的欧几里得性质，通常采用 3D CNN 来编码此类数据并处理后续任务。
- en: •
  id: totrans-27
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: The 3D surface of a protein is the exterior layer of the protein’s atoms and
    is pivotal in protein-ligand interactions. Each point on this protein surface
    can be distinguished by its associated chemical (e.g., hydrophobic, electrostatic)
    and geometric (e.g., local shape, curvature) attributes. Protein surfaces can
    be represented as meshes, polygons that demarcate the surface’s contours, or point
    clouds, sets of nodes that specify the surface’s position at a particular resolution
    level.
  id: totrans-28
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 蛋白质的 3D 表面是蛋白质原子的外部层，在蛋白质-配体相互作用中至关重要。蛋白质表面上的每个点可以通过其相关的化学（例如，疏水性、电静力性）和几何（例如，局部形状、曲率）属性来区分。蛋白质表面可以表示为网格、标示表面轮廓的多边形，或点云、在特定分辨率下指定表面位置的节点集合。
- en: •
  id: totrans-29
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: 3D graphs are prevalently utilized to describe protein structural data, wherein
    atoms serve as nodes and covalent bonds as edges. Edges can also be formed by
    linking the k-nearest neighbors. Geometric GNNs [[15](#bib.bib15), [36](#bib.bib36)]
    are adept at processing protein 3D graphs.
  id: totrans-30
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 3D 图广泛用于描述蛋白质结构数据，其中原子作为节点，共价键作为边。边还可以通过连接 k 个最近邻来形成。几何 GNNs [[15](#bib.bib15),
    [36](#bib.bib36)] 擅长处理蛋白质 3D 图。
- en: 'As for the ligand molecules, their representations vary from 1D strings, e.g.,
    simplified molecular-input line-entry system (SMILES) [[37](#bib.bib37)] to 2D
    and 3D graphs [[38](#bib.bib38)] where nodes represent atoms and edges represent
    bonds (Figure [3](#S2.F3 "Figure 3 ‣ 2.2 Symmetries ‣ 2 Preliminaries ‣ Geometric
    Deep Learning for Structure-Based Drug Design: A Survey")).'
  id: totrans-31
  prefs: []
  type: TYPE_NORMAL
  zh: '至于配体分子，它们的表示形式从 1D 字符串（例如，简化分子输入线性输入系统（SMILES）[[37](#bib.bib37)]）到 2D 和 3D
    图 [[38](#bib.bib38)]，其中节点代表原子，边代表键（见图 [3](#S2.F3 "Figure 3 ‣ 2.2 Symmetries ‣
    2 Preliminaries ‣ Geometric Deep Learning for Structure-Based Drug Design: A Survey")）。'
- en: '![Refer to caption](img/7bb03609a9576d53ae93f77492b5cb47.png)'
  id: totrans-32
  prefs: []
  type: TYPE_IMG
  zh: '![参考说明](img/7bb03609a9576d53ae93f77492b5cb47.png)'
- en: 'Figure 1: Structure-based drug design tasks discussed in this survey: (a) binding
    site prediction identifies areas of the protein structure that can act as binding
    sites for ligands (Section [3.1](#S3.SS1 "3.1 Binding Site Prediction ‣ 3 Structure-based
    Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based Drug Design: A
    Survey")); (b) binding pose generation or protein-ligand docking focus on predicting
    the binding conformations of the protein-ligand complex (Section [3.2](#S3.SS2
    "3.2 Binding Pose Prediction ‣ 3 Structure-based Drug Design Tasks ‣ Geometric
    Deep Learning for Structure-Based Drug Design: A Survey")); (c) *de novo* ligand
    generation designs binding ligands from scratch with the structural information
    of the target protein (Section [3.3](#S3.SS3 "3.3 De Novo Ligand Generation ‣
    3 Structure-based Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based
    Drug Design: A Survey")); (d) linker design combines disconnected molecular fragments
    into a combined ligand molecule conditioned on the target protein (Section [3.4](#S3.SS4
    "3.4 Linker Design ‣ 3 Structure-based Drug Design Tasks ‣ Geometric Deep Learning
    for Structure-Based Drug Design: A Survey")); (e) binding affinity prediction
    predicts the affinity between a protein and a ligand given their binding structure
    (Section [3.5](#S3.SS5 "3.5 Binding Affinity Prediction ‣ 3 Structure-based Drug
    Design Tasks ‣ Geometric Deep Learning for Structure-Based Drug Design: A Survey")).'
  id: totrans-33
  prefs: []
  type: TYPE_NORMAL
  zh: '图 1：本调查讨论的基于结构的药物设计任务：（a）结合位点预测识别可以作为配体结合位点的蛋白质结构区域（第[3.1](#S3.SS1 "3.1 Binding
    Site Prediction ‣ 3 Structure-based Drug Design Tasks ‣ Geometric Deep Learning
    for Structure-Based Drug Design: A Survey")节）；（b）结合构象生成或蛋白质-配体对接关注预测蛋白质-配体复合体的结合构象（第[3.2](#S3.SS2
    "3.2 Binding Pose Prediction ‣ 3 Structure-based Drug Design Tasks ‣ Geometric
    Deep Learning for Structure-Based Drug Design: A Survey")节）；（c）*de novo* 配体生成从头设计结合配体，利用目标蛋白的结构信息（第[3.3](#S3.SS3
    "3.3 De Novo Ligand Generation ‣ 3 Structure-based Drug Design Tasks ‣ Geometric
    Deep Learning for Structure-Based Drug Design: A Survey")节）；（d）连接子设计将断开的分子片段结合成一个综合配体分子，条件是目标蛋白（第[3.4](#S3.SS4
    "3.4 Linker Design ‣ 3 Structure-based Drug Design Tasks ‣ Geometric Deep Learning
    for Structure-Based Drug Design: A Survey")节）；（e）结合亲和力预测在给定结合结构的情况下预测蛋白质和配体之间的亲和力（第[3.5](#S3.SS5
    "3.5 Binding Affinity Prediction ‣ 3 Structure-based Drug Design Tasks ‣ Geometric
    Deep Learning for Structure-Based Drug Design: A Survey")节）。'
- en: '![Refer to caption](img/c32c8f83661ff4f980da16c6c4d0f789.png)'
  id: totrans-34
  prefs: []
  type: TYPE_IMG
  zh: '![参见说明](img/c32c8f83661ff4f980da16c6c4d0f789.png)'
- en: (a) 3D grid
  id: totrans-35
  prefs: []
  type: TYPE_NORMAL
  zh: (a) 3D 网格
- en: '![Refer to caption](img/c81013bd2cbc28655631ef9e1cf63b23.png)'
  id: totrans-36
  prefs: []
  type: TYPE_IMG
  zh: '![参见说明](img/c81013bd2cbc28655631ef9e1cf63b23.png)'
- en: (b) 3D surface
  id: totrans-37
  prefs: []
  type: TYPE_NORMAL
  zh: (b) 3D 表面
- en: '![Refer to caption](img/62aabb8356612933b561cd7cc4c23d73.png)'
  id: totrans-38
  prefs: []
  type: TYPE_IMG
  zh: '![参见说明](img/62aabb8356612933b561cd7cc4c23d73.png)'
- en: (c) 3D graph
  id: totrans-39
  prefs: []
  type: TYPE_NORMAL
  zh: (c) 3D 图
- en: 'Figure 2: 3D representations of proteins used for geometric deep learning:
    (a) 3D grid, (b) 3D surface, and (c) 3D graph, illustrated for PDB ID 2avd.'
  id: totrans-40
  prefs: []
  type: TYPE_NORMAL
  zh: 图 2：用于几何深度学习的蛋白质的 3D 表示：（a）3D 网格，（b）3D 表面，以及（c）3D 图，图示为 PDB ID 2avd。
- en: 2.2 Symmetries
  id: totrans-41
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 2.2 对称性
- en: 'Incorporating the symmetry priors into neural network architectures as inductive
    bias is an effective strategy to build generalizable models [[39](#bib.bib39),
    [12](#bib.bib12)]. The main symmetry groups in protein-ligand systems include
    the Euclidean group E(3), the particular Euclidean group SE(3), and the permutation
    group [[12](#bib.bib12)]. Both E(3) and SE(3) include rotation and translation
    transformations in the 3D Euclidean space. E(3) further covers the reflection
    operation. These transformations are essential for geometric deep learning because
    the output should obey the underlying physics rules that predicted properties
    of proteins/ligands should not change under the transformation of coordinate systems
    and atom orders. SE(3) is applicable when a neural network aims to differentiate
    chiral systems [[40](#bib.bib40)], which are systems that are not superimposable
    on their mirror images, much like left and right human hands. In chemistry and
    biology, chiral molecules can exhibit unique properties, e.g., a drug might be
    therapeutic, while its mirror image might be harmful or inactive. Formally, let
    $\mathcal{T}$ denote the transformation, $f$ be the neural network, and ${\bm{x}}$
    be the input data. The output of the neural network $f({\bm{x}})$ can transform
    equivariantly or invariantly with respect to $\mathcal{T}$ if satisfy the following
    constraints:'
  id: totrans-42
  prefs: []
  type: TYPE_NORMAL
  zh: 将对称先验融入神经网络架构作为归纳偏差是构建可泛化模型的有效策略[[39](#bib.bib39), [12](#bib.bib12)]。蛋白质-配体系统中的主要对称群包括欧几里得群E(3)、特定的欧几里得群SE(3)以及置换群[[12](#bib.bib12)]。E(3)和SE(3)都包括3D欧几里得空间中的旋转和平移变换。E(3)还涵盖了反射操作。这些变换对于几何深度学习至关重要，因为输出应该遵循基础物理规则，预测的蛋白质/配体属性在坐标系统和原子顺序的变换下不应改变。当神经网络旨在区分手性系统时，SE(3)是适用的[[40](#bib.bib40)]，这些系统无法与其镜像重叠，就像左右手一样。在化学和生物学中，手性分子可以表现出独特的性质，例如，一种药物可能具有治疗效果，而其镜像可能是有害或无效的。正式地，设$\mathcal{T}$表示变换，$f$为神经网络，${\bm{x}}$为输入数据。如果满足以下约束，神经网络$f({\bm{x}})$的输出可以对$\mathcal{T}$进行等变或不变变换：
- en: •
  id: totrans-43
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: 'Equivariance: $f({\bm{x}})$ is equivariant to a transformation $\mathcal{T}$
    if the transformation of input ${\bm{x}}$ commutes with the transformation of
    $f({\bm{x}})$ via a transformation $\mathcal{T}^{\prime}$ of the same symmetry
    group, i.e, $f(\mathcal{T}({\bm{x}}))=\mathcal{T}^{\prime}f({\bm{x}})$. Such symmetry
    is important as the predicted vector outputs (e.g., forces, coordinates) should
    not depend on the choice of coordinate systems.'
  id: totrans-44
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 等变性：$f({\bm{x}})$对变换$\mathcal{T}$是等变的，如果输入${\bm{x}}$的变换与通过相同对称群的变换$\mathcal{T}^{\prime}$的$f({\bm{x}})$的变换是对易的，即$f(\mathcal{T}({\bm{x}}))=\mathcal{T}^{\prime}f({\bm{x}})$。这种对称性很重要，因为预测的向量输出（例如，力、坐标）不应依赖于坐标系统的选择。
- en: •
  id: totrans-45
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: 'Invariance: Invariance is a special case of equivariance where $f({\bm{x}})$
    is invariant to $\mathcal{T}$ if $\mathcal{T}^{\prime}$ is the identity transformation:
    $f(\mathcal{T}({\bm{x}}))=\mathcal{T}^{\prime}f({\bm{x}})=f({\bm{x}})$. Such symmetry
    prior is important as the predicted scalar properties of a certain molecule/protein
    (e.g., energies) should be the same under the transformation of coordinate systems.'
  id: totrans-46
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 不变性：不变性是等变性的特例，其中$f({\bm{x}})$对$\mathcal{T}$是不变的，如果$\mathcal{T}^{\prime}$是单位变换：$f(\mathcal{T}({\bm{x}}))=\mathcal{T}^{\prime}f({\bm{x}})=f({\bm{x}})$。这种对称先验很重要，因为某个分子/蛋白质的预测标量属性（例如，能量）在坐标系统变换下应保持不变。
- en: '![Refer to caption](img/bb73c6e4cef3025fb098fffe449ae8f6.png)'
  id: totrans-47
  prefs: []
  type: TYPE_IMG
  zh: '![参见说明](img/bb73c6e4cef3025fb098fffe449ae8f6.png)'
- en: (a) 2D molecular graph
  id: totrans-48
  prefs: []
  type: TYPE_NORMAL
  zh: (a) 2D 分子图
- en: '![Refer to caption](img/9d783e3a4aab136aab9b1e50dd755757.png)'
  id: totrans-49
  prefs: []
  type: TYPE_IMG
  zh: '![参见说明](img/9d783e3a4aab136aab9b1e50dd755757.png)'
- en: (b) 3D molecular graph
  id: totrans-50
  prefs: []
  type: TYPE_NORMAL
  zh: (b) 3D 分子图
- en: 'Figure 3: Representing molecules as (a) 2D graphs and (b) 3D graphs.'
  id: totrans-51
  prefs: []
  type: TYPE_NORMAL
  zh: '图3: 表示分子为 (a) 2D 图和 (b) 3D 图。'
- en: 2.3 Predictive Methods
  id: totrans-52
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 2.3 预测方法
- en: Next we summarize the main predictive methods for predictive tasks, i.e., binding
    site and affinity predictions. These methods are also widely used as the structure
    encoding backbones for generative models.
  id: totrans-53
  prefs: []
  type: TYPE_NORMAL
  zh: 接下来，我们总结了用于预测任务的主要预测方法，即结合位点和亲和力预测。这些方法也广泛用于生成模型的结构编码骨架。
- en: 2.3.1 Convolutional Neural Networks (CNNs)
  id: totrans-54
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 2.3.1 卷积神经网络 (CNNs)
- en: CNNs are widely used for image processing where the input elements, i.e., pixels,
    are arranged spatially. CNNs rely on the shared-weight architecture of convolution
    kernels or filters that slide along input features and provide translation-equivariant
    outputs. Convolution kernels and filters can vary with data structure. For example,
    for the 3D surface data, MaSIF [[17](#bib.bib17)] defines geodesic convolutional
    layers with the geodesic polar coordinates. For the 3D grid data, 3D CNNs are
    widely used [[41](#bib.bib41), [42](#bib.bib42)].
  id: totrans-55
  prefs: []
  type: TYPE_NORMAL
  zh: CNN 广泛用于图像处理，其中输入元素，即像素，按空间方式排列。CNN 依赖于共享权重的卷积核或滤波器架构，这些卷积核或滤波器沿输入特征滑动并提供平移等变的输出。卷积核和滤波器可以根据数据结构变化。例如，对于
    3D 表面数据，MaSIF [[17](#bib.bib17)] 定义了具有测地极坐标的测地卷积层。对于 3D 网格数据，广泛使用 3D CNN [[41](#bib.bib41),
    [42](#bib.bib42)]。
- en: 2.3.2 Graph Neural Networks (GNNs)
  id: totrans-56
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 2.3.2 图神经网络（GNNs）
- en: 'GNNs are widely used to model relational data. Most GNNs follow a message-passing
    paradigm. Let the $h_{i}$ be the node feature of the $i$-th node in the graph
    and $e_{ij}$ be the edge feature for the optional edge connecting node $i$ and
    $j$. GNNs iteratively conduct message computation and neighborhood aggregation
    operations for each node (or edge). Generally, we have:'
  id: totrans-57
  prefs: []
  type: TYPE_NORMAL
  zh: GNNs 广泛用于建模关系数据。大多数 GNNs 遵循消息传递范式。令 $h_{i}$ 为图中第 $i$ 个节点的节点特征，$e_{ij}$ 为连接节点
    $i$ 和 $j$ 的可选边的边特征。GNNs 迭代地对每个节点（或边）进行消息计算和邻域聚合操作。一般来说，我们有：
- en: '|  | $\displaystyle m_{ij}$ | $\displaystyle=\psi_{m}(h_{i},h_{j},e_{ij}),$
    |  | (1) |'
  id: totrans-58
  prefs: []
  type: TYPE_TB
  zh: '|  | $\displaystyle m_{ij}$ | $\displaystyle=\psi_{m}(h_{i},h_{j},e_{ij}),$
    |  | (1) |'
- en: '|  | $\displaystyle h_{i}^{\prime}$ | $\displaystyle=\psi_{h}(\{m_{ij}\}_{j\in\mathcal{N}(i)},h_{i}),$
    |  | (2) |'
  id: totrans-59
  prefs: []
  type: TYPE_TB
  zh: '|  | $\displaystyle h_{i}^{\prime}$ | $\displaystyle=\psi_{h}(\{m_{ij}\}_{j\in\mathcal{N}(i)},h_{i}),$
    |  | (2) |'
- en: where $\mathcal{N}(i)$ denote the set of neighbors of node $i$, $h_{i}^{\prime}$
    is the updated node feature, and $\psi_{m},\psi_{h}$ are learnable functions.
  id: totrans-60
  prefs: []
  type: TYPE_NORMAL
  zh: 其中 $\mathcal{N}(i)$ 表示节点 $i$ 的邻居集合，$h_{i}^{\prime}$ 是更新后的节点特征，而 $\psi_{m},\psi_{h}$
    是可学习的函数。
- en: 'For the 3D structural data, each node in the 3D graph has scalar features and
    contains 3D coordinates. Equivariant graph neural networks are proposed to incorporate
    geometric symmetry into model building [[43](#bib.bib43)]. Let $\bm{v}_{i}\in\mathbb{R}^{3}$
    denote the 3D coordinate, we have:'
  id: totrans-61
  prefs: []
  type: TYPE_NORMAL
  zh: 对于 3D 结构数据，3D 图中的每个节点都有标量特征并包含 3D 坐标。提出了等变图神经网络，将几何对称性融入模型构建中 [[43](#bib.bib43)]。令
    $\bm{v}_{i}\in\mathbb{R}^{3}$ 表示 3D 坐标，我们有：
- en: '|  | $\displaystyle m_{ij}$ | $\displaystyle=\psi_{m}(\bm{v}_{i},\bm{v}_{j},h_{i},h_{j},e_{ij}),$
    |  | (3) |'
  id: totrans-62
  prefs: []
  type: TYPE_TB
  zh: '|  | $\displaystyle m_{ij}$ | $\displaystyle=\psi_{m}(\bm{v}_{i},\bm{v}_{j},h_{i},h_{j},e_{ij}),$
    |  | (3) |'
- en: '|  | $\displaystyle\bm{m}_{ij}$ | $\displaystyle=\psi_{\bm{m}}(\bm{v}_{i},\bm{v}_{j},h_{i},h_{j},e_{ij}),$
    |  | (4) |'
  id: totrans-63
  prefs: []
  type: TYPE_TB
  zh: '|  | $\displaystyle\bm{m}_{ij}$ | $\displaystyle=\psi_{\bm{m}}(\bm{v}_{i},\bm{v}_{j},h_{i},h_{j},e_{ij}),$
    |  | (4) |'
- en: '|  | $\displaystyle h_{i}^{\prime}$ | $\displaystyle=\psi_{h}(\{m_{ij}\}_{j\in\mathcal{N}(i)},h_{i}),$
    |  | (5) |'
  id: totrans-64
  prefs: []
  type: TYPE_TB
  zh: '|  | $\displaystyle h_{i}^{\prime}$ | $\displaystyle=\psi_{h}(\{m_{ij}\}_{j\in\mathcal{N}(i)},h_{i}),$
    |  | (5) |'
- en: '|  | $\displaystyle\bm{v}_{i}^{\prime}$ | $\displaystyle=\psi_{\bm{v}}(\{\bm{m}_{ij}\}_{j\in\mathcal{N}(i)},\bm{v}_{i}),$
    |  | (6) |'
  id: totrans-65
  prefs: []
  type: TYPE_TB
  zh: '|  | $\displaystyle\bm{v}_{i}^{\prime}$ | $\displaystyle=\psi_{\bm{v}}(\{\bm{m}_{ij}\}_{j\in\mathcal{N}(i)},\bm{v}_{i}),$
    |  | (6) |'
- en: where $m_{ij}$ and $\bm{m}_{ij}$ are scalar and vector messages. $\psi_{m}$
    and $\psi_{h}$ are geometrically invariant functions while $\psi_{\bm{m}}$ and
    $\psi_{\bm{v}}$ are geometrically equivariant functions. Compared with traditional
    3D CNNs, geometrically equivariant GNNs do not require the voxelization of input
    data while still maintaining the desirable equivariance. Some representative equivariant
    GNNs are SchNet [[44](#bib.bib44)], EGNN [[15](#bib.bib15)], GVP [[45](#bib.bib45)],
    DimeNet [[46](#bib.bib46), [47](#bib.bib47)], GMN [[16](#bib.bib16)], SphereNet [[48](#bib.bib48)],
    and ComENet [[49](#bib.bib49)].
  id: totrans-66
  prefs: []
  type: TYPE_NORMAL
  zh: 其中 $m_{ij}$ 和 $\bm{m}_{ij}$ 是标量和向量消息。$\psi_{m}$ 和 $\psi_{h}$ 是几何不变函数，而 $\psi_{\bm{m}}$
    和 $\psi_{\bm{v}}$ 是几何等变函数。与传统的 3D CNNs 相比，几何等变 GNNs 不需要对输入数据进行体素化，同时仍保持所需的等变性。一些代表性的等变
    GNNs 包括 SchNet [[44](#bib.bib44)]、EGNN [[15](#bib.bib15)]、GVP [[45](#bib.bib45)]、DimeNet
    [[46](#bib.bib46), [47](#bib.bib47)]、GMN [[16](#bib.bib16)]、SphereNet [[48](#bib.bib48)]
    和 ComENet [[49](#bib.bib49)]。
- en: 2.3.3 Graph Transformers
  id: totrans-67
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 2.3.3 图变换器
- en: 'Transformers were originally developed for sequential data [[50](#bib.bib50)].
    Transformer architectures were recently adapted to 2D and 3D graph data and achieved
    superior performance [[51](#bib.bib51), [52](#bib.bib52), [53](#bib.bib53), [54](#bib.bib54),
    [55](#bib.bib55)] than GNNs on node and graph classification tasks. A transformer
    is composed of stacked transformer blocks, where each block consists of two layers:
    a self-attention layer followed by a feed-forward layer with normalizations (e.g.,
    LayerNorm [[56](#bib.bib56)]) and skip connections for both layers. For an input
    feature matrix $\textit{{H}}^{(l)}$, the $(l+1)$-th self-attention block works
    as follows:'
  id: totrans-68
  prefs: []
  type: TYPE_NORMAL
  zh: Transformer最初是为序列数据开发的[[50](#bib.bib50)]。最近，Transformer架构被适应于二维和三维图数据，并在节点和图分类任务中取得了优于GNNs的表现[[51](#bib.bib51),
    [52](#bib.bib52), [53](#bib.bib53), [54](#bib.bib54), [55](#bib.bib55)]。一个Transformer由堆叠的Transformer块组成，每个块包括两层：自注意力层，后接一个前馈层，并且这两层都有归一化（例如LayerNorm
    [[56](#bib.bib56)]）和跳跃连接。对于输入特征矩阵$\textit{{H}}^{(l)}$，第$(l+1)$-th自注意力块的工作流程如下：
- en: '|  | $\displaystyle\textit{{A}}^{(l)}$ | $\displaystyle={\rm softmax}\left(\frac{\textit{{H}}^{(l)}\textit{{W}}^{(l)}_{Q}(\textit{{H}}^{(l)}\textit{{W}}^{(l)}_{K})^{\top}}{\sqrt{d}}\right);$
    |  | (7) |'
  id: totrans-69
  prefs: []
  type: TYPE_TB
  zh: '|  | $\displaystyle\textit{{A}}^{(l)}$ | $\displaystyle={\rm softmax}\left(\frac{\textit{{H}}^{(l)}\textit{{W}}^{(l)}_{Q}(\textit{{H}}^{(l)}\textit{{W}}^{(l)}_{K})^{\top}}{\sqrt{d}}\right);$
    |  | (7) |'
- en: '|  | $\displaystyle\textit{{H}}^{(l+1)}$ | $\displaystyle=\textit{{H}}^{(l)}+\sum_{i=1}^{B}\textit{{A}}^{(l)}\textit{{H}}^{(l)}\textit{{W}}^{(l)}_{V}\textit{{W}}^{(l)}_{O},$
    |  | (8) |'
  id: totrans-70
  prefs: []
  type: TYPE_TB
  zh: '|  | $\displaystyle\textit{{H}}^{(l+1)}$ | $\displaystyle=\textit{{H}}^{(l)}+\sum_{i=1}^{B}\textit{{A}}^{(l)}\textit{{H}}^{(l)}\textit{{W}}^{(l)}_{V}\textit{{W}}^{(l)}_{O},$
    |  | (8) |'
- en: where A is the attention matrix, $B$ is the total number of attention heads,
    $d$ is the dimension size, $\textit{{W}}^{(l)}_{Q}$, $\textit{{W}}^{(l)}_{K}$,
    and $\textit{{W}}^{(l)}_{V}$ are learnable transformation matrices at layer $l$.
  id: totrans-71
  prefs: []
  type: TYPE_NORMAL
  zh: 其中A是注意力矩阵，$B$是注意力头的总数，$d$是维度大小，$\textit{{W}}^{(l)}_{Q}$、$\textit{{W}}^{(l)}_{K}$和$\textit{{W}}^{(l)}_{V}$是第$l$层的可学习变换矩阵。
- en: To generalize transformers to graphs, positional encodings are indispensable
    for encoding topological and geometric information [[51](#bib.bib51), [55](#bib.bib55)].
    Popular positional encodings are based on shortest paths [[51](#bib.bib51)], PageRank
    [[57](#bib.bib57)], and eigenvectors [[58](#bib.bib58)]. Positional encodings
    are necessary for graph transformers to consider graph connectivity–without positional
    encodings the models would ignore the strong inductive bias of edges and would
    attend to any pair of nodes. Representative graph transformers include Graphormer
    [[51](#bib.bib51)], Transformer-M [[55](#bib.bib55)], and Equiformer [[54](#bib.bib54)].
    For example, Transformer-M [[55](#bib.bib55)] develops two separated channels
    to encode both 2D and 3D structural information of molecules. The 2D channel uses
    encodings based on atom degrees, shortest path distance, and 2D graph structure.
    In the 3D channel, Gaussian basis kernel functions [[59](#bib.bib59)] are used
    to encode 3D spatial distances between atoms.
  id: totrans-72
  prefs: []
  type: TYPE_NORMAL
  zh: 为了将Transformers推广到图数据中，位置编码是不可或缺的，它们用于编码拓扑和几何信息[[51](#bib.bib51), [55](#bib.bib55)]。常见的位置编码基于最短路径[[51](#bib.bib51)]、PageRank
    [[57](#bib.bib57)]和特征向量[[58](#bib.bib58)]。位置编码对于图Transformer来说是必要的，因为没有位置编码，模型将忽视边的强归纳偏置，并且会关注任意节点对。代表性的图Transformer包括Graphormer
    [[51](#bib.bib51)]、Transformer-M [[55](#bib.bib55)]和Equiformer [[54](#bib.bib54)]。例如，Transformer-M
    [[55](#bib.bib55)]开发了两个分开的通道来编码分子的二维和三维结构信息。二维通道使用基于原子度、最短路径距离和二维图结构的编码。在三维通道中，使用高斯基函数[[59](#bib.bib59)]来编码原子之间的三维空间距离。
- en: 2.4 Generative Methods
  id: totrans-73
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 2.4 生成方法
- en: Next section summarizes generative methods for SBDD tasks, including autoregressive
    models, flow models, variational autoencoders, and diffusion models.
  id: totrans-74
  prefs: []
  type: TYPE_NORMAL
  zh: 下一节总结了SBDD任务的生成方法，包括自回归模型、流模型、变分自编码器和扩散模型。
- en: 2.4.1 Autoregressive Models (ARs)
  id: totrans-75
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 2.4.1 自回归模型 (ARs)
- en: 'A data point ${\bm{x}}$ can be factorized into a set of components $\{x_{0},x_{1},\dots,x_{d-1}\}$,
    where $d$ is the number of components. These components can be pixels in images
    and nodes and edges in graphs. The components may have complicated underlying
    dependencies, making the direct generation of ${\bm{x}}$ challenging. With predefined
    or learned orders, the autoregressive models factorize the joint distribution
    of ${\bm{x}}$ into the product of $d$ likelihoods as follows:'
  id: totrans-76
  prefs: []
  type: TYPE_NORMAL
  zh: 数据点 ${\bm{x}}$ 可以分解为一组组件 $\{x_{0},x_{1},\dots,x_{d-1}\}$，其中 $d$ 是组件的数量。这些组件可以是图像中的像素或图中的节点和边。组件可能具有复杂的潜在依赖关系，使得直接生成
    ${\bm{x}}$ 具有挑战性。通过预定义或学习到的顺序，自回归模型将 ${\bm{x}}$ 的联合分布分解为 $d$ 个似然度的乘积，如下所示：
- en: '|  | $\small{p({\bm{x}})=\prod_{i=1}^{d}p(x_{i}&#124;x_{1},x_{2},...,x_{i-1}).}$
    |  | (9) |'
  id: totrans-77
  prefs: []
  type: TYPE_TB
  zh: '|  | $\small{p({\bm{x}})=\prod_{i=1}^{d}p(x_{i}|x_{1},x_{2},...,x_{i-1}).}$
    |  | (9) |'
- en: 'Autoregressive models sequentially generate ${\bm{x}}$: In each step of a generative
    process, the next subcomponent is predicted based on the previously generated
    subcomponents.'
  id: totrans-78
  prefs: []
  type: TYPE_NORMAL
  zh: 自回归模型依次生成 ${\bm{x}}$：在生成过程的每一步中，基于先前生成的子组件来预测下一个子组件。
- en: 2.4.2 Flow Models
  id: totrans-79
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 2.4.2 流模型
- en: 'A flow model aims to learn a parameterized invertible function between a data
    point x and the latent variable ${\bm{z}}$: $f:{\bm{z}}\in\mathbb{R}^{d}\xrightarrow{}{\bm{x}}\in\mathbb{R}^{d}$.
    The latent distribution $p({\bm{z}})$ is a predefined probability distribution,
    e.g., a Gaussian distribution. The data distribution $p({\bm{x}})$ is unknown.
    But given a data point ${\bm{x}}$, its likelihood can be computed with the change-of-variable
    theorem:'
  id: totrans-80
  prefs: []
  type: TYPE_NORMAL
  zh: 流模型旨在学习一个参数化的可逆函数，将数据点 x 和潜在变量 ${\bm{z}}$ 之间进行映射：$f:{\bm{z}}\in\mathbb{R}^{d}\xrightarrow{}{\bm{x}}\in\mathbb{R}^{d}$。潜在分布
    $p({\bm{z}})$ 是预定义的概率分布，例如高斯分布。数据分布 $p({\bm{x}})$ 是未知的。但给定一个数据点 ${\bm{x}}$，可以通过变量变化定理计算其似然度：
- en: '|  | $\small{p({\bm{x}})=p({\bm{z}})\Big{&#124;}\text{det}\Big{(}\frac{df^{-1}({\bm{x}})}{d{\bm{x}}}\Big{)}\Big{&#124;},}$
    |  | (10) |'
  id: totrans-81
  prefs: []
  type: TYPE_TB
  zh: '|  | $\small{p({\bm{x}})=p({\bm{z}})\Big{|}\text{det}\Big{(}\frac{df^{-1}({\bm{x}})}{d{\bm{x}}}\Big{)}\Big{|},}$
    |  | (10) |'
- en: where $\text{det}(\cdot)$ is the matrix determinant and $\frac{df^{-1}({\bm{x}})}{d{\bm{x}}}$
    is the Jacobian matrix.
  id: totrans-82
  prefs: []
  type: TYPE_NORMAL
  zh: 其中 $\text{det}(\cdot)$ 是矩阵行列式，$\frac{df^{-1}({\bm{x}})}{d{\bm{x}}}$ 是雅可比矩阵。
- en: In the sampling process, a latent variable ${\bm{z}}$ is first sampled from
    a predefined latent distribution $p({\bm{z}})$. Then the corresponding data point
    ${\bm{x}}$ is obtained by performing a feedforward transformation ${\bm{x}}=f({\bm{z}})$.
    Therefore, $f$ must be differentiable, and the computation of ${\rm det}J$ should
    be tractable for training and sampling efficiency. A common choice is the affine
    coupling layers [[60](#bib.bib60), [61](#bib.bib61)] where the computation of
    ${\rm det}J$ is very efficient because $J$ is an upper triangular matrix.
  id: totrans-83
  prefs: []
  type: TYPE_NORMAL
  zh: 在采样过程中，首先从预定义的潜在分布 $p({\bm{z}})$ 中采样一个潜在变量 ${\bm{z}}$。然后通过执行前向变换 ${\bm{x}}=f({\bm{z}})$
    获得相应的数据点 ${\bm{x}}$。因此，$f$ 必须是可微的，并且 ${\rm det}J$ 的计算应该对训练和采样效率是可行的。一个常见的选择是仿射耦合层
    [[60](#bib.bib60), [61](#bib.bib61)]，其中 ${\rm det}J$ 的计算非常高效，因为 $J$ 是上三角矩阵。
- en: 2.4.3 Variational Autoencoders (VAEs)
  id: totrans-84
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 2.4.3 变分自编码器（VAEs）
- en: 'Variational autoencoders (VAEs) [[62](#bib.bib62)] maximize the evidence lower
    bound (ELBO) of $p({\bm{x}})$. VAEs introduce the latent variable ${\bm{z}}$ to
    express the likelihood of ${\bm{x}}$ as:'
  id: totrans-85
  prefs: []
  type: TYPE_NORMAL
  zh: 变分自编码器（VAEs）[[62](#bib.bib62)] 最大化 $p({\bm{x}})$ 的证据下界（ELBO）。VAEs 引入了潜在变量 ${\bm{z}}$
    来表示 ${\bm{x}}$ 的似然度，如下所示：
- en: '|  | $\displaystyle\small\log p({\bm{x}})$ | $\displaystyle=\log\int_{\bm{z}}p({\bm{z}})p({\bm{x}}&#124;{\bm{z}})d{\bm{z}}$
    |  | (11) |'
  id: totrans-86
  prefs: []
  type: TYPE_TB
  zh: '|  | $\displaystyle\small\log p({\bm{x}})$ | $\displaystyle=\log\int_{\bm{z}}p({\bm{z}})p({\bm{x}}|{\bm{z}})d{\bm{z}}$
    |  | (11) |'
- en: '|  |  | $\displaystyle\geq\mathbb{E}_{q({\bm{z}}&#124;{\bm{x}})}\big{[}\log
    p({\bm{x}}&#124;{\bm{z}})\big{]}-D_{KL}(q({\bm{z}}&#124;{\bm{x}})&#124;&#124;p({\bm{z}}))$
    |  | (12) |'
  id: totrans-87
  prefs: []
  type: TYPE_TB
  zh: '|  |  | $\displaystyle\geq\mathbb{E}_{q({\bm{z}}|{\bm{x}})}\big{[}\log p({\bm{x}}|{\bm{z}})\big{]}-D_{KL}(q({\bm{z}}|{\bm{x}})||p({\bm{z}}))$
    |  | (12) |'
- en: '|  |  | $\displaystyle\triangleq\text{ELBO}.$ |  | (13) |'
  id: totrans-88
  prefs: []
  type: TYPE_TB
  zh: '|  |  | $\displaystyle\triangleq\text{ELBO}.$ |  | (13) |'
- en: Here, $p({\bm{z}})$ represents the prior distribution of ${\bm{x}}$. For tractable
    calculation, parameterized encoder $q({\bm{z}}|{\bm{x}})$ is usually used to approximate
    $p({\bm{z}}|{\bm{x}})$, also known as the variational inference technique. The
    first term of ELBO is reconstruction loss, which quantifies the information loss
    of reconstructing ${\bm{x}}$ from latent representations. The standard Gaussian
    prior $p({\bm{z}})\sim\mathcal{N}(0,\textit{{I}})$ typically leads to mean-squared
    error (MSE) loss for the first term. The second term in ELBO is the KL-divergence
    term, ensuring that our learned distribution $q({\bm{z}}|{\bm{x}})$ is similar
    to the true prior distribution.
  id: totrans-89
  prefs: []
  type: TYPE_NORMAL
  zh: 在这里，$p({\bm{z}})$ 代表 ${\bm{x}}$ 的先验分布。为了便于计算，通常使用参数化编码器 $q({\bm{z}}|{\bm{x}})$
    来近似 $p({\bm{z}}|{\bm{x}})$，这也被称为变分推断技术。ELBO 的第一个项是重构损失，它量化了从潜在表示重构 ${\bm{x}}$
    的信息损失。标准的高斯先验 $p({\bm{z}})\sim\mathcal{N}(0,\textit{{I}})$ 通常导致第一个项的均方误差（MSE）损失。ELBO
    中的第二个项是 KL 散度项，确保我们学习的分布 $q({\bm{z}}|{\bm{x}})$ 与真实的先验分布相似。
- en: 2.4.4 Diffusion Probabilistic Models
  id: totrans-90
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 2.4.4 扩散概率模型
- en: Diffusion models [[63](#bib.bib63), [64](#bib.bib64)] are generative models
    inspired by non-equilibrium thermodynamics. A diffusion model defines a Markovian
    chain of random diffusion process where each step adds noise to the data, and
    then it learns the reverse of this process via neural networks to reconstruct
    data points from noise distributions, e.g., isotropic Gaussian.
  id: totrans-91
  prefs: []
  type: TYPE_NORMAL
  zh: 扩散模型 [[63](#bib.bib63), [64](#bib.bib64)] 是受非平衡热力学启发的生成模型。扩散模型定义了一个随机扩散过程的马尔可夫链，每一步都向数据中添加噪声，然后通过神经网络学习该过程的反向，以从噪声分布（例如各向同性高斯）中重建数据点。
- en: 'Let ${\bm{x}}_{0}\sim p({\bm{x}})$ denote the input data point and ${\bm{x}}_{t}$
    for $t=1,\dots,T$ indicate a series of noised representations with the same dimension
    as ${\bm{x}}_{0}$. The forward diffusion process can be expressed as:'
  id: totrans-92
  prefs: []
  type: TYPE_NORMAL
  zh: 设 ${\bm{x}}_{0}\sim p({\bm{x}})$ 表示输入数据点，${\bm{x}}_{t}$ 对于 $t=1,\dots,T$ 表示一系列与
    ${\bm{x}}_{0}$ 维度相同的噪声表示。正向扩散过程可以表示为：
- en: '|  | $\displaystyle q({\bm{x}}_{t}&#124;{\bm{x}}_{t-1})$ | $\displaystyle=\mathcal{N}({\bm{x}}_{t};\sqrt{1-\beta_{t}}{\bm{x}}_{t-1},\beta_{t}\textit{{I}}),$
    |  | (14) |'
  id: totrans-93
  prefs: []
  type: TYPE_TB
  zh: '|  | $\displaystyle q({\bm{x}}_{t}&#124;{\bm{x}}_{t-1})$ | $\displaystyle=\mathcal{N}({\bm{x}}_{t};\sqrt{1-\beta_{t}}{\bm{x}}_{t-1},\beta_{t}\textit{{I}}),$
    |  | (14) |'
- en: 'where $\beta_{t}\in(0,1)$ controls the strength of Gaussian noise added in
    each step. A desirable property of the diffusion process is that a closed form
    of the intermediate state can be obtained. Let $\alpha_{t}=1-\beta_{t}$, and $\bar{\alpha}_{t}=\prod_{i=1}^{t}\alpha_{i}$,
    we have:'
  id: totrans-94
  prefs: []
  type: TYPE_NORMAL
  zh: 其中 $\beta_{t}\in(0,1)$ 控制在每一步中添加的高斯噪声的强度。扩散过程的一个理想特性是可以获得中间状态的封闭形式。设 $\alpha_{t}=1-\beta_{t}$，$\bar{\alpha}_{t}=\prod_{i=1}^{t}\alpha_{i}$，我们有：
- en: '|  | $\small{q({\bm{x}}_{t}&#124;{\bm{x}}_{0})=\mathcal{N}({\bm{x}}_{t};\sqrt{\bar{\alpha}_{t}}{\bm{x}}_{0},(1-\bar{\alpha}_{t})\textit{{I}}).}$
    |  | (15) |'
  id: totrans-95
  prefs: []
  type: TYPE_TB
  zh: '|  | $\small{q({\bm{x}}_{t}&#124;{\bm{x}}_{0})=\mathcal{N}({\bm{x}}_{t};\sqrt{\bar{\alpha}_{t}}{\bm{x}}_{0},(1-\bar{\alpha}_{t})\textit{{I}}).}$
    |  | (15) |'
- en: 'Another desirable feature of the reverse diffusion process, i.e., the denoising
    process, is that it can be computed in a closed form when conditioned on ${\bm{x}}_{0}$
    using Bayes theorem:'
  id: totrans-96
  prefs: []
  type: TYPE_NORMAL
  zh: 反向扩散过程，即去噪过程的另一个理想特性是，当条件为 ${\bm{x}}_{0}$ 时，可以使用贝叶斯定理以封闭形式计算：
- en: '|  | $\displaystyle p_{\theta}({\bm{x}}_{t-1}&#124;{\bm{x}}_{t})$ | $\displaystyle=\mathcal{N}({\bm{x}}_{t-1};\bm{\mu}_{t}({\bm{x}}_{0},{\bm{x}}_{t}),\widetilde{\beta}_{t}\textit{{I}}),$
    |  | (16) |'
  id: totrans-97
  prefs: []
  type: TYPE_TB
  zh: '|  | $\displaystyle p_{\theta}({\bm{x}}_{t-1}&#124;{\bm{x}}_{t})$ | $\displaystyle=\mathcal{N}({\bm{x}}_{t-1};\bm{\mu}_{t}({\bm{x}}_{0},{\bm{x}}_{t}),\widetilde{\beta}_{t}\textit{{I}}),$
    |  | (16) |'
- en: 'where the parameters can be obtained analytically:'
  id: totrans-98
  prefs: []
  type: TYPE_NORMAL
  zh: 其中，参数可以通过解析方法获得：
- en: '|  | $\displaystyle\bm{\mu}_{t}({\bm{x}}_{0},{\bm{x}}_{t})$ | $\displaystyle=\frac{\sqrt{\bar{\alpha}_{t-1}}\beta_{t}}{1-\bar{\alpha}_{t}}{\bm{x}}_{0}+\frac{\sqrt{\alpha_{t}}(1-\bar{\alpha}_{t-1})}{1-\bar{\alpha}_{t}}{\bm{x}}_{t},$
    |  | (17) |'
  id: totrans-99
  prefs: []
  type: TYPE_TB
  zh: '|  | $\displaystyle\bm{\mu}_{t}({\bm{x}}_{0},{\bm{x}}_{t})$ | $\displaystyle=\frac{\sqrt{\bar{\alpha}_{t-1}}\beta_{t}}{1-\bar{\alpha}_{t}}{\bm{x}}_{0}+\frac{\sqrt{\alpha_{t}}(1-\bar{\alpha}_{t-1})}{1-\bar{\alpha}_{t}}{\bm{x}}_{t},$
    |  | (17) |'
- en: '|  | $\displaystyle\widetilde{\beta}_{t}$ | $\displaystyle=\frac{1-\bar{\alpha}_{t-1}}{1-\bar{\alpha}_{t}}\beta_{t}.$
    |  |'
  id: totrans-100
  prefs: []
  type: TYPE_TB
  zh: '|  | $\displaystyle\widetilde{\beta}_{t}$ | $\displaystyle=\frac{1-\bar{\alpha}_{t-1}}{1-\bar{\alpha}_{t}}\beta_{t}.$
    |  |'
- en: 'Similar to variational autoencoders, the objective of diffusion models is to
    maximize the variational lower bound of log-likelihood of $p({\bm{x}})$ as:'
  id: totrans-101
  prefs: []
  type: TYPE_NORMAL
  zh: 类似于变分自编码器，扩散模型的目标是最大化 $p({\bm{x}})$ 的对数似然的变分下界，如下所示：
- en: '|  |  | $\displaystyle-\log p({\bm{x}})\leq\underbrace{KL[q({\bm{x}}_{T}&#124;{\bm{x}}_{0})&#124;&#124;p_{\theta}({\bm{x}}_{T})]}_{\rm
    prior\ loss\ \mathcal{L}_{T}}$ |  |'
  id: totrans-102
  prefs: []
  type: TYPE_TB
  zh: '|  |  | $\displaystyle-\log p({\bm{x}})\leq\underbrace{KL[q({\bm{x}}_{T}&#124;{\bm{x}}_{0})&#124;&#124;p_{\theta}({\bm{x}}_{T})]}_{\rm
    prior\ loss\ \mathcal{L}_{T}}$ |  |'
- en: '|  |  | $\displaystyle~{}~{}~{}+\sum_{t=2}^{T}\underbrace{KL[q({\bm{x}}_{t-1}&#124;{\bm{x}}_{t},{\bm{x}}_{0})&#124;&#124;p_{\theta}({\bm{x}}_{t-1}&#124;{\bm{x}}_{t})]}_{\rm
    diffusion\ loss\ \mathcal{L}_{t-1}}-\underbrace{\mathbb{E}_{q}[\log p_{\theta}({\bm{x}}_{0}&#124;{\bm{x}}_{1})]}_{\rm
    reconstruction\ loss\ \mathcal{L}_{0}}.$ |  |'
  id: totrans-103
  prefs: []
  type: TYPE_TB
  zh: '|  |  | $\displaystyle~{}~{}~{}+\sum_{t=2}^{T}\underbrace{KL[q({\bm{x}}_{t-1}&#124;{\bm{x}}_{t},{\bm{x}}_{0})&#124;&#124;p_{\theta}({\bm{x}}_{t-1}&#124;{\bm{x}}_{t})]}_{\rm
    diffusion\ loss\ \mathcal{L}_{t-1}}-\underbrace{\mathbb{E}_{q}[\log p_{\theta}({\bm{x}}_{0}&#124;{\bm{x}}_{1})]}_{\rm
    reconstruction\ loss\ \mathcal{L}_{0}}.$ |  |'
- en: 'Here, $\mathcal{L}_{T}$ is a constant and $\mathcal{L}_{0}$ can be estimated
    using an auxiliary model [[64](#bib.bib64), [65](#bib.bib65)]. For $\{\mathcal{L}_{t-1}\}_{t=2}^{T}$,
    diffusion models adopt a neural network $\epsilon_{\theta}$ to predict the noise.
    More specifically, we can reparameterize Equation [15](#S2.E15 "Equation 15 ‣
    2.4.4 Diffusion Probabilistic Models ‣ 2.4 Generative Methods ‣ 2 Preliminaries
    ‣ Geometric Deep Learning for Structure-Based Drug Design: A Survey") as ${\bm{x}}_{t}=\sqrt{\bar{\alpha}_{t}}{\bm{x}}_{0}+\sqrt{(1-\bar{\alpha}_{t})}\epsilon_{t},\epsilon_{t}\sim\mathcal{N}(0,\textit{{I}})$.
    The following training objective is widely adopted:'
  id: totrans-104
  prefs: []
  type: TYPE_NORMAL
  zh: '在这里，$\mathcal{L}_{T}$ 是一个常数，而 $\mathcal{L}_{0}$ 可以通过辅助模型 [[64](#bib.bib64),
    [65](#bib.bib65)] 来估算。对于 $\{\mathcal{L}_{t-1}\}_{t=2}^{T}$，扩散模型采用神经网络 $\epsilon_{\theta}$
    来预测噪声。更具体地，我们可以将方程 [15](#S2.E15 "Equation 15 ‣ 2.4.4 Diffusion Probabilistic Models
    ‣ 2.4 Generative Methods ‣ 2 Preliminaries ‣ Geometric Deep Learning for Structure-Based
    Drug Design: A Survey") 重新参数化为 ${\bm{x}}_{t}=\sqrt{\bar{\alpha}_{t}}{\bm{x}}_{0}+\sqrt{(1-\bar{\alpha}_{t})}\epsilon_{t},\epsilon_{t}\sim\mathcal{N}(0,\textit{{I}})$。以下训练目标被广泛采用：'
- en: '|  | $\small{\mathcal{L}=\mathbb{E}_{t}\Big{[}\&#124;\epsilon_{t}-\epsilon_{\theta}({\bm{x}}_{t},t)\&#124;^{2}\Big{]}.}$
    |  |'
  id: totrans-105
  prefs: []
  type: TYPE_TB
  zh: '|  | $\small{\mathcal{L}=\mathbb{E}_{t}\Big{[}\&#124;\epsilon_{t}-\epsilon_{\theta}({\bm{x}}_{t},t)\&#124;^{2}\Big{]}.}$
    |  |'
- en: 2.5 Other Methods
  id: totrans-106
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 2.5 其他方法
- en: Apart from the generative methods previously discussed, several alternative
    techniques such as Reinforcement Learning (RL) [[66](#bib.bib66)], Genetic Algorithm
    (GA) [[67](#bib.bib67)], and Monte Carlo Tree Search (MCTS) [[21](#bib.bib21),
    [52](#bib.bib52)] are utilized to probe the chemical space for properties of interest.
    Additionally, drawing inspiration from molecular dynamics and fragment-based drug
    design, innovative methods grounded on virtual dynamics (VD) [[68](#bib.bib68)]
    and fragment-based molecule generation (Fragment) [[69](#bib.bib69)] have been
    introduced. For instance, in generating 3D molecules suited to a target protein,
    VD-Gen [[68](#bib.bib68)] initializes numerous virtual particles within the pocket.
    These particles are then iteratively adjusted to mirror the spatial arrangement
    of molecular atoms. A 3D molecule is subsequently derived from the stabilized
    virtual particles. In contrast, in fragment-based molecule generation, a motif
    vocabulary is initially established by isolating prevalent molecular fragments
    (referred to as motifs) from the dataset. During the generative phase, molecules
    are generated by autoregressively appending new fragments, ensuring the resulting
    local structures maintain realism.
  id: totrans-107
  prefs: []
  type: TYPE_NORMAL
  zh: 除了之前讨论的生成方法外，还利用了几种替代技术，如强化学习（RL）[[66](#bib.bib66)]、遗传算法（GA）[[67](#bib.bib67)]
    和蒙特卡洛树搜索（MCTS）[[21](#bib.bib21), [52](#bib.bib52)]，以探索化学空间中的感兴趣性质。此外，受到分子动力学和片段基础药物设计的启发，基于虚拟动力学（VD）[[68](#bib.bib68)]
    和片段基础分子生成（Fragment）[[69](#bib.bib69)] 的创新方法已被引入。例如，在生成适合目标蛋白的3D分子时，VD-Gen [[68](#bib.bib68)]
    在口袋内初始化了大量虚拟粒子。这些粒子随后会被反复调整，以反映分子原子的空间排列。随后，从稳定的虚拟粒子中生成一个3D分子。相比之下，在片段基础分子生成中，首先通过从数据集中分离出常见的分子片段（称为模体）来建立一个模体词汇。在生成阶段，通过自回归地附加新片段来生成分子，确保生成的局部结构保持真实。
- en: 'TABLE I: Summary of structure-based drug design models with geometric deep
    learning reviewed in this paper.'
  id: totrans-108
  prefs: []
  type: TYPE_NORMAL
  zh: 表 I：本论文回顾的结构基础药物设计模型的总结，包含几何深度学习。
- en: '| Task | Model | Input | Output | Method |'
  id: totrans-109
  prefs: []
  type: TYPE_TB
  zh: '| 任务 | 模型 | 输入 | 输出 | 方法 |'
- en: '| Binding site prediction | MaSIF [[17](#bib.bib17)] | Protein Surface | Binding
    Site Probability | CNN |'
  id: totrans-110
  prefs: []
  type: TYPE_TB
  zh: '| 结合位点预测 | MaSIF [[17](#bib.bib17)] | 蛋白质表面 | 结合位点概率 | CNN |'
- en: '| dMaSIF [[70](#bib.bib70)] | Protein Surface | Binding Site Probability |
    CNN |'
  id: totrans-111
  prefs: []
  type: TYPE_TB
  zh: '| dMaSIF [[70](#bib.bib70)] | 蛋白质表面 | 结合位点概率 | CNN |'
- en: '| PeSTo [[71](#bib.bib71)] | Protein 3D-Graph | Binding Site Probability |
    Transformer |'
  id: totrans-112
  prefs: []
  type: TYPE_TB
  zh: '| PeSTo [[71](#bib.bib71)] | 蛋白质3D图 | 结合位点概率 | Transformer |'
- en: '| ScanNet [[72](#bib.bib72)] | Protein 3D-Graph | Binding Site Probability
    | GNN |'
  id: totrans-113
  prefs: []
  type: TYPE_TB
  zh: '| ScanNet [[72](#bib.bib72)] | 蛋白质3D图 | 结合位点概率 | GNN |'
- en: '| PocketMiner [[73](#bib.bib73)] | Protein 3D-Graph | Binding Site Probability
    | GNN |'
  id: totrans-114
  prefs: []
  type: TYPE_TB
  zh: '| PocketMiner [[73](#bib.bib73)] | 蛋白质3D图 | 结合位点概率 | GNN |'
- en: '| PIPGCN [[74](#bib.bib74)] | Protein 3D-Graph | Binding Site Probability |
    GNN |'
  id: totrans-115
  prefs: []
  type: TYPE_TB
  zh: '| PIPGCN [[74](#bib.bib74)] | 蛋白质3D图 | 结合位点概率 | GNN |'
- en: '| EquiPocket [[75](#bib.bib75)] | Protein 3D-Graph | Binding Site Probability
    | GNN |'
  id: totrans-116
  prefs: []
  type: TYPE_TB
  zh: '| EquiPocket [[75](#bib.bib75)] | 蛋白质3D图 | 结合位点概率 | GNN |'
- en: '| NodeCoder [[76](#bib.bib76)] | Protein 3D-Graph | Binding Site Probability
    | GNN |'
  id: totrans-117
  prefs: []
  type: TYPE_TB
  zh: '| NodeCoder [[76](#bib.bib76)] | 蛋白质3D图 | 结合位点概率 | GNN |'
- en: '| DeepSite [[41](#bib.bib41)] | Protein Grid | Binding Site Probability | 3DCNN
    |'
  id: totrans-118
  prefs: []
  type: TYPE_TB
  zh: '| DeepSite [[41](#bib.bib41)] | 蛋白质网格 | 结合位点概率 | 3DCNN |'
- en: '| PUResNet [[42](#bib.bib42)] | Protein Grid | Binding Site Probability | 3DCNN
    |'
  id: totrans-119
  prefs: []
  type: TYPE_TB
  zh: '| PUResNet [[42](#bib.bib42)] | 蛋白质网格 | 结合位点概率 | 3DCNN |'
- en: '| Binding pose generation | EquiBind [[35](#bib.bib35)] | Ligand 2D-Graph+Protein
    3D-Graph | Complex 3D-Graph | Keypoint Align |'
  id: totrans-120
  prefs: []
  type: TYPE_TB
  zh: '| 结合姿态生成 | EquiBind [[35](#bib.bib35)] | 配体2D图+蛋白质3D图 | 复杂的3D图 | 关键点对齐 |'
- en: '| DeepDock [[77](#bib.bib77)] | Ligand 2D-Graph+Protein Surface | Complex 3D-Graph
    | Dist. Pred. |'
  id: totrans-121
  prefs: []
  type: TYPE_TB
  zh: '| DeepDock [[77](#bib.bib77)] | 配体2D图+蛋白质表面 | 复杂的3D图 | 距离预测 |'
- en: '| TankBind [[78](#bib.bib78)] | Ligand 2D-Graph+Protein 3D-Graph | Complex
    3D-Graph | Dist. Pred. |'
  id: totrans-122
  prefs: []
  type: TYPE_TB
  zh: '| TankBind [[78](#bib.bib78)] | 配体2D图+蛋白质3D图 | 复杂的3D图 | 距离预测 |'
- en: '| EDM-Dock [[79](#bib.bib79)] | Ligand 2D-Graph+Protein 3D-Graph | Complex
    3D-Graph | Dist. Pred. |'
  id: totrans-123
  prefs: []
  type: TYPE_TB
  zh: '| EDM-Dock [[79](#bib.bib79)] | 配体2D图+蛋白质3D图 | 复杂的3D图 | 距离预测 |'
- en: '| DPL [[80](#bib.bib80)] | Ligand 2D-Graph+Protein Sequence | Complex 3D-Graph
    | Diffusion |'
  id: totrans-124
  prefs: []
  type: TYPE_TB
  zh: '| DPL [[80](#bib.bib80)] | 配体2D图+蛋白质序列 | 复杂的3D图 | 扩散 |'
- en: '| DiffDock [[18](#bib.bib18)] | Ligand 2D-Graph+Protein 3D-Graph | Complex
    3D-Graph | Diffusion |'
  id: totrans-125
  prefs: []
  type: TYPE_TB
  zh: '| DiffDock [[18](#bib.bib18)] | 配体2D图+蛋白质3D图 | 复杂的3D图 | 扩散 |'
- en: '| NeuralPLexer [[81](#bib.bib81)] | Ligand 2D-Graph+Protein Sequence | Complex
    3D-Graph | Diffusion |'
  id: totrans-126
  prefs: []
  type: TYPE_TB
  zh: '| NeuralPLexer [[81](#bib.bib81)] | 配体2D图+蛋白质序列 | 复杂的3D图 | 扩散 |'
- en: '| DynamicBind [[82](#bib.bib82)] | Ligand 2D-Graph+Protein Sequence | Complex
    3D-Graph | Diffusion |'
  id: totrans-127
  prefs: []
  type: TYPE_TB
  zh: '| DynamicBind [[82](#bib.bib82)] | 配体2D图+蛋白质序列 | 复杂的3D图 | 扩散 |'
- en: '| E3Bind [[83](#bib.bib83)] | Ligand 2D-Graph+Protein 3D-Graph | Complex 3D-Graph
    | Iterative Update |'
  id: totrans-128
  prefs: []
  type: TYPE_TB
  zh: '| E3Bind [[83](#bib.bib83)] | 配体2D图+蛋白质3D图 | 复杂的3D图 | 迭代更新 |'
- en: '| DeepRMSD [[84](#bib.bib84)] | Ligand 2D-Graph+Protein 3D-Graph | Complex
    3D-Graph | Iterative Update |'
  id: totrans-129
  prefs: []
  type: TYPE_TB
  zh: '| DeepRMSD [[84](#bib.bib84)] | 配体2D图+蛋白质3D图 | 复杂的3D图 | 迭代更新 |'
- en: '| 3T [[85](#bib.bib85)] | Ligand 2D-Graph+Protein 3D-Graph | Complex 3D-Graph
    | Iterative Update |'
  id: totrans-130
  prefs: []
  type: TYPE_TB
  zh: '| 3T [[85](#bib.bib85)] | 配体2D图+蛋白质3D图 | 复杂的3D图 | 迭代更新 |'
- en: '| Binding affinity prediction | SIGN [[24](#bib.bib24)] | Complex 3D-Graph
    | Binding Affinity | GNN |'
  id: totrans-131
  prefs: []
  type: TYPE_TB
  zh: '| 结合亲和力预测 | SIGN [[24](#bib.bib24)] | 复杂的3D图 | 结合亲和力 | GNN |'
- en: '| PIGNet [[86](#bib.bib86)] | Complex 3D-Graph | Binding Affinity | GNN |'
  id: totrans-132
  prefs: []
  type: TYPE_TB
  zh: '| PIGNet [[86](#bib.bib86)] | 复杂的3D图 | 结合亲和力 | GNN |'
- en: '| HOLOPROT [[87](#bib.bib87)] | Complex 3D-Graph+Surface | Binding Affinity
    | GNN |'
  id: totrans-133
  prefs: []
  type: TYPE_TB
  zh: '| HOLOPROT [[87](#bib.bib87)] | 复杂的3D图+表面 | 结合亲和力 | GNN |'
- en: '| PLIG [[88](#bib.bib88)] | Complex 3D-Graph | Binding Affinity | GNN |'
  id: totrans-134
  prefs: []
  type: TYPE_TB
  zh: '| PLIG [[88](#bib.bib88)] | 复杂的3D图 | 结合亲和力 | GNN |'
- en: '| PaxNet [[89](#bib.bib89)] | Complex 3D-Graph | Binding Affinity | GNN |'
  id: totrans-135
  prefs: []
  type: TYPE_TB
  zh: '| PaxNet [[89](#bib.bib89)] | 复杂的3D图 | 结合亲和力 | GNN |'
- en: '| IGN [[90](#bib.bib90)] | Complex 3D-Graph | Binding Affinity | GNN |'
  id: totrans-136
  prefs: []
  type: TYPE_TB
  zh: '| IGN [[90](#bib.bib90)] | 复杂的3D图 | 结合亲和力 | GNN |'
- en: '| GIGN [[91](#bib.bib91)] | Complex 3D-Graph | Binding Affinity | GNN |'
  id: totrans-137
  prefs: []
  type: TYPE_TB
  zh: '| GIGN [[91](#bib.bib91)] | 复杂的3D图 | 结合亲和力 | GNN |'
- en: '| GraphscoreDTA [[92](#bib.bib92)] | Complex 3D-Graph | Binding Affinity |
    GNN |'
  id: totrans-138
  prefs: []
  type: TYPE_TB
  zh: '| GraphscoreDTA [[92](#bib.bib92)] | 复杂的3D图 | 结合亲和力 | GNN |'
- en: '| PLANET [[93](#bib.bib93)] | Complex 3D-Graph | Binding Affinity | GNN |'
  id: totrans-139
  prefs: []
  type: TYPE_TB
  zh: '| PLANET [[93](#bib.bib93)] | 复杂的3D图 | 结合亲和力 | GNN |'
- en: '| DOX_BDW [[94](#bib.bib94)] | Complex 3D-Graph | Binding Affinity | GNN |'
  id: totrans-140
  prefs: []
  type: TYPE_TB
  zh: '| DOX_BDW [[94](#bib.bib94)] | 复杂的3D图 | 结合亲和力 | GNN |'
- en: '| MBP [[95](#bib.bib95)] | Complex 3D-Graph | Binding Affinity | GNN |'
  id: totrans-141
  prefs: []
  type: TYPE_TB
  zh: '| MBP [[95](#bib.bib95)] | 复杂的3D图 | 结合亲和力 | GNN |'
- en: '| Pafnucy [[96](#bib.bib96)] | Complex 3D-Grid | Binding Affinity | CNN |'
  id: totrans-142
  prefs: []
  type: TYPE_TB
  zh: '| Pafnucy [[96](#bib.bib96)] | 复杂的3D网格 | 结合亲和力 | CNN |'
- en: '| DeepAtom [[97](#bib.bib97)] | Complex 3D-Grid | Binding Affinity | CNN |'
  id: totrans-143
  prefs: []
  type: TYPE_TB
  zh: '| DeepAtom [[97](#bib.bib97)] | 复杂的3D网格 | 结合亲和力 | CNN |'
- en: '| RoseNet  [[98](#bib.bib98)] | Complex 3D-Grid | Binding Affinity | CNN |'
  id: totrans-144
  prefs: []
  type: TYPE_TB
  zh: '| RoseNet [[98](#bib.bib98)] | 复杂的3D网格 | 结合亲和力 | CNN |'
- en: '| IEConv [[99](#bib.bib99)] | Complex 3D-Graph | Binding Affinity | CNN |'
  id: totrans-145
  prefs: []
  type: TYPE_TB
  zh: '| IEConv [[99](#bib.bib99)] | 复杂的3D图 | 结合亲和力 | CNN |'
- en: '| SGCNN [[100](#bib.bib100)] | Complex 3D-Graph | Binding Affinity | CNN |'
  id: totrans-146
  prefs: []
  type: TYPE_TB
  zh: '| SGCNN [[100](#bib.bib100)] | 复杂 3D-图 | 结合亲和力 | CNN |'
- en: '| Fusion [[101](#bib.bib101)] | Complex 3D-Grid+3D-Graph | Binding Affinity
    | CNN + GNN |'
  id: totrans-147
  prefs: []
  type: TYPE_TB
  zh: '| Fusion [[101](#bib.bib101)] | 复杂 3D-网格+3D-图 | 结合亲和力 | CNN + GNN |'
- en: '| *de novo* ligand generation | AutoGrow [[102](#bib.bib102)] | Pocket 3D-Graph
    | Ligand 3D-Graph | GA |'
  id: totrans-148
  prefs: []
  type: TYPE_TB
  zh: '| *de novo* 配体生成 | AutoGrow [[102](#bib.bib102)] | 口袋 3D-图 | 配体 3D-图 | GA |'
- en: '| RGA [[67](#bib.bib67)] | Pocket 3D-Graph | Ligand 3D-Graph | GA |'
  id: totrans-149
  prefs: []
  type: TYPE_TB
  zh: '| RGA [[67](#bib.bib67)] | 口袋 3D-图 | 配体 3D-图 | GA |'
- en: '| liGAN [[103](#bib.bib103)] | Pocket Grid | Ligand 3D-Graph | VAE |'
  id: totrans-150
  prefs: []
  type: TYPE_TB
  zh: '| liGAN [[103](#bib.bib103)] | 口袋网格 | 配体 3D-图 | VAE |'
- en: '| RELATION [[104](#bib.bib104)] | Pocket Grid | Ligand Smiles | VAE |'
  id: totrans-151
  prefs: []
  type: TYPE_TB
  zh: '| RELATION [[104](#bib.bib104)] | 口袋网格 | 配体 Smiles | VAE |'
- en: '| SQUID [[105](#bib.bib105)] | Target Shape Point Cloud | Ligand 3D-Graph |
    VAE+Fragment |'
  id: totrans-152
  prefs: []
  type: TYPE_TB
  zh: '| SQUID [[105](#bib.bib105)] | 目标形状点云 | 配体 3D-图 | VAE+片段 |'
- en: '| DeepLigBuilder [[21](#bib.bib21)] | Pocket 3D-Graph | Ligand 3D-Graph | MCTS+RL
    |'
  id: totrans-153
  prefs: []
  type: TYPE_TB
  zh: '| DeepLigBuilder [[21](#bib.bib21)] | 口袋 3D-图 | 配体 3D-图 | MCTS+RL |'
- en: '| DeepLigBuilder+ [[52](#bib.bib52)] | Pocket 3D-Graph | Ligand 3D-Graph |
    MCTS+RL |'
  id: totrans-154
  prefs: []
  type: TYPE_TB
  zh: '| DeepLigBuilder+ [[52](#bib.bib52)] | 口袋 3D-图 | 配体 3D-图 | MCTS+RL |'
- en: '| 3DSBDD [[2](#bib.bib2)] | Pocket 3D-Graph | Ligand 3D-Graph | AR |'
  id: totrans-155
  prefs: []
  type: TYPE_TB
  zh: '| 3DSBDD [[2](#bib.bib2)] | 口袋 3D-图 | 配体 3D-图 | AR |'
- en: '| Pocket2Mol [[19](#bib.bib19)] | Pocket 3D-Graph | Ligand 3D-Graph | AR |'
  id: totrans-156
  prefs: []
  type: TYPE_TB
  zh: '| Pocket2Mol [[19](#bib.bib19)] | 口袋 3D-图 | 配体 3D-图 | AR |'
- en: '| DESERT [[106](#bib.bib106)] | Pocket Grid | Ligand 3D-Graph | AR |'
  id: totrans-157
  prefs: []
  type: TYPE_TB
  zh: '| DESERT [[106](#bib.bib106)] | 口袋网格 | 配体 3D-图 | AR |'
- en: '| PrefixMol [[107](#bib.bib107)] | Pocket 3D-Graph | Ligand Smiles | AR |'
  id: totrans-158
  prefs: []
  type: TYPE_TB
  zh: '| PrefixMol [[107](#bib.bib107)] | 口袋 3D-图 | 配体 Smiles | AR |'
- en: '| FLAG [[69](#bib.bib69)] | Pocket 3D-Graph | Ligand 3D-Graph | AR+Fragment
    |'
  id: totrans-159
  prefs: []
  type: TYPE_TB
  zh: '| FLAG [[69](#bib.bib69)] | 口袋 3D-图 | 配体 3D-图 | AR+片段 |'
- en: '| DrugGPS [[108](#bib.bib108)] | Pocket 3D-Graph | Ligand 3D-Graph | AR+Fragment
    |'
  id: totrans-160
  prefs: []
  type: TYPE_TB
  zh: '| DrugGPS [[108](#bib.bib108)] | 口袋 3D-图 | 配体 3D-图 | AR+片段 |'
- en: '| Lingo3DMol [[109](#bib.bib109)] | Pocket 3D-Graph | Ligand 3D-Graph | AR+Fragment
    |'
  id: totrans-161
  prefs: []
  type: TYPE_TB
  zh: '| Lingo3DMol [[109](#bib.bib109)] | 口袋 3D-图 | 配体 3D-图 | AR+片段 |'
- en: '| GraphBP [[110](#bib.bib110)] | Pocket 3D-Graph | Ligand 3D-Graph | Flow |'
  id: totrans-162
  prefs: []
  type: TYPE_TB
  zh: '| GraphBP [[110](#bib.bib110)] | 口袋 3D-图 | 配体 3D-图 | 流 |'
- en: '| MolCode [[111](#bib.bib111)] | Pocket 3D-Graph | Ligand 3D-Graph | Flow |'
  id: totrans-163
  prefs: []
  type: TYPE_TB
  zh: '| MolCode [[111](#bib.bib111)] | 口袋 3D-图 | 配体 3D-图 | 流 |'
- en: '| GraphVF [[112](#bib.bib112)] | Pocket 3D-Graph | Ligand 3D-Graph | Flow+Fragment
    |'
  id: totrans-164
  prefs: []
  type: TYPE_TB
  zh: '| GraphVF [[112](#bib.bib112)] | 口袋 3D-图 | 配体 3D-图 | 流+片段 |'
- en: '| SENF  [[113](#bib.bib113)] | Pocket 3D-Graph | Ligand 3D-Graph | Flow |'
  id: totrans-165
  prefs: []
  type: TYPE_TB
  zh: '| SENF [[113](#bib.bib113)] | 口袋 3D-图 | 配体 3D-图 | 流 |'
- en: '| DiffSBDD [[1](#bib.bib1)] | Pocket 3D-Graph | Ligand 3D-Graph | Diffusion
    |'
  id: totrans-166
  prefs: []
  type: TYPE_TB
  zh: '| DiffSBDD [[1](#bib.bib1)] | 口袋 3D-图 | 配体 3D-图 | 扩散 |'
- en: '| TargetDiff [[114](#bib.bib114)] | Pocket 3D-Graph | Ligand 3D-Graph | Diffusion
    |'
  id: totrans-167
  prefs: []
  type: TYPE_TB
  zh: '| TargetDiff [[114](#bib.bib114)] | 口袋 3D-图 | 配体 3D-图 | 扩散 |'
- en: '| DiffBP [[115](#bib.bib115)] | Pocket 3D-Graph | Ligand 3D-Graph | Diffusion
    |'
  id: totrans-168
  prefs: []
  type: TYPE_TB
  zh: '| DiffBP [[115](#bib.bib115)] | 口袋 3D-图 | 配体 3D-图 | 扩散 |'
- en: '| DecompDiff [[116](#bib.bib116)] | Pocket 3D-Graph | Ligand 3D-Graph | Diffusion
    |'
  id: totrans-169
  prefs: []
  type: TYPE_TB
  zh: '| DecompDiff [[116](#bib.bib116)] | 口袋 3D-图 | 配体 3D-图 | 扩散 |'
- en: '| ShapeMol [[117](#bib.bib117)] | Target Shape Point Cloud | Ligand 3D-Graph
    | Diffusion |'
  id: totrans-170
  prefs: []
  type: TYPE_TB
  zh: '| ShapeMol [[117](#bib.bib117)] | 目标形状点云 | 配体 3D-图 | 扩散 |'
- en: '| VD-Gen [[68](#bib.bib68)] | Pocket 3D-Graph | Ligand 3D-Graph | VD |'
  id: totrans-171
  prefs: []
  type: TYPE_TB
  zh: '| VD-Gen [[68](#bib.bib68)] | 口袋 3D-图 | 配体 3D-图 | VD |'
- en: 'TABLE I: Summary of structure-based drug design models with geometric deep
    learning reviewed in this paper (continued).'
  id: totrans-172
  prefs: []
  type: TYPE_NORMAL
  zh: 表 I：本论文中回顾的基于结构的药物设计模型的几何深度学习总结（续）。
- en: '| Task | Model | Input | Output | Method |'
  id: totrans-173
  prefs: []
  type: TYPE_TB
  zh: '| 任务 | 模型 | 输入 | 输出 | 方法 |'
- en: '| Linker design | DeLinker [[118](#bib.bib118)] | Pocket 3D-Graph+Ligand Fragments
    | Ligand 2D-Graph | VAE |'
  id: totrans-174
  prefs: []
  type: TYPE_TB
  zh: '| Linker design | DeLinker [[118](#bib.bib118)] | 口袋 3D-图+配体片段 | 配体 2D-图 |
    VAE |'
- en: '| 3Dlinker [[20](#bib.bib20)] | Pocket 3D-Graph+Ligand Fragments | Ligand 3D-Graph
    | VAE |'
  id: totrans-175
  prefs: []
  type: TYPE_TB
  zh: '| 3Dlinker [[20](#bib.bib20)] | 口袋 3D-图+配体片段 | 配体 3D-图 | VAE |'
- en: '| DEVELOP [[119](#bib.bib119)] | Pocket 3D-Graph+Ligand Fragments | Ligand
    3D-Graph | VAE |'
  id: totrans-176
  prefs: []
  type: TYPE_TB
  zh: '| DEVELOP [[119](#bib.bib119)] | 口袋 3D-图+配体片段 | 配体 3D-图 | VAE |'
- en: '| Link-INVENT [[120](#bib.bib120)] | Pocket 3D-Graph+Ligand Fragments | Ligand
    2D-Graph | RL |'
  id: totrans-177
  prefs: []
  type: TYPE_TB
  zh: '| Link-INVENT [[120](#bib.bib120)] | 口袋 3D-图+配体片段 | 配体 2D-图 | RL |'
- en: '| PROTAC-INVENT [[66](#bib.bib66)] | Pocket 3D-Graph+Ligand Fragments | Ligand
    3D-Graph | RL |'
  id: totrans-178
  prefs: []
  type: TYPE_TB
  zh: '| PROTAC-INVENT [[66](#bib.bib66)] | 口袋 3D-图+配体片段 | 配体 3D-图 | RL |'
- en: '| DiffLinker [[121](#bib.bib121)] | Pocket 3D-Graph+Ligand Fragments | Ligand
    3D-Graph | Diffusion |'
  id: totrans-179
  prefs: []
  type: TYPE_TB
  zh: '| DiffLinker [[121](#bib.bib121)] | 口袋 3D-图+配体片段 | 配体 3D-图 | 扩散 |'
- en: 3 Structure-based Drug Design Tasks
  id: totrans-180
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 结构基础药物设计任务
- en: 3.1 Binding Site Prediction
  id: totrans-181
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 3.1 结合位点预测
- en: 3.1.1 Problem Formulation
  id: totrans-182
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.1.1 问题表述
- en: The protein surface encompasses the outermost regions of proteins, interacting
    with the environment. It is typically characterized as a continuous shape with
    added geometric and chemical attributes. Predicting binding sites based on these
    protein surface representations is fundamental for other SBDD tasks, including
    binding pose generation and *de novo* ligand generation. Formally, let’s represent
    the target protein surface as $\mathcal{S}$ (for instance, in the form of a mesh
    or point cloud). The goal is to devise a predictive model $f(\mathcal{S})$ that
    determines the likelihood of each point on the surface being a binding site.
  id: totrans-183
  prefs: []
  type: TYPE_NORMAL
  zh: 蛋白质表面涵盖了蛋白质的最外层区域，与环境进行相互作用。它通常被描述为具有附加几何和化学属性的连续形状。基于这些蛋白质表面表示来预测结合位点是其他结构基础药物设计（SBDD）任务的基础，包括结合姿势生成和*de
    novo*配体生成。形式上，我们将目标蛋白质表面表示为$\mathcal{S}$（例如，以网格或点云的形式）。目标是设计一个预测模型$f(\mathcal{S})$，以确定表面上每个点作为结合位点的可能性。
- en: 3.1.2 Representative Methods
  id: totrans-184
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.1.2 代表性方法
- en: 'The Molecular Surface Interaction Fingerprinting (MaSIF) [[17](#bib.bib17)]
    is a pioneering method that use 3D mesh-based geometric deep learning to predict
    protein interaction sites (first row in Figure [4](#S3.F4 "Figure 4 ‣ 3.1.2 Representative
    Methods ‣ 3.1 Binding Site Prediction ‣ 3 Structure-based Drug Design Tasks ‣
    Geometric Deep Learning for Structure-Based Drug Design: A Survey")). In MaSIF,
    the protein surface data is described in the geodesic space, where the distance
    between two points on the surface is measured by “walking” between the two points
    along the surface. To encode the protein surface, MaSIF decomposes the surface
    into overlapping radial patches with a fixed geodesic radius. Each point within
    a patch is assigned an array of precomputed geometric (e.g., shape index and distance-dependent
    curvature) and chemical (e.g., hydropathy, continuum electrostatics, and free
    electrons/protons) features (Figure [4](#S3.F4 "Figure 4 ‣ 3.1.2 Representative
    Methods ‣ 3.1 Binding Site Prediction ‣ 3 Structure-based Drug Design Tasks ‣
    Geometric Deep Learning for Structure-Based Drug Design: A Survey")bc). MaSIF
    then learns to embed the surface patch’s input features into fingerprints for
    binding site prediction with convolutional neural networks (Figure [4](#S3.F4
    "Figure 4 ‣ 3.1.2 Representative Methods ‣ 3.1 Binding Site Prediction ‣ 3 Structure-based
    Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based Drug Design: A
    Survey")d).'
  id: totrans-185
  prefs: []
  type: TYPE_NORMAL
  zh: '分子表面相互作用指纹（MaSIF）[[17](#bib.bib17)]是一种开创性的方法，利用基于3D网格的几何深度学习来预测蛋白质相互作用位点（见图[4](#S3.F4
    "Figure 4 ‣ 3.1.2 Representative Methods ‣ 3.1 Binding Site Prediction ‣ 3 Structure-based
    Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based Drug Design: A
    Survey")）。在MaSIF中，蛋白质表面数据在测地空间中进行描述，其中表面上两个点之间的距离通过在表面上“行走”来测量。为了编码蛋白质表面，MaSIF将表面分解为重叠的径向补丁，并具有固定的测地半径。每个补丁中的点被分配一组预计算的几何（例如，形状指数和距离依赖曲率）和化学（例如，疏水性、连续电荷和自由电子/质子）特征（见图[4](#S3.F4
    "Figure 4 ‣ 3.1.2 Representative Methods ‣ 3.1 Binding Site Prediction ‣ 3 Structure-based
    Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based Drug Design: A
    Survey")bc）。然后，MaSIF通过卷积神经网络学习将表面补丁的输入特征嵌入到结合位点预测的指纹中（见图[4](#S3.F4 "Figure 4 ‣
    3.1.2 Representative Methods ‣ 3.1 Binding Site Prediction ‣ 3 Structure-based
    Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based Drug Design: A
    Survey")d）。'
- en: 'However, MaSIF [[17](#bib.bib17)] is limited by the reliance on precomputed
    meshes, handcrafted features, and significant computation time. dMaSIF [[70](#bib.bib70)]
    extend MaSIF and proposes an efficient end-to-end prediction framework based on
    3D point cloud representations of protein. In Figure [4](#S3.F4 "Figure 4 ‣ 3.1.2
    Representative Methods ‣ 3.1 Binding Site Prediction ‣ 3 Structure-based Drug
    Design Tasks ‣ Geometric Deep Learning for Structure-Based Drug Design: A Survey"),
    it is shown that dMaSIF [[70](#bib.bib70)] conducts all the computations on the
    fly and is 600 times faster than MaSIF [[17](#bib.bib17)] while obtaining prediction
    results with a similar accuracy level.'
  id: totrans-186
  prefs: []
  type: TYPE_NORMAL
  zh: '然而，MaSIF [[17](#bib.bib17)]受限于对预计算网格、手工特征和大量计算时间的依赖。dMaSIF [[70](#bib.bib70)]扩展了MaSIF，并提出了一种基于蛋白质3D点云表示的高效端到端预测框架。在图[4](#S3.F4
    "Figure 4 ‣ 3.1.2 Representative Methods ‣ 3.1 Binding Site Prediction ‣ 3 Structure-based
    Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based Drug Design: A
    Survey")中，显示dMaSIF [[70](#bib.bib70)]在飞行过程中进行所有计算，比MaSIF [[17](#bib.bib17)]快600倍，同时获得相似准确度的预测结果。'
- en: Furthermore, some recent works model protein surfaces as 3D graphs and design
    GNN [[72](#bib.bib72)] or Graph Transformer-based methods [[71](#bib.bib71)] for
    efficient and precise binding site prediction. For example, ScanNet [[72](#bib.bib72)]
    builds representations of atoms and amino acids based on the spatial-chemical
    arrangement of protein and leverages GNN with specially designed filters for prediction;
    PeSTo [[71](#bib.bib71)] is a rotation-equivariant transformer-based neural network
    that acts directly on protein atoms for binding site prediction.
  id: totrans-187
  prefs: []
  type: TYPE_NORMAL
  zh: 此外，一些最新的研究将蛋白质表面建模为3D图，并设计了基于GNN的[[72](#bib.bib72)]或图变换器的[[71](#bib.bib71)]方法以实现高效和精确的绑定位点预测。例如，ScanNet
    [[72](#bib.bib72)]根据蛋白质的空间化学排列构建原子和氨基酸的表示，并利用具有特别设计的滤波器的GNN进行预测；PeSTo [[71](#bib.bib71)]是一个旋转等变的变换器基础神经网络，直接作用于蛋白质原子进行绑定位点预测。
- en: '![Refer to caption](img/285dcc2eef8970d41faf6d694a5b1894.png)'
  id: totrans-188
  prefs: []
  type: TYPE_IMG
  zh: '![参见说明](img/285dcc2eef8970d41faf6d694a5b1894.png)'
- en: 'Figure 4: Overview of MaSIF [[17](#bib.bib17)] and dMaSIF [[70](#bib.bib70)]
    for binding site prediction. They have similar steps, and each step’s average
    running time per protein is marked. MaSIF precomputes steps in a-c, whereas dMaSIF
    computes them on the fly and is 600 times faster than MaSIF.'
  id: totrans-189
  prefs: []
  type: TYPE_NORMAL
  zh: 图4：MaSIF [[17](#bib.bib17)]和dMaSIF [[70](#bib.bib70)]在绑定位点预测中的概述。它们有类似的步骤，每个步骤每个蛋白质的平均运行时间都有标记。MaSIF预计算了步骤a-c，而dMaSIF则即时计算，速度比MaSIF快600倍。
- en: 3.1.3 Datasets
  id: totrans-190
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.1.3 数据集
- en: Protein Data Bank (PDB) [[122](#bib.bib122)] contains 3D structural protein
    data obtained by X-ray crystallography, NMR spectroscopy, and cryo-electron microscopy.
  id: totrans-191
  prefs: []
  type: TYPE_NORMAL
  zh: 蛋白质数据银行（PDB）[[122](#bib.bib122)]包含通过X射线晶体学、NMR光谱学和冷冻电子显微镜获得的3D结构蛋白质数据。
- en: Dockground [[123](#bib.bib123)] provides a comprehensive set of protein-protein
    docking complexes extracted from the PDB.
  id: totrans-192
  prefs: []
  type: TYPE_NORMAL
  zh: Dockground [[123](#bib.bib123)] 提供了一套全面的从PDB提取的蛋白质-蛋白质对接复合物。
- en: 3.1.4 Evaluation Metrics
  id: totrans-193
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.1.4 评估指标
- en: As there is typically no threshold for the binding site prediction, ROC-AUC
    is widely used for the evaluation.
  id: totrans-194
  prefs: []
  type: TYPE_NORMAL
  zh: 由于通常没有绑定位点预测的阈值，ROC-AUC被广泛用于评估。
- en: 3.1.5 Limitations and Future Directions
  id: totrans-195
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.1.5 限制与未来方向
- en: Although remarkable success has been achieved by applying geometric deep learning
    for binding site prediction, there are two limitations of existing methods that
    must be addressed in future research. The first is to predict the binding site
    conditioned on the binding ligands. Since binding ligands have various biochemical
    characteristics, such as varying size, polar and hydrophobic groups, binding pockets
    have specificity to ligands, and it is reasonable to consider ligand information
    in binding site prediction. The second open question is to predict cryptic pockets
    that are not apparent in experimentally determined structures. However, caused
    by protein structural fluctuations [[124](#bib.bib124), [125](#bib.bib125)], ligands
    can bind to cryptic pockets and modulate protein function via inhibition or activation.
    Therefore, the ability to accurately and rapidly predict cryptic pockets is an
    important opportunity to expand the space of druggable proteome. PocketMiner[[73](#bib.bib73)]
    is a pioneering work on cryptic pocket prediction, and we expect to see more research
    in this area.
  id: totrans-196
  prefs: []
  type: TYPE_NORMAL
  zh: 尽管应用几何深度学习在绑定位点预测中取得了显著成功，但现有方法有两个限制需要在未来研究中解决。首先是根据结合配体预测绑定位点。由于结合配体具有各种生化特征，如不同的大小、极性和疏水性基团，绑定口袋对配体具有特异性，因此在绑定位点预测中考虑配体信息是合理的。第二个开放问题是预测在实验确定结构中不明显的隐蔽口袋。然而，由于蛋白质结构波动[[124](#bib.bib124),
    [125](#bib.bib125)]，配体可以结合到隐蔽口袋中，并通过抑制或激活调节蛋白质功能。因此，准确和快速预测隐蔽口袋的能力是扩展药物靶蛋白组的一个重要机会。PocketMiner
    [[73](#bib.bib73)] 是隐蔽口袋预测方面的开创性工作，我们期待在这一领域看到更多的研究。
- en: 3.2 Binding Pose Prediction
  id: totrans-197
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 3.2 绑定姿势预测
- en: 3.2.1 Problem Formulation
  id: totrans-198
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.2.1 问题公式化
- en: Predicting the binding mode of a ligand molecule to a target protein, commonly
    referred to as molecular docking, is a fundamental challenge in drug discovery
    with a wide range of practical applications. We can represent the target protein
    structure as $\mathcal{P}$, the ligand’s 2D graph as $G$, and the 3D structure
    of the ligand as $R$. The primary goal is to develop a model for $p(R|G,\mathcal{P})$
    model that can be used to predict the 3D binding pose of the ligand.
  id: totrans-199
  prefs: []
  type: TYPE_NORMAL
  zh: 预测配体分子与靶蛋白的结合模式，通常称为分子对接，是药物发现中的一个基本挑战，具有广泛的实际应用。我们可以将靶蛋白结构表示为$\mathcal{P}$，配体的二维图表示为$G$，配体的三维结构表示为$R$。主要目标是开发一个用于预测配体三维结合姿势的$p(R|G,\mathcal{P})$模型。
- en: 3.2.2 Representative Methods
  id: totrans-200
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.2.2 代表性方法
- en: Traditional molecular docking methods rely on manually designed scoring functions
    and extensive conformation sampling to predict the optimal binding conformation.
    More recently, this research area has witnessed significant advancements by applying
    geometric deep-learning techniques, resulting in remarkable progress. One noteworthy
    progress in this field is EquiBind [[35](#bib.bib35)], which marks the first instance
    of incorporating a geometric deep learning model into the task of molecular docking.
    Specifically, EquiBind [[35](#bib.bib35)] employs an SE(3)-equivariant geometric
    deep learning model to facilitate direct-shot predictions of both the receptor’s
    binding site location and the bound pose of the ligand. This is achieved by predicting
    and aligning key pocket landmarks on the ligand and the protein. In comparative
    evaluations against traditional methods like VINA [[126](#bib.bib126)] and SMINA,
    EquiBind substantially enhances docking efficiency, outperforming them by orders
    of magnitude—by a factor ranging from 3 to 5. TANKBind [[80](#bib.bib80)] further
    improves over EquiBind by combining a divide-and-conquer strategy and a Trigonometry-Aware
    Neural network. TANKBind predicts the inter-molecular distance matrix and then
    takes a numerical approach to generate specific ligand coordinates based on the
    inter-molecular distance matrix, coordinates of protein nodes, and the pair distance
    matrix of ligand nodes. Following in the footsteps of TANKBind, E3Bind [[83](#bib.bib83)]
    uses a divide-and-conquer strategy and designs a trigonometry-aware equivariant
    graph network to iteratively update the ligand coordinates. This framework can
    directly predict the coordinates without the employ of a numerical approach-based
    generation process. Generally, these methods treat the binding pose generation
    task as a regression problem.
  id: totrans-201
  prefs: []
  type: TYPE_NORMAL
  zh: 传统的分子对接方法依赖于手动设计的评分函数和广泛的构象采样来预测最佳结合构象。近年来，通过应用几何深度学习技术，该研究领域取得了显著进展，取得了显著进展。在这一领域的一个值得注意的进展是EquiBind [[35](#bib.bib35)]，这是将几何深度学习模型首次应用于分子对接任务的实例。具体而言，EquiBind [[35](#bib.bib35)]采用了一个SE(3)-等变几何深度学习模型，以实现对受体结合位点位置和配体结合姿势的直接预测。这是通过预测和对齐配体和蛋白质上的关键口袋标志来实现的。在与传统方法如VINA [[126](#bib.bib126)]和SMINA的比较评估中，EquiBind显著提高了对接效率，比它们高出几个数量级——提高了3到5倍。TANKBind [[80](#bib.bib80)]通过结合分治策略和三角学感知神经网络进一步改进了EquiBind。TANKBind预测分子间距离矩阵，然后采用数值方法根据分子间距离矩阵、蛋白质节点坐标和配体节点对距离矩阵生成特定的配体坐标。继TANKBind之后，E3Bind [[83](#bib.bib83)]使用分治策略，并设计了一个三角学感知等变图网络，以迭代更新配体坐标。该框架可以直接预测坐标，无需数值方法生成过程。一般来说，这些方法将结合姿势生成任务视为回归问题。
- en: 'In contrast to the prevalent approach, DiffDock [[18](#bib.bib18)] introduces
    a groundbreaking perspective by framing it as a generative modeling problem (Figure [5](#S3.F5
    "Figure 5 ‣ 3.2.2 Representative Methods ‣ 3.2 Binding Pose Prediction ‣ 3 Structure-based
    Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based Drug Design: A
    Survey")). As a diffusion generative model over the non-Euclidean manifold of
    ligand poses, DiffDock maps the manifold to the product space of the degrees of
    ligand freedom (translational, rotational, and torsional) involved in docking
    and develops an efficient diffusion process on this space. The diffusion model
    generates a set of candidate poses for each input protein-ligand pair, and a trained
    confidence model is employed to pick out the most likely pose. In scenarios of
    blind docking, where binding sites are not provided, DiffDock achieves comparable
    inference efficiency and significant performance improvement over chemoinformatics
    and geometric deep learning methods.'
  id: totrans-202
  prefs: []
  type: TYPE_NORMAL
  zh: '与普遍采用的方法不同，DiffDock [[18](#bib.bib18)] 通过将其框架设定为生成建模问题引入了突破性的视角（图 [5](#S3.F5
    "Figure 5 ‣ 3.2.2 Representative Methods ‣ 3.2 Binding Pose Prediction ‣ 3 Structure-based
    Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based Drug Design: A
    Survey")）。作为一种在配体姿态的非欧几里得流形上的扩散生成模型，DiffDock 将流形映射到涉及对接的配体自由度（平移、旋转和扭转）的乘积空间，并在该空间上开发了高效的扩散过程。扩散模型为每对输入的蛋白质-配体对生成一组候选姿态，经过训练的置信模型被用来挑选出最可能的姿态。在盲对接的情况下，即没有提供结合位点，DiffDock
    在推断效率上达到了与化学信息学和几何深度学习方法相当的水平，并且显著提升了性能。'
- en: Generally, previous works predominantly focus on rigid docking, where proteins
    are considered rigid bodies and the flexibility of protein structures is ignored;
    it is crucial to acknowledge that protein structures are inherently flexible and
    can undergo intrinsic or induced conformational changes [[127](#bib.bib127)].
    Unfortunately, these aspects are overlooked by the methods above. Recent methods,
    such as NeuralPLexer [[81](#bib.bib81)] and DynamicBind [[82](#bib.bib82)], consider
    the flexibility of protein structures, resulting in superior performance in predicting
    protein-ligand complex structures. NeuralPLexer [[81](#bib.bib81)], for instance,
    incorporates a diffusion model that integrates essential biophysical constraints
    coupled with a multi-scale geometric deep learning system. This combination enables
    the iterative sampling of residue-level contact maps and the determination of
    all heavy-atom coordinates within the protein-ligand complex. Following the path
    blazed by DiffDock[[18](#bib.bib18)], DynamicBind [[82](#bib.bib82)] not only
    considers the degree of ligand freedom (translational, rotational, and torsional)
    but also takes into account the degree of freedom within protein side chains (torsional).
    These methods exhibit significant potential for advancing the field of geometric
    deep learning in dynamic docking scenarios.
  id: totrans-203
  prefs: []
  type: TYPE_NORMAL
  zh: 通常，之前的研究主要集中在刚性对接上，其中蛋白质被视为刚性体，忽略了蛋白质结构的柔性；然而，必须承认蛋白质结构本质上是柔性的，并且可以经历固有的或诱导的构象变化 [[127](#bib.bib127)]。不幸的是，上述方法忽略了这些方面。近年来的方法，例如
    NeuralPLexer [[81](#bib.bib81)] 和 DynamicBind [[82](#bib.bib82)]，考虑了蛋白质结构的柔性，从而在预测蛋白质-配体复合物结构方面表现更优。例如，NeuralPLexer [[81](#bib.bib81)]
    结合了扩散模型，该模型集成了基本的生物物理约束以及多尺度几何深度学习系统。这种组合使得残基级接触图的迭代采样成为可能，并确定蛋白质-配体复合物中所有重原子的坐标。继
    DiffDock[[18](#bib.bib18)] 开创的路径之后，DynamicBind [[82](#bib.bib82)] 不仅考虑了配体自由度（平移、旋转和扭转），还考虑了蛋白质侧链内的自由度（扭转）。这些方法在动态对接场景中的几何深度学习领域展示了显著的潜力。
- en: 'TABLE II: Summary of different metrics of representative molecular docking
    methods on PDBBind dataset for blind docking task. Unless otherwise specified,
    the default input is assumed to be the holo conformation of the protein. The best
    results are highlighted in bold.'
  id: totrans-204
  prefs: []
  type: TYPE_NORMAL
  zh: 表 II：PDBBind 数据集上代表性分子对接方法在盲对接任务中的不同指标总结。除非另有说明，默认输入假定为蛋白质的 holo 构象。最佳结果以粗体突出显示。
- en: Method Top-1 Ligand RMSD Top-1 Ligand Centroid Time(s) ($\downarrow$) Percentiles
    ($\downarrow$) Below threshold ($\uparrow$) Percentiles ($\downarrow$) Below threshold
    ($\uparrow$) 25th 50th 75th 2 Å 5 Å 25th 50th 75th 2 Å 5 Å VINA [[126](#bib.bib126)]
    5.7 10.7 21.4 5.5 21.2 1.9 6.2 20.1 26.5 47.1 206 QVINA-W [[128](#bib.bib128)]
    2.5 7.7 23.7 20.9 40.2 0.9 3.7 22.9 41.0 54.6 10 GNINA [[129](#bib.bib129)] 2.4
    7.7 17.9 22.9 40.8 0.8 3.7 23.1 40.2 53.6 127 SMINA [[130](#bib.bib130)] 3.1 7.1
    17.9 18.7 38.0 1.0 2.6 16.1 41.6 59.8 126 GLIDE [[131](#bib.bib131)] 2.6 9.3 28.1
    21.8 33.6 0.8 5.6 26.9 36.1 48.7 1405 EquiBind [[35](#bib.bib35)] 3.8 6.2 10.3
    5.5 39.1 1.3 2.6 7.4 40.0 67.5 0.04 TANKBind [[78](#bib.bib78)] 2.5 4.0 8.5 20.4
    59.0 0.9 1.8 4.4 55.1 77.1 2.5 E3bind [[83](#bib.bib83)] 2.1 3.8 7.8 23.4 60.0
    0.8 1.5 4.0 60.0 78.8 2.1 DiffDock [[18](#bib.bib18)] 1.4 3.3 7.3 38.2 63.2 0.5
    1.2 3.2 64.5 80.5 40 DiffDock (Apo) [[18](#bib.bib18)] - - - 21.7 - - - - - -
    10 NeuralPLexer (Apo) [[81](#bib.bib81)] 1.3 2.8 5.9 39.5 69.7 - - - - - 2.1 DynamicBind
    (Apo) [[82](#bib.bib82)] - - - 33.0 65.0 - - - - - - ![Refer to caption](img/934b3279c34a9cef2eeb8126f2ec3885.png)
  id: totrans-205
  prefs: []
  type: TYPE_NORMAL
  zh: 方法 Top-1 配体 RMSD Top-1 配体质心 时间(s) ($\downarrow$) 百分位数 ($\downarrow$) 低于阈值 ($\uparrow$)
    百分位数 ($\downarrow$) 低于阈值 ($\uparrow$) 25th 50th 75th 2 Å 5 Å 25th 50th 75th 2
    Å 5 Å VINA [[126](#bib.bib126)] 5.7 10.7 21.4 5.5 21.2 1.9 6.2 20.1 26.5 47.1
    206 QVINA-W [[128](#bib.bib128)] 2.5 7.7 23.7 20.9 40.2 0.9 3.7 22.9 41.0 54.6
    10 GNINA [[129](#bib.bib129)] 2.4 7.7 17.9 22.9 40.8 0.8 3.7 23.1 40.2 53.6 127
    SMINA [[130](#bib.bib130)] 3.1 7.1 17.9 18.7 38.0 1.0 2.6 16.1 41.6 59.8 126 GLIDE
    [[131](#bib.bib131)] 2.6 9.3 28.1 21.8 33.6 0.8 5.6 26.9 36.1 48.7 1405 EquiBind
    [[35](#bib.bib35)] 3.8 6.2 10.3 5.5 39.1 1.3 2.6 7.4 40.0 67.5 0.04 TANKBind [[78](#bib.bib78)]
    2.5 4.0 8.5 20.4 59.0 0.9 1.8 4.4 55.1 77.1 2.5 E3bind [[83](#bib.bib83)] 2.1
    3.8 7.8 23.4 60.0 0.8 1.5 4.0 60.0 78.8 2.1 DiffDock [[18](#bib.bib18)] 1.4 3.3
    7.3 38.2 63.2 0.5 1.2 3.2 64.5 80.5 40 DiffDock (Apo) [[18](#bib.bib18)] - - -
    21.7 - - - - - - 10 NeuralPLexer (Apo) [[81](#bib.bib81)] 1.3 2.8 5.9 39.5 69.7
    - - - - - 2.1 DynamicBind (Apo) [[82](#bib.bib82)] - - - 33.0 65.0 - - - - - -
    ![Refer to caption](img/934b3279c34a9cef2eeb8126f2ec3885.png)
- en: 'Figure 5: Overview of DiffDock [[18](#bib.bib18)] for binding pose prediction.
    The model takes as input the separate ligand and protein structures. Randomly
    sampled initial poses are denoised via a reverse diffusion process over translational,
    rotational, and torsional degrees of freedom. A trained confidence model ranks
    the sampled poses to produce a final prediction and confidence score.'
  id: totrans-206
  prefs: []
  type: TYPE_NORMAL
  zh: '图 5: DiffDock [[18](#bib.bib18)] 在结合姿势预测中的概述。该模型以单独的配体和蛋白质结构作为输入。通过在平移、旋转和扭转自由度上的逆扩散过程来去噪随机采样的初始姿势。一个训练过的置信度模型对采样的姿势进行排序，以生成最终预测和置信度评分。'
- en: 3.2.3 Datasets
  id: totrans-207
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.2.3 数据集
- en: 'PDBBind [[132](#bib.bib132)] is a subset of the PDB [[133](#bib.bib133)] that
    contains experimentally measured 3D structures of protein-ligand complexes. The
    newest version, PDBBind v2020, contains 19,443 protein-ligand complexes with 3,890
    unique receptors and 15,193 unique ligands. This dataset is often used for molecular
    docking tasks. Nevertheless, while nearly all geometric deep learning methods
    are trained on this dataset, variations exist in the detailed settings, as outlined
    in Table [IV](#S3.T4 "Table IV ‣ 3.2.6 Limitations and Future Directions ‣ 3.2
    Binding Pose Prediction ‣ 3 Structure-based Drug Design Tasks ‣ Geometric Deep
    Learning for Structure-Based Drug Design: A Survey").'
  id: totrans-208
  prefs: []
  type: TYPE_NORMAL
  zh: 'PDBBind [[132](#bib.bib132)] 是 PDB [[133](#bib.bib133)] 的一个子集，包含实验测量的蛋白质-配体复合物的
    3D 结构。最新版本 PDBBind v2020 包含 19,443 个蛋白质-配体复合物，其中有 3,890 个独特的受体和 15,193 个独特的配体。该数据集通常用于分子对接任务。然而，尽管几乎所有几何深度学习方法都是在此数据集上训练的，但详细设置存在变异，如表
    [IV](#S3.T4 "Table IV ‣ 3.2.6 Limitations and Future Directions ‣ 3.2 Binding
    Pose Prediction ‣ 3 Structure-based Drug Design Tasks ‣ Geometric Deep Learning
    for Structure-Based Drug Design: A Survey") 中所述。'
- en: 3.2.4 Evaluation Metrics
  id: totrans-209
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.2.4 评估指标
- en: Centroid Distance calculates the distance between the averaged coordinates of
    the predicted and truly bound ligand atoms.
  id: totrans-210
  prefs: []
  type: TYPE_NORMAL
  zh: Centroid Distance 计算预测和真实结合配体原子的平均坐标之间的距离。
- en: 'Ligand Root Mean Square Deviation (L-RMSD) is the mean squared error between
    the atoms of the predicted and bound ligands. Formally, let $R\in\mathbb{R}^{n\times
    3}$ and $\hat{R}\in\mathbb{R}^{n\times 3}$ be the predicted and the ground truth
    ligand coordinates, where $n$ is the number of atoms. The L-RMSD is obtained with:'
  id: totrans-211
  prefs: []
  type: TYPE_NORMAL
  zh: 配体均方根偏差 (L-RMSD) 是预测配体和结合配体原子之间的均方误差。正式地，设 $R\in\mathbb{R}^{n\times 3}$ 和 $\hat{R}\in\mathbb{R}^{n\times
    3}$ 分别为预测的和实际的配体坐标，其中 $n$ 是原子数量。L-RMSD 计算公式为：
- en: '|  | $\text{L-RMSD}(R,\hat{R})=\big{(}\frac{1}{n}\sum_{i=1}^{n}&#124;&#124;R_{i}-\hat{R}_{i}&#124;&#124;^{2}\big{)}^{\frac{1}{2}},$
    |  | (18) |'
  id: totrans-212
  prefs: []
  type: TYPE_TB
  zh: '|  | $\text{L-RMSD}(R,\hat{R})=\big{(}\frac{1}{n}\sum_{i=1}^{n}&#124;&#124;R_{i}-\hat{R}_{i}&#124;&#124;^{2}\big{)}^{\frac{1}{2}},$
    |  | (18) |'
- en: where $R_{i}$ and $\hat{R}_{i}$ denote the coordinate of the $i$-th atom.
  id: totrans-213
  prefs: []
  type: TYPE_NORMAL
  zh: 其中 $R_{i}$ 和 $\hat{R}_{i}$ 表示第 $i$ 个原子的坐标。
- en: 'Kabsch RMSD is the lowest possible RMSD that the roto-translation transformation
    of the ligand can obtain. It first uses the Kabsch algorithm to superimpose the
    two structures and then calculates the RMSD score similar to Equation. [18](#S3.E18
    "Equation 18 ‣ 3.2.4 Evaluation Metrics ‣ 3.2 Binding Pose Prediction ‣ 3 Structure-based
    Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based Drug Design: A
    Survey").'
  id: totrans-214
  prefs: []
  type: TYPE_NORMAL
  zh: 'Kabsch RMSD 是配体通过旋转-平移变换可以获得的最低RMSD。它首先使用Kabsch算法对两种结构进行叠加，然后计算类似于方程 [18](#S3.E18
    "Equation 18 ‣ 3.2.4 Evaluation Metrics ‣ 3.2 Binding Pose Prediction ‣ 3 Structure-based
    Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based Drug Design: A
    Survey")的RMSD得分。'
- en: PoseBusters [[134](#bib.bib134)] is a novel test suite designed to assess the
    chemical and physical plausibility of ligand poses, complementing accuracy-based
    metrics like RMSD. The PoseBusters test suite consists of 18 checks in total,
    organized into three groups of tests to evaluate chemical, intramolecular, and
    intermolecular validity.
  id: totrans-215
  prefs: []
  type: TYPE_NORMAL
  zh: PoseBusters [[134](#bib.bib134)] 是一个新颖的测试套件，旨在评估配体构象的化学和物理合理性，补充了像RMSD这样的基于准确性的指标。PoseBusters测试套件总共包含18个检查，分为三组测试，用于评估化学、分子内和分子间的有效性。
- en: 3.2.5 Benchmark Performance
  id: totrans-216
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.2.5 基准性能
- en: 'In Table [II](#S3.T2 "Table II ‣ 3.2.2 Representative Methods ‣ 3.2 Binding
    Pose Prediction ‣ 3 Structure-based Drug Design Tasks ‣ Geometric Deep Learning
    for Structure-Based Drug Design: A Survey"), the performance of selected molecular
    docking methods is displayed. NeuralPLexer and DynamicBind focus on dynamic docking,
    while the remaining methods address rigid docking. Dynamic docking methods use
    the apo conformation of proteins, and rigid docking methods apply the holo conformation.
    The table indicates that DiffDock performs well in rigid docking, and NeuralPLexer
    is effective in dynamic docking scenarios.'
  id: totrans-217
  prefs: []
  type: TYPE_NORMAL
  zh: '在表 [II](#S3.T2 "Table II ‣ 3.2.2 Representative Methods ‣ 3.2 Binding Pose
    Prediction ‣ 3 Structure-based Drug Design Tasks ‣ Geometric Deep Learning for
    Structure-Based Drug Design: A Survey")中，展示了所选分子对接方法的性能。NeuralPLexer 和 DynamicBind
    专注于动态对接，而其余方法则处理刚性对接。动态对接方法使用蛋白质的apo构象，而刚性对接方法应用holo构象。表中指出，DiffDock 在刚性对接中表现良好，而NeuralPLexer
    在动态对接场景中有效。'
- en: 3.2.6 Limitations and Future Directions
  id: totrans-218
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.2.6 限制与未来方向
- en: 'Ever since EquiBind [[35](#bib.bib35)] pioneered the incorporation of geometric
    deep learning into molecular docking tasks, a series of geometric deep learning-based
    docking methods have emerged. Although these methods exhibit notable enhancements
    in the RMSD metric for blind docking tasks, they face challenges in generating
    physically plausible ligand poses. Research by Buttenschoen et al.[[134](#bib.bib134)]
    demonstrate that even for data with RMSD less than 2.0 Å predicted by DiffDock,
    only 36.8% of the data represents physically plausible ligand poses (Table [III](#S3.T3
    "Table III ‣ 3.2.6 Limitations and Future Directions ‣ 3.2 Binding Pose Prediction
    ‣ 3 Structure-based Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based
    Drug Design: A Survey")), with steric clashes between the protein and ligand being
    a prevalent issue. These findings underscore the ongoing challenge for geometric
    deep-learning models to generate accurate and physically plausible ligand poses.
    What’s more, the recent development of GPU-accelerated sampling methods, such
    as VINA-GPU [[135](#bib.bib135)] and DSDP [[136](#bib.bib136)], achieve significant
    acceleration in speed. Analyses suggest that current molecular docking has no
    efficiency advantage and fails to predict physically valid poses. Thus, in the
    future, it will be imperative to expand more intrinsic advantages of geometric
    deep learning models, such as considering the protein side chain’s flexibility.'
  id: totrans-219
  prefs: []
  type: TYPE_NORMAL
  zh: '自从EquiBind [[35](#bib.bib35)] 开创性地将几何深度学习引入分子对接任务以来，基于几何深度学习的对接方法应运而生。尽管这些方法在盲对接任务的RMSD指标上表现出显著的提升，但它们在生成物理上合理的配体构象方面仍面临挑战。Buttenschoen等人的研究[[134](#bib.bib134)]
    表明，即使对于DiffDock预测的RMSD小于2.0 Å的数据，只有36.8%的数据代表了物理上合理的配体构象（表 [III](#S3.T3 "Table
    III ‣ 3.2.6 Limitations and Future Directions ‣ 3.2 Binding Pose Prediction ‣
    3 Structure-based Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based
    Drug Design: A Survey")），其中蛋白质和配体之间的空间冲突是一个普遍问题。这些发现突显了几何深度学习模型在生成准确且物理上合理的配体构象方面仍面临的挑战。此外，最近开发的GPU加速采样方法，如VINA-GPU [[135](#bib.bib135)]
    和DSDP [[136](#bib.bib136)]，在速度上取得了显著的加速。分析表明，目前的分子对接方法在效率上没有优势，并且无法预测物理有效的构象。因此，未来将需要拓展几何深度学习模型的更多内在优势，例如考虑蛋白质侧链的灵活性。'
- en: 'TABLE III: Summary of different metrics of representative molecular docking
    methods on PoseBuster [[134](#bib.bib134)] dataset for blind docking task. Data
    points pass all PoseBuster tests and are denoted as ”PB-Valid”.'
  id: totrans-220
  prefs: []
  type: TYPE_NORMAL
  zh: 表 III：PoseBuster [[134](#bib.bib134)] 数据集上代表性分子对接方法的不同指标总结。数据点通过所有PoseBuster测试，并标记为“PB-Valid”。
- en: '| Method | $\%$ RMSD $\leq$ 2.0 Å | $\%$ RMSD $\leq$ 2.0 Å (PB-Valid) |'
  id: totrans-221
  prefs: []
  type: TYPE_TB
  zh: '| 方法 | $\%$ RMSD $\leq$ 2.0 Å | $\%$ RMSD $\leq$ 2.0 Å (PB-Valid) |'
- en: '| VINA [[137](#bib.bib137)] | 52 | 51 |'
  id: totrans-222
  prefs: []
  type: TYPE_TB
  zh: '| VINA [[137](#bib.bib137)] | 52 | 51 |'
- en: '| EquiBind [[35](#bib.bib35)] | 2.6 | 0.0 |'
  id: totrans-223
  prefs: []
  type: TYPE_TB
  zh: '| EquiBind [[35](#bib.bib35)] | 2.6 | 0.0 |'
- en: '| TANKBind [[78](#bib.bib78)] | 15 | 2.6 |'
  id: totrans-224
  prefs: []
  type: TYPE_TB
  zh: '| TANKBind [[78](#bib.bib78)] | 15 | 2.6 |'
- en: '| DiffDock [[18](#bib.bib18)] | 38 | 14 |'
  id: totrans-225
  prefs: []
  type: TYPE_TB
  zh: '| DiffDock [[18](#bib.bib18)] | 38 | 14 |'
- en: 'TABLE IV: Datasets used by geometric deep learning-based molecular docking
    methods.'
  id: totrans-226
  prefs: []
  type: TYPE_NORMAL
  zh: 表 IV：几何深度学习基础的分子对接方法使用的数据集。
- en: '| Method | Training and validation sets |'
  id: totrans-227
  prefs: []
  type: TYPE_TB
  zh: '| 方法 | 训练和验证集 |'
- en: '| EquiBind [[35](#bib.bib35)], E3Bind [[83](#bib.bib83)], DiffDock [[18](#bib.bib18)]
    | PDBbind 2020 General Set with complexes published before 2019 and without those
    with ligands found in the test set—17,347 complexes in total. |'
  id: totrans-228
  prefs: []
  type: TYPE_TB
  zh: '| EquiBind [[35](#bib.bib35)]、E3Bind [[83](#bib.bib83)]、DiffDock [[18](#bib.bib18)]
    | PDBbind 2020 通用集，包含2019年前发布的复合物，不包括测试集中发现的配体—总计17,347个复合物。 |'
- en: '| TankBind [[78](#bib.bib78)], DynamicBind[[82](#bib.bib82)] | PDBbind 2020
    General Set with complexes published before 2019 and without those failing pre-processing—18,755
    complexes in total. |'
  id: totrans-229
  prefs: []
  type: TYPE_TB
  zh: '| TankBind [[78](#bib.bib78)]、DynamicBind[[82](#bib.bib82)] | PDBbind 2020
    通用集，包含2019年前发布的复合物，不包括未通过预处理的复合物—总计18,755个复合物。 |'
- en: '| NeuralPlexer [[81](#bib.bib81)] | Constructing a new dataset, PL2019-74k,
    based on the PDB accessed in April 2022\. PL2019-74k is obtained by removing samples
    deposited after January 2019 and samples with UniProt ID in the PocketMiner dataset,
    resulting in 74,477 samples for model training. |'
  id: totrans-230
  prefs: []
  type: TYPE_TB
  zh: '| NeuralPlexer [[81](#bib.bib81)] | 基于2022年4月访问的PDB构建的新数据集PL2019-74k。PL2019-74k通过去除2019年1月之后提交的样本和PocketMiner数据集中具有UniProt
    ID的样本获得，总共74,477个样本用于模型训练。 |'
- en: 'TABLE V: Training setting, testing setting, and test performance of binding
    affinity prediction models.'
  id: totrans-231
  prefs: []
  type: TYPE_NORMAL
  zh: 表 V：结合亲和力预测模型的训练设置、测试设置和测试性能。
- en: Method Year Training set Testing set RMSE ($\downarrow$) PCC ($\uparrow$) Pafnucy [[96](#bib.bib96)]
    2018 PDBbind v2016 general set (N=11,906) PDBbind v2016 core set (N=290) 1.420
    0.780 DeepAtom [[97](#bib.bib97)] 2019 PDBbind v2016 refined set (N=3,390) PDBbind
    v2016 core set (N=290) 1.318 0.807 OnionNet [[138](#bib.bib138)] 2019 PDBbind
    v2016 general set (N=11,906) PDBbind v2016 core set (N=290) 1.287 0.816 PIGNet [[86](#bib.bib86)]
    2021 PDBbind v2019 refined augment set (N=1,656,600) PDBbind v2016 core set (N=283)
    - 0.749 Fusion [[101](#bib.bib101)] 2021 PDBbind v2016 general set (N=-) PDBbind
    v2016 core set (N=290) 1.270 0.820 OnionNet-2 [[139](#bib.bib139)] 2021 PDBbind
    v2019 general set (N=17,367) PDBbind v2016 core set (N=285) 1.164 0.864 IGN [[90](#bib.bib90)]
    2021 PDBbind v2016 general set (N=8,298) PDBbind v2016 core set (N=262) 1.220
    0.837 SIGN [[21](#bib.bib21)] 2021 PDBbind v2016 refined set (N=3,390) PDBbind
    v2016 core set (N=290) 1.316 0.797 PLIG [[88](#bib.bib88)] 2022 PDBbind v2020
    general set + PDBbind v2016 refined set (N=19,451) PDBbind v2016 core set (N=285)
    1.210 0.840 PaxNet [[89](#bib.bib89)] 2022 PDBbind v2016 refined set (N=3,390)
    PDBbind v2016 core set (N=290) 1.263 0.815 GLI [[140](#bib.bib140)] 2022 PDBbind
    v2016 refined set (N=3,390) PDBbind v2016 core set (N=290) 1.294 - GIGN [[91](#bib.bib91)]
    2023 PDBbind v2016 general set (N=11,906) PDBbind v2016 core set (N=290) 1.190
    0.840 KIDA [[100](#bib.bib100)] 2023 PDBbind v2016 general set (N=12,500) PDBbind
    v2016 core set (N=285) 1.291 0.837 GraphscoreDTA [[92](#bib.bib92)] 2023 PDBbind
    v2019 general set (N=9,869) PDBbind v2016 core set (N=279) 1.249 0.831 PLANET [[93](#bib.bib93)]
    2023 PDBbind v2020 general set (N=15,616) PDBbind v2016 core set (N=285) 1.247
    0.824 MBP [[95](#bib.bib95)] 2023 PDBbind v2016 refined set (N=3,390) PDBbind
    v2016 core set (N=290) 1.263 0.825
  id: totrans-232
  prefs: []
  type: TYPE_NORMAL
  zh: 方法 年份 训练集 测试集 RMSE ($\downarrow$) PCC ($\uparrow$) Pafnucy [[96](#bib.bib96)]
    2018 PDBbind v2016 普通集 (N=11,906) PDBbind v2016 核心集 (N=290) 1.420 0.780 DeepAtom [[97](#bib.bib97)]
    2019 PDBbind v2016 精细集 (N=3,390) PDBbind v2016 核心集 (N=290) 1.318 0.807 OnionNet [[138](#bib.bib138)]
    2019 PDBbind v2016 普通集 (N=11,906) PDBbind v2016 核心集 (N=290) 1.287 0.816 PIGNet [[86](#bib.bib86)]
    2021 PDBbind v2019 精细增强集 (N=1,656,600) PDBbind v2016 核心集 (N=283) - 0.749 Fusion [[101](#bib.bib101)]
    2021 PDBbind v2016 普通集 (N=-) PDBbind v2016 核心集 (N=290) 1.270 0.820 OnionNet-2 [[139](#bib.bib139)]
    2021 PDBbind v2019 普通集 (N=17,367) PDBbind v2016 核心集 (N=285) 1.164 0.864 IGN [[90](#bib.bib90)]
    2021 PDBbind v2016 普通集 (N=8,298) PDBbind v2016 核心集 (N=262) 1.220 0.837 SIGN [[21](#bib.bib21)]
    2021 PDBbind v2016 精细集 (N=3,390) PDBbind v2016 核心集 (N=290) 1.316 0.797 PLIG [[88](#bib.bib88)]
    2022 PDBbind v2020 普通集 + PDBbind v2016 精细集 (N=19,451) PDBbind v2016 核心集 (N=285)
    1.210 0.840 PaxNet [[89](#bib.bib89)] 2022 PDBbind v2016 精细集 (N=3,390) PDBbind
    v2016 核心集 (N=290) 1.263 0.815 GLI [[140](#bib.bib140)] 2022 PDBbind v2016 精细集
    (N=3,390) PDBbind v2016 核心集 (N=290) 1.294 - GIGN [[91](#bib.bib91)] 2023 PDBbind
    v2016 普通集 (N=11,906) PDBbind v2016 核心集 (N=290) 1.190 0.840 KIDA [[100](#bib.bib100)]
    2023 PDBbind v2016 普通集 (N=12,500) PDBbind v2016 核心集 (N=285) 1.291 0.837 GraphscoreDTA [[92](#bib.bib92)]
    2023 PDBbind v2019 普通集 (N=9,869) PDBbind v2016 核心集 (N=279) 1.249 0.831 PLANET [[93](#bib.bib93)]
    2023 PDBbind v2020 普通集 (N=15,616) PDBbind v2016 核心集 (N=285) 1.247 0.824 MBP [[95](#bib.bib95)]
    2023 PDBbind v2016 精细集 (N=3,390) PDBbind v2016 核心集 (N=290) 1.263 0.825
- en: 3.3 *De Novo* Ligand Generation
  id: totrans-233
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 3.3 *De Novo* 配体生成
- en: 3.3.1 Problem Formulation
  id: totrans-234
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.3.1 问题表述
- en: The goal of *de novo* ligand generation is to generate valid 3D molecular structures
    that can fit and bind to specific protein binding sites. De novo generation involves
    generating a molecule while no reference ligand molecule is given, i.e., developing
    molecules from scratch. Formally, let $\mathcal{P}$ denote the protein structure
    and $\mathcal{G}$ be the 3D ligand molecule. The objective is to learn a conditional
    generative model $p(\mathcal{G}|\mathcal{P})$ to capture the distribution of protein-ligand
    pairs.
  id: totrans-235
  prefs: []
  type: TYPE_NORMAL
  zh: '*de novo* 配体生成的目标是生成有效的三维分子结构，这些结构可以适配并结合特定的蛋白质结合位点。*de novo* 生成涉及在没有参考配体分子的情况下生成一个分子，即从头开发分子。正式地，设
    $\mathcal{P}$ 表示蛋白质结构，$\mathcal{G}$ 为三维配体分子。目标是学习一个条件生成模型 $p(\mathcal{G}|\mathcal{P})$
    以捕捉蛋白质-配体对的分布。'
- en: 3.3.2 Representative Methods
  id: totrans-236
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.3.2 代表性方法
- en: Early methods on *de novo* ligand generation represent the target protein as
    a 3D grid and employ 3D CNN as the encoder. For example, LiGAN [[141](#bib.bib141)]
    uses a conditional variational autoencoder trained on atomic density grid representations
    of protein-ligand structures for ligand generation. The molecular structures of
    ligands are then constructed by further atom fitting and bond inference from the
    generated atom densities. However, as a preliminary work, LiGAN does not satisfy
    the desirable equivariance property.
  id: totrans-237
  prefs: []
  type: TYPE_NORMAL
  zh: 早期的 *de novo* 配体生成方法将目标蛋白质表示为 3D 网格，并使用 3D CNN 作为编码器。例如，**LiGAN** [[141](#bib.bib141)]
    使用条件变分自编码器，在蛋白质-配体结构的原子密度网格表示上进行训练以生成配体。然后，通过进一步的原子拟合和从生成的原子密度中推断键，构建配体的分子结构。然而，作为初步工作，**LiGAN**
    并不满足期望的等变性属性。
- en: The follow-up methods represent the target protein and ligand as 3D graphs/point
    clouds, and the equivariance is achieved by leveraging equivariant GNNs for context
    encoding. For example, 3DSBDD [[142](#bib.bib142)] uses SchNet [[143](#bib.bib143)]
    to encode the 3D context of binding sites and estimate the probability density
    of atom’s occurrences in 3D space. The atoms are sampled auto-regressively until
    there is no room for new atoms. GraphBP [[144](#bib.bib144)] adopts the framework
    of normalizing flow [[145](#bib.bib145)] and constructs local coordinate systems
    to predict atom types and relative positions.
  id: totrans-238
  prefs: []
  type: TYPE_NORMAL
  zh: 后续方法将目标蛋白质和配体表示为 3D 图/点云，通过利用等变 GNN 进行上下文编码来实现等变性。例如，**3DSBDD** [[142](#bib.bib142)]
    使用 **SchNet** [[143](#bib.bib143)] 编码结合位点的 3D 上下文，并估计原子在 3D 空间中出现的概率密度。原子是自回归地采样，直到没有空间容纳新原子为止。**GraphBP**
    [[144](#bib.bib144)] 采用正则化流 [[145](#bib.bib145)] 框架，构建局部坐标系统来预测原子类型和相对位置。
- en: Pocket2Mol [[19](#bib.bib19)] adopts the geometric vector perceptrons [[146](#bib.bib146)]
    and the vector-based neural network [[147](#bib.bib147)] as the context encoder.
    Inspired by AlphaFold [[7](#bib.bib7)] for protein structure prediction, Pocket2Mol
    incorporates a triangular self-attention in the encoder, where the attention bias
    is designed to capture the geometric constraints. Pocket2Mol jointly predicts
    frontier atoms, atomic positions, atom types, and covalent chemical bonds. With
    vector-based neurons, Pocket2Mol can efficiently sample drug molecules from tractable
    distributions without relying on MCMC.
  id: totrans-239
  prefs: []
  type: TYPE_NORMAL
  zh: '**Pocket2Mol** [[19](#bib.bib19)] 采用几何向量感知机 [[146](#bib.bib146)] 和基于向量的神经网络
    [[147](#bib.bib147)] 作为上下文编码器。受到 **AlphaFold** [[7](#bib.bib7)] 在蛋白质结构预测中的启发，**Pocket2Mol**
    在编码器中引入了三角形自注意力，其中注意力偏置设计用于捕捉几何约束。**Pocket2Mol** 共同预测前沿原子、原子位置、原子类型和共价化学键。通过基于向量的神经元，**Pocket2Mol**
    可以高效地从可处理的分布中采样药物分子，而无需依赖 MCMC。'
- en: 'By leveraging the chemical priors of molecular fragments such as functional
    groups, FLAG [[69](#bib.bib69)] and DrugGPS [[108](#bib.bib108)] propose to generate
    ligand molecules fragment-by-fragment and yield more realistic substructures.
    For example, in FLAG [[69](#bib.bib69)], a motif vocabulary is firstly constructed
    by preprocessing the dataset and extracting molecular fragments with high occurrence
    frequencies (i.e., motif). Drug molecules are constructed auto-regressively in
    the generation process with motifs as the building blocks. At each generation
    step, as shown in Figure [6](#S3.F6 "Figure 6 ‣ 3.3.2 Representative Methods ‣
    3.3 De Novo Ligand Generation ‣ 3 Structure-based Drug Design Tasks ‣ Geometric
    Deep Learning for Structure-Based Drug Design: A Survey"), a 3D graph neural network
    encodes the intermediate context information, selects the focal motif, predicts
    the next motif type, and attaches the new motif to the generated molecule. Since
    the bond lengths/angles are largely determined, FLAG leverages cheminformatics
    tools [[148](#bib.bib148)] to effectively determine them and focus on training
    neural networks for rotation angle prediction.'
  id: totrans-240
  prefs: []
  type: TYPE_NORMAL
  zh: '通过利用分子片段的化学先验知识，如功能基团，**FLAG** [[69](#bib.bib69)] 和 **DrugGPS** [[108](#bib.bib108)]
    提出了逐片段生成配体分子的方案，从而产生更为真实的子结构。例如，在 **FLAG** [[69](#bib.bib69)] 中，首先通过预处理数据集并提取高频出现的分子片段（即**动机**）来构建一个动机词汇表。在生成过程中，药物分子是以动机为构建块自回归地生成的。在每个生成步骤中，如图
    [6](#S3.F6 "Figure 6 ‣ 3.3.2 Representative Methods ‣ 3.3 De Novo Ligand Generation
    ‣ 3 Structure-based Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based
    Drug Design: A Survey") 所示，3D 图神经网络对中间上下文信息进行编码，选择焦点动机，预测下一个动机类型，并将新动机附加到生成的分子上。由于键长/角度在很大程度上已确定，**FLAG**
    利用化学信息学工具 [[148](#bib.bib148)] 有效地确定这些参数，并专注于训练神经网络以预测旋转角度。'
- en: 'Building based on FLAG [[69](#bib.bib69)], DrugGPS [[108](#bib.bib108)] further
    considers the generalizability issue of structure-based drug design models: the
    amount of high-quality protein-ligand complex data is rather limited and the target
    protein pocket may not be in the training dataset. The trained model struggles
    to generate good drug candidates for the unseen target protein. DrugGPS[[108](#bib.bib108)]
    effectively incorporates the protein subpocket prior to generalizable drug molecule
    generation. Although two protein pockets might be dissimilar overall, they may
    still bind the same fragment if they share similar subpockets [[149](#bib.bib149)].
    To capture the subpocket-level similarities/invariance among the binding pockets,
    DrugGPS[[108](#bib.bib108)] proposes to learn subpocket prototypes and construct
    a global interaction graph to model the subpocket prototype-molecular motif interactions
    during training.'
  id: totrans-241
  prefs: []
  type: TYPE_NORMAL
  zh: 基于 FLAG [[69](#bib.bib69)]，DrugGPS [[108](#bib.bib108)] 进一步考虑了基于结构的药物设计模型的泛化问题：高质量蛋白质-配体复合物数据量非常有限，而且目标蛋白质口袋可能不在训练数据集中。训练好的模型难以为未见过的目标蛋白质生成良好的药物候选物。DrugGPS[[108](#bib.bib108)]
    有效地结合了蛋白质子口袋先验，以实现具有泛化能力的药物分子生成。尽管两个蛋白质口袋整体上可能不相似，但如果它们共享类似的子口袋，它们仍可能结合相同的片段 [[149](#bib.bib149)]。为了捕捉结合口袋之间的子口袋级别的相似性/不变性，DrugGPS[[108](#bib.bib108)]
    提出了学习子口袋原型，并在训练过程中构建全局交互图来建模子口袋原型-分子基序之间的相互作用。
- en: Recently, motivated by the powerful generation capability of the Diffusion models,
    Diffusion-based methods such as DiffSBDD [[1](#bib.bib1)], TargetDiff [[114](#bib.bib114)],
    and DecompDiff [[116](#bib.bib116)] are proposed for non-autoregressive ligand
    generation and achieve superior performance. For example, TargetDiff [[114](#bib.bib114)]
    learns a joint drug molecule generative process of both continuous atom coordinates
    and categorical atom types with an SE(3)-equivariant network conditioned on the
    protein pocket. Further studies show that TargetDiff [[114](#bib.bib114)] can
    also extract representative features from protein-ligand complexes to estimate
    the binding affinity, providing an effective virtual screening method. Inspired
    by pharmaceutical practices, DecompDiff [[116](#bib.bib116)] considers different
    roles of atoms in the ligand and decomposes the ligand molecule and prior into
    two parts, namely arms and scaffold for drug design. The arms are responsible
    for the interactions with the binding regions for higher affinity, whereas the
    scaffold’s role involves placing the arms accurately within the intended binding
    regions. Moreover, DecompDiff [[116](#bib.bib116)] incorporates both bond diffusion
    in the model and additional validity guidance in the sampling phase to improve
    the properties of the generated molecules.
  id: totrans-242
  prefs: []
  type: TYPE_NORMAL
  zh: 最近，受到扩散模型强大生成能力的激励，基于扩散的方法，如DiffSBDD [[1](#bib.bib1)]、TargetDiff [[114](#bib.bib114)]
    和 DecompDiff [[116](#bib.bib116)]，被提出用于非自回归配体生成，并取得了优越的性能。例如，TargetDiff [[114](#bib.bib114)]
    学习了一个联合药物分子生成过程，该过程涉及连续原子坐标和分类原子类型，并采用了以蛋白质口袋为条件的SE(3)-等变网络。进一步的研究表明，TargetDiff [[114](#bib.bib114)]
    还可以从蛋白质-配体复合物中提取代表性特征来估计结合亲和力，提供了一种有效的虚拟筛选方法。受到制药实践的启发，DecompDiff [[116](#bib.bib116)]
    考虑了配体中原子的不同角色，将配体分子和先验分解为两个部分，即药物设计中的臂和支架。臂负责与结合区域的相互作用以提高亲和力，而支架的角色则是将臂准确地放置在预期的结合区域内。此外，DecompDiff [[116](#bib.bib116)]
    在模型中结合了键的扩散，并在采样阶段增加了额外的有效性指导，以改善生成分子的性质。
- en: 'TABLE VI: Comparison of the properties of the reference molecules and the generated
    molecules by different *de novo* ligand generation methods. Vina Score indicates
    the Vina scoring function is directly calculated without ligand redocking or local
    optimization. Vina Min denotes that the ligand is locally minimized. Vina Dock
    indicates the ligand is locally optimized and redocked.'
  id: totrans-243
  prefs: []
  type: TYPE_NORMAL
  zh: '表 VI: 不同的*de novo* 配体生成方法对参考分子和生成分子的属性进行比较。Vina Score 表示 Vina 评分函数是在没有配体重新对接或局部优化的情况下直接计算的。Vina
    Min 表示配体在局部进行了最小化。Vina Dock 表示配体在局部优化并重新对接。'
- en: <svg version="1.1" height="19.07" width="79.26" overflow="visible"><g transform="translate(0,19.07)
    scale(1,-1)"><g  transform="translate(0,0)"><g transform="translate(0,9.61) scale(1,
    -1)"><foreignobject width="37.67" height="9.61" overflow="visible">Model</foreignobject></g></g>
    <g  transform="translate(39.63,9.61)"><g transform="translate(0,9.46) scale(1,
    -1)"><foreignobject width="39.63" height="9.46" overflow="visible">Metric</foreignobject></g></g></g></svg>
    Vina Score ($\downarrow$) Vina Min ($\downarrow$) Vina Dock ($\downarrow$) High
    Affinity ($\uparrow$) QED ($\uparrow$) SA ($\uparrow$) Diversity ($\uparrow$)
    Avg. Med. Avg. Med. Avg. Med. Avg. Med. Avg. Med. Avg. Med. Avg. Med. Reference
    -6.36 -6.46 -6.71 -6.49 -7.45 -7.26 - - 0.48 0.47 0.73 0.74 - - liGAN [[103](#bib.bib103)]
    - - - - -6.33 -6.20 21.1% 11.1% 0.39 0.39 0.59 0.57 0.66 0.67 GraphBP [[110](#bib.bib110)]
    - - - - -4.80 -4.70 14.2% 6.7% 0.43 0.45 0.49 0.48 0.79 0.78 3DSBDD [[2](#bib.bib2)]
    -5.75 -5.64 -6.18 -5.88 -6.75 -6.62 37.9% 31.0% 0.51 0.50 0.63 0.63 0.70 0.70
    Pocket2Mol [[19](#bib.bib19)] -5.14 -4.70 -6.42 -5.82 -7.15 -6.79 48.4% 51.0%
    0.56 0.57 0.74 0.75 0.69 0.71 TargetDiff [[114](#bib.bib114)] -5.47 -6.30 -6.64
    -6.83 -7.80 -7.91 58.1% 59.1% 0.48 0.48 0.58 0.58 0.72 0.71 FLAG [[69](#bib.bib69)]
    -5.30 -5.89 -6.46 -6.68 -7.25 -7.17 53.7% 54.8% 0.50 0.51 0.75 0.72 0.70 0.73
    DrugGPS[[108](#bib.bib108)] -5.45 -5.81 -6.49 -6.88 -7.36 -7.42 54.9% 55.7% 0.59
    0.58 0.72 0.73 0.71 0.74 Decompdiff[[116](#bib.bib116)] -5.67 -6.04 -7.04 -7.09
    -8.39 -8.43 64.4% 71.0% 0.45 0.43 0.61 0.60 0.68 0.68 ![Refer to caption](img/de8644eadc31b8268420a42e5aa8bef6.png)
  id: totrans-244
  prefs: []
  type: TYPE_NORMAL
  zh: <svg version="1.1" height="19.07" width="79.26" overflow="visible"><g transform="translate(0,19.07)
    scale(1,-1)"><g  transform="translate(0,0)"><g transform="translate(0,9.61) scale(1,
    -1)"><foreignobject width="37.67" height="9.61" overflow="visible">模型</foreignobject></g></g>
    <g  transform="translate(39.63,9.61)"><g transform="translate(0,9.46) scale(1,
    -1)"><foreignobject width="39.63" height="9.46" overflow="visible">指标</foreignobject></g></g></g></svg>
    Vina 评分 ($\downarrow$) Vina 最小 ($\downarrow$) Vina 对接 ($\downarrow$) 高亲和力 ($\uparrow$)
    QED ($\uparrow$) SA ($\uparrow$) 多样性 ($\uparrow$) 平均值 中位数 平均值 中位数 平均值 中位数 平均值
    中位数 平均值 中位数 平均值 中位数 平均值 中位数 参考 -6.36 -6.46 -6.71 -6.49 -7.45 -7.26 - - 0.48 0.47
    0.73 0.74 - - liGAN [[103](#bib.bib103)] - - - - -6.33 -6.20 21.1% 11.1% 0.39
    0.39 0.59 0.57 0.66 0.67 GraphBP [[110](#bib.bib110)] - - - - -4.80 -4.70 14.2%
    6.7% 0.43 0.45 0.49 0.48 0.79 0.78 3DSBDD [[2](#bib.bib2)] -5.75 -5.64 -6.18 -5.88
    -6.75 -6.62 37.9% 31.0% 0.51 0.50 0.63 0.63 0.70 0.70 Pocket2Mol [[19](#bib.bib19)]
    -5.14 -4.70 -6.42 -5.82 -7.15 -6.79 48.4% 51.0% 0.56 0.57 0.74 0.75 0.69 0.71
    TargetDiff [[114](#bib.bib114)] -5.47 -6.30 -6.64 -6.83 -7.80 -7.91 58.1% 59.1%
    0.48 0.48 0.58 0.58 0.72 0.71 FLAG [[69](#bib.bib69)] -5.30 -5.89 -6.46 -6.68
    -7.25 -7.17 53.7% 54.8% 0.50 0.51 0.75 0.72 0.70 0.73 DrugGPS [[108](#bib.bib108)]
    -5.45 -5.81 -6.49 -6.88 -7.36 -7.42 54.9% 55.7% 0.59 0.58 0.72 0.73 0.71 0.74
    Decompdiff [[116](#bib.bib116)] -5.67 -6.04 -7.04 -7.09 -8.39 -8.43 64.4% 71.0%
    0.45 0.43 0.61 0.60 0.68 0.68 ![参考图示](img/de8644eadc31b8268420a42e5aa8bef6.png)
- en: 'Figure 6: Overview of FLAG [[69](#bib.bib69)] for *de novo* ligand generation.
    There are four steps in each iteration: (a) context encoding and focal motif selection,
    (b) next motif prediction, (c) motif attachments enumeration and prediction, and
    (d) rotation angle prediction and structure refinement.'
  id: totrans-245
  prefs: []
  type: TYPE_NORMAL
  zh: 图 6：FLAG [[69](#bib.bib69)] 用于*de novo* 配体生成的概述。每次迭代包含四个步骤：（a）上下文编码和焦点基序选择，（b）下一个基序预测，（c）基序附加枚举和预测，以及（d）旋转角度预测和结构优化。
- en: 3.3.3 Datasets
  id: totrans-246
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.3.3 数据集
- en: CrossDocked dataset [[150](#bib.bib150)] is widely used in structure-based *de
    novo* ligand design [[2](#bib.bib2), [19](#bib.bib19)], which contains 22.5 million
    protein-molecule structures by cross-docking the Protein Data Bank [[122](#bib.bib122)].
    Considering the variability in the cross-docked complex qualities, existing methods
    typically employ filtering steps. After filtering out data points whose binding
    pose RMSD is greater than 1 Å, a refined subset with around 180,000 data points
    is obtained. For the dataset split, mmseqs2 [[151](#bib.bib151)] is widely used
    to cluster data at 30$\%$ sequence identity, 100,000 protein-ligand pairs are
    randomly drawn for training and 100 proteins from the remaining clusters for testing.
    One hundred molecules for each protein pocket in the test set are sampled to evaluate
    generative models.
  id: totrans-247
  prefs: []
  type: TYPE_NORMAL
  zh: CrossDocked 数据集 [[150](#bib.bib150)] 广泛用于基于结构的*de novo* 配体设计 [[2](#bib.bib2),
    [19](#bib.bib19)]，其中包含通过交叉对接蛋白质数据银行 [[122](#bib.bib122)] 获得的2250万蛋白质-分子结构。考虑到交叉对接复合物质量的变异，现有方法通常采用过滤步骤。在过滤掉结合位点
    RMSD 大于 1 Å 的数据点后，获得了一个包含大约 180,000 个数据点的精炼子集。对于数据集拆分，mmseqs2 [[151](#bib.bib151)]
    广泛用于在 30$\%$ 序列同一性下进行数据聚类，从剩余簇中随机抽取 100,000 对蛋白质-配体对用于训练，从剩余簇中抽取 100 个蛋白质用于测试。测试集中每个蛋白质口袋抽取
    100 个分子用于评估生成模型。
- en: Binding MOAD [[152](#bib.bib152)] contains experimentally determined complexed
    protein-ligand structures. The dataset is filtered and split based on the proteins’
    enzyme commission number [[153](#bib.bib153)]. Specifically, the split ensures
    different sets do not contain proteins from the same Enzyme Commission Number
    (EC Number) main class. Finally, there are 40,354 protein-ligand pairs for training
    and 130 for testing.
  id: totrans-248
  prefs: []
  type: TYPE_NORMAL
  zh: Binding MOAD [[152](#bib.bib152)] 包含实验上确定的复合蛋白-配体结构。数据集根据蛋白质的酶委员会编号[[153](#bib.bib153)]进行了筛选和拆分。具体来说，拆分确保不同的数据集中不包含来自相同酶委员会编号（EC编号）主类的蛋白质。最终，有40,354对蛋白质-配体对用于训练，130对用于测试。
- en: 3.3.4 Evaluation Metrics
  id: totrans-249
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.3.4 评价指标
- en: 'The following metrics are widely used in related works [[2](#bib.bib2), [19](#bib.bib19),
    [144](#bib.bib144), [108](#bib.bib108), [69](#bib.bib69)] to evaluate the qualities
    of the sampled molecules: (1) Validity is the percentage of chemically valid molecules
    among all generated molecules. A molecule is valid if it can be sanitized by RDkit
    [[148](#bib.bib148)]. (2) Vina Score measures the binding affinity between the
    generated molecules and the protein pockets. It can be calculated with traditional
    docking methods such as AutoDock Vina [[137](#bib.bib137), [154](#bib.bib154)]
    or trained CNN scoring functions [[155](#bib.bib155)]. Before calculating the
    vina score, the generated molecular structures are refined by universal force
    fields [[156](#bib.bib156)]. (3) High Affinity is calculated as the percentage
    of pockets whose generated molecules have higher affinity to the references in
    the test set. (3) QED measures how likely a molecule is a potential drug candidate.
    (4) Synthetic Accessibility (SA) indicates the difficulty of drug synthesis (the
    score is normalized between 0 and 1, and higher values indicate more accessible
    synthesis). (5) LogP is the octanol-water partition coefficient (LogP values should
    be between -0.4 and 5.6 to be promising drug candidates [[157](#bib.bib157)]).
    (6) Lipinski (Lip.) calculates how many rules the molecule obeys the Lipinski’s
    rule of five [[158](#bib.bib158)]. (7) Sim. Train represents the Tanimoto similarity
    [[159](#bib.bib159)] with the most similar molecules in the training set. (8)
    Diversity (Div.) measures the diversity of generated molecules for a binding pocket
    (It is calculated as 1 - average pairwise Tanimoto similarities). (9) Time records
    the cost of generating 100 valid molecules for a pocket.'
  id: totrans-250
  prefs: []
  type: TYPE_NORMAL
  zh: 以下指标在相关研究中广泛使用[[2](#bib.bib2), [19](#bib.bib19), [144](#bib.bib144), [108](#bib.bib108),
    [69](#bib.bib69)]来评估采样分子的质量：（1）有效性是指所有生成的分子中化学有效分子的百分比。如果分子可以通过RDkit [[148](#bib.bib148)]进行清理，则认为它是有效的。（2）Vina
    Score 测量生成的分子与蛋白质口袋之间的结合亲和力。它可以通过传统的对接方法，如AutoDock Vina [[137](#bib.bib137), [154](#bib.bib154)]，或训练的CNN评分函数[[155](#bib.bib155)]来计算。在计算Vina
    Score之前，生成的分子结构会通过通用力场[[156](#bib.bib156)]进行优化。（3）高亲和力计算为生成的分子对测试集中参考物质具有更高亲和力的口袋的百分比。（4）QED
    衡量分子作为潜在药物候选者的可能性。（5）合成可及性（SA）表示药物合成的难度（分数在0到1之间标准化，较高的值表示更易于合成）。（6）LogP 是辛醇-水分配系数（LogP值应在-0.4到5.6之间，才是有前景的药物候选者[[157](#bib.bib157)]）。（7）Lipinski（Lip.）计算分子遵循Lipinski五规则的数量[[158](#bib.bib158)]。（8）Sim.
    Train 表示与训练集中最相似分子的Tanimoto相似性[[159](#bib.bib159)]。（9）Diversity (Div.) 测量生成的分子对结合口袋的多样性（计算为1
    - 平均对比Tanimoto相似性）。(10) Time 记录生成100个有效分子的时间成本。
- en: 3.3.5 Bechmark Performance
  id: totrans-251
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.3.5 性能基准
- en: 'We benchmark representative *de novo* ligand generation methods on the CrossDocked
    dataset in Table [VI](#S3.T6 "Table VI ‣ 3.3.2 Representative Methods ‣ 3.3 De
    Novo Ligand Generation ‣ 3 Structure-based Drug Design Tasks ‣ Geometric Deep
    Learning for Structure-Based Drug Design: A Survey"). Generally, there is not
    a single method that is optimal on all the metrics. We can observe that diffusion-based
    methods achieve the best performance on binding affinity (Vina-related metrics).
    This may be attributed to their non-autoregressive generation scheme that facilitates
    global optimization. As for QED and SA, fragment-based methods such as DrugGPS
    achieve the most competitive performance. This may be explained by incorporating
    drug-like fragments, effectively increasing drug-likeliness and synthesizability.'
  id: totrans-252
  prefs: []
  type: TYPE_NORMAL
  zh: '我们在表 [VI](#S3.T6 "Table VI ‣ 3.3.2 Representative Methods ‣ 3.3 De Novo Ligand
    Generation ‣ 3 Structure-based Drug Design Tasks ‣ Geometric Deep Learning for
    Structure-Based Drug Design: A Survey")上基准测试了代表性的*de novo*配体生成方法。通常，没有一种方法在所有指标上都是最优的。我们可以观察到，基于扩散的方法在结合亲和力（Vina相关指标）上表现最佳。这可能归因于其非自回归生成方案，促进了全局优化。至于QED和SA，基于片段的方法，如DrugGPS，表现最为竞争力。这可以通过引入类药物片段来解释，这有效地提高了药物样性和合成性。'
- en: 3.3.6 Limitations and Future Directions
  id: totrans-253
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.3.6 限制与未来方向
- en: 'Despite the success of applying geometric deep learning for *de novo* ligand
    generation, it is still challenging to explore the vast chemical space and generate
    high-quality drug candidates with satisfied properties. Generally, current methods
    have the following limitations and require further explorations: (1) failing to
    consider essential chemical priors; (2) lacking ligand optimization methods; (3)
    noncomprehensive evaluation metrics.'
  id: totrans-254
  prefs: []
  type: TYPE_NORMAL
  zh: 尽管将几何深度学习应用于*de novo*配体生成取得了成功，但探索广阔的化学空间并生成具有满意属性的高质量药物候选物仍然具有挑战性。一般来说，当前的方法存在以下限制，并需要进一步探索：（1）未能考虑基本的化学先验；（2）缺乏配体优化方法；（3）评估指标不全面。
- en: Firstly, most current methods fail to consider essential chemical priors such
    as molecular motifs and protein-ligand interaction patterns. Therefore, the generated
    ligand molecules may have invalid 3D structures and limited binding affinity with
    the target protein. FLAG [[69](#bib.bib69)] and DrugGPS [[108](#bib.bib108)] have
    tried to leverage chemical priors of motifs and subpockets in the model construction.
    In the future, we expect more methods that leverage the chemical priors for high-quality
    ligand generation.
  id: totrans-255
  prefs: []
  type: TYPE_NORMAL
  zh: 首先，大多数当前的方法未能考虑基本的化学先验，如分子基序和蛋白质-配体相互作用模式。因此，生成的配体分子可能具有无效的3D结构，并且与目标蛋白质的结合亲和力有限。FLAG
    [[69](#bib.bib69)]和DrugGPS [[108](#bib.bib108)] 已尝试在模型构建中利用基序和子口袋的化学先验。未来，我们期望有更多利用化学先验进行高质量配体生成的方法。
- en: Secondly, existing works fail to explicitly optimize drug properties in the
    generation process. In practice, it is challenging to directly generate drug candidates
    satisfying a series of property constraints. A common practice is sampling promising
    lead compounds and then conducting lead optimization. Therefore, exploring multiple-property
    optimization methods for *de novo* ligand generation is one future direction.
  id: totrans-256
  prefs: []
  type: TYPE_NORMAL
  zh: 其次，现有的工作未能在生成过程中明确优化药物属性。在实践中，直接生成满足一系列属性约束的药物候选物具有挑战性。一种常见的做法是采样有前景的先导化合物，然后进行先导优化。因此，探索多属性优化方法用于*de
    novo*配体生成是未来的一个方向。
- en: Thirdly, the current evaluation metrics are noncomprehension, and most focus
    on 2D molecule properties such as QED and SA. A recent work, PoseCheck [[160](#bib.bib160)],
    proposes four metrics to evaluate the generated molecules’ poses, including interaction
    profiles, steric clashes, strain energy, and redocking RMSD. Their evaluations
    show that the ligand molecule generated by existing methods often exhibits nonphysical
    features such as steric clashes, hydrogen placement issues, and high strain energy.
    In the future, we expect more comprehensive evaluation metrics and more advanced
    ligand generative models that address the shortcomings.
  id: totrans-257
  prefs: []
  type: TYPE_NORMAL
  zh: 第三，当前的评估指标缺乏全面性，大多集中在如QED和SA等2D分子属性上。最近的工作，PoseCheck [[160](#bib.bib160)]，提出了四个指标来评估生成分子的姿态，包括相互作用概况、空间冲突、应变能和重新对接RMSD。他们的评估显示，现有方法生成的配体分子通常表现出非物理特性，如空间冲突、氢原子定位问题和高应变能。未来，我们期望出现更全面的评估指标和更先进的配体生成模型，以解决这些不足之处。
- en: '![Refer to caption](img/e7935f22d5f3c5c82e5f22e727a5d611.png)'
  id: totrans-258
  prefs: []
  type: TYPE_IMG
  zh: '![参见说明](img/e7935f22d5f3c5c82e5f22e727a5d611.png)'
- en: 'Figure 7: Overview of DiffLinker [[121](#bib.bib121)] for linker design. The
    inputs are the molecular fragments and the protein pocket (optional). The output
    is the linker that links the fragments into a complete molecule. DiffLinker is
    an E(3)-equivariant diffusion-based model. In the generation process, the probabilities
    of linker sizes are first computed for the input fragments. Next, linker atoms
    are sampled and denoised using a conditioned equivariant diffusion model. The
    bottom shows the linker generation process with linker atoms highlighted in orange.'
  id: totrans-259
  prefs: []
  type: TYPE_NORMAL
  zh: 图 7：DiffLinker [[121](#bib.bib121)] 在链接器设计中的概述。输入是分子片段和蛋白质口袋（可选）。输出是将片段连接成完整分子的链接器。DiffLinker
    是一个 E(3) 等变的基于扩散的模型。在生成过程中，首先计算输入片段的链接器大小概率。接着，使用条件等变扩散模型对链接器原子进行采样和去噪。底部展示了链接器生成过程，链接器原子以橙色突出显示。
- en: 3.4 Linker Design
  id: totrans-260
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 3.4 链接器设计
- en: 3.4.1 Problem Formulation
  id: totrans-261
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.4.1 问题表述
- en: Most small molecular drugs bind to the target protein and inhibit its activity.
    However, due to the complexity of diseases, some amino acids in target proteins
    may mutate, leading to weak binding affinity and drug falling off. To solve this
    problem, an emerging therapeutic mechanism involving proteolysis targeting chimera
    (PROTAC) can inhibit protein functions by prompting complete degradation of the
    target protein. Specifically, PROTAC contains two molecular fragments and a linker
    that links the fragments into a complete molecule. One fragment in PROTAC binds
    the target protein and the other fragment binds another molecule that can degrade
    the target protein. Because PROTAC only requires high selectivity in binding its
    targets instead of inhibiting the target protein’s activity, much attention is
    focused on repurposing previously ineffective inhibitor molecules as PROTAC for
    the next generation of drugs. One critical problem in PROTAC is linker design,
    which generates the linker conditioned on the given fragments and the target protein.
    Formally, denote the target protein as $\mathcal{P}$, the molecular fragments
    as $\mathcal{F}$, and the linker as $\mathcal{L}$; the objective is to learn a
    conditional generative model $p(\mathcal{L}|\mathcal{F,P})$.
  id: totrans-262
  prefs: []
  type: TYPE_NORMAL
  zh: 大多数小分子药物通过结合目标蛋白质来抑制其活性。然而，由于疾病的复杂性，目标蛋白质中的某些氨基酸可能会突变，导致结合亲和力降低，药物脱落。为了解决这个问题，一种新兴的治疗机制涉及蛋白酶体靶向嵌合体（PROTAC），它通过促使目标蛋白质的完全降解来抑制蛋白质功能。具体而言，PROTAC
    包含两个分子片段和一个将这些片段连接成完整分子的链接器。PROTAC 中的一个片段结合目标蛋白质，另一个片段结合能够降解目标蛋白质的其他分子。因为 PROTAC
    只需要在结合其靶标时具有高选择性，而不是抑制目标蛋白质的活性，因此许多关注点集中在将以前无效的抑制剂分子重新利用为下一代药物的 PROTAC 上。PROTAC
    的一个关键问题是链接器设计，它根据给定的片段和目标蛋白质生成链接器。形式上，设目标蛋白质为 $\mathcal{P}$，分子片段为 $\mathcal{F}$，链接器为
    $\mathcal{L}$；目标是学习一个条件生成模型 $p(\mathcal{L}|\mathcal{F,P})$。
- en: 'TABLE VII: Linker design performance comparisons on the ZINC test sets. Given
    anchors denotes that the anchors are known to the model. Sampled size indicates
    the linker size is sampled and is not necessarily the same as the ground truth.'
  id: totrans-263
  prefs: []
  type: TYPE_NORMAL
  zh: 表 VII：在 ZINC 测试集上的链接器设计性能比较。给定的锚点表示这些锚点是已知的。采样大小表示链接器的大小是采样的，并不一定与真实情况相同。
- en: Model QED ($\uparrow$) SA ($\uparrow$) Valid ($\uparrow$) Unique ($\uparrow$)
    Novel ($\uparrow$) DeLinker[[118](#bib.bib118)] 0.64 0.77 98.3% 44.2% 47.1% 3DLinker
    [[20](#bib.bib20)] (given anchors) 0.65 0.77 99.3% 29.0% 41.2% 3DLinker [[20](#bib.bib20)]
    0.65 0.76 71.5% 29.2% 41.9% DiffLinker [[121](#bib.bib121)] 0.68 0.78 93.8% 24.0%
    30.3% DiffLinker [[121](#bib.bib121)] (given anchors) 0.68 0.77 97.6% 22.7% 32.4%
    DiffLinker [[121](#bib.bib121)] (sampled size) 0.65 0.76 90.6% 51.4% 42.9% DiffLinker
    [[121](#bib.bib121)] (given anchors, sampled size) 0.65 0.76 94.8% 50.9% 47.7%
  id: totrans-264
  prefs: []
  type: TYPE_NORMAL
  zh: 模型 QED ($\uparrow$) SA ($\uparrow$) 有效 ($\uparrow$) 唯一 ($\uparrow$) 新颖 ($\uparrow$)
    DeLinker [[118](#bib.bib118)] 0.64 0.77 98.3% 44.2% 47.1% 3DLinker [[20](#bib.bib20)]（给定锚点）
    0.65 0.77 99.3% 29.0% 41.2% 3DLinker [[20](#bib.bib20)] 0.65 0.76 71.5% 29.2%
    41.9% DiffLinker [[121](#bib.bib121)] 0.68 0.78 93.8% 24.0% 30.3% DiffLinker [[121](#bib.bib121)]（给定锚点）
    0.68 0.77 97.6% 22.7% 32.4% DiffLinker [[121](#bib.bib121)]（采样大小） 0.65 0.76 90.6%
    51.4% 42.9% DiffLinker [[121](#bib.bib121)]（给定锚点，采样大小） 0.65 0.76 94.8% 50.9% 47.7%
- en: 3.4.2 Representative Methods
  id: totrans-265
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.4.2 代表性方法
- en: DeLinker [[118](#bib.bib118)] uses VAE and autoregressively generates the atoms
    and edges of the linker. Only simple geometric information, such as the relative
    distances and orientations, is considered in DeLinker, and the output is the 2D
    molecule graph. 3Dlinker [[20](#bib.bib20)] also generates linker autoregressively
    but can further generate the 3D molecule structure without specifying the anchor
    atoms, i.e., the atoms of fragments for linking. The anchor node, next node type,
    edge, and coordinate are predicted sequentially in each step.
  id: totrans-266
  prefs: []
  type: TYPE_NORMAL
  zh: DeLinker [[118](#bib.bib118)] 使用变分自编码器（VAE）自回归地生成连接体的原子和边。在 DeLinker 中，仅考虑简单的几何信息，如相对距离和方向，输出的是二维分子图。3Dlinker
    [[20](#bib.bib20)] 也自回归地生成连接体，但可以进一步生成三维分子结构，而无需指定锚原子，即用于连接的片段的原子。锚节点、下一个节点类型、边和坐标在每一步中顺序预测。
- en: Link-INVENT [[120](#bib.bib120)] and PROTAC-INVENT [[66](#bib.bib66)] are reinforcement
    learning-based methods. Link-INVENT [[120](#bib.bib120)] expands the widely used
    REINVENT [[161](#bib.bib161)] model and incorporates a reward function to optimize
    the length, linearity, and flexibility of generated linkers. However, Link-INVENT [[120](#bib.bib120)]
    only focuses on 2D linker generation. PROTAC-INVENT [[66](#bib.bib66)] can jointly
    sample the 2D molecular graphs and the 3D structures of linkers inside the target
    protein pocket.
  id: totrans-267
  prefs: []
  type: TYPE_NORMAL
  zh: Link-INVENT [[120](#bib.bib120)] 和 PROTAC-INVENT [[66](#bib.bib66)] 是基于强化学习的方法。Link-INVENT
    [[120](#bib.bib120)] 扩展了广泛使用的 REINVENT [[161](#bib.bib161)] 模型，并结合奖励函数来优化生成的连接体的长度、线性度和灵活性。然而，Link-INVENT
    [[120](#bib.bib120)] 仅关注二维连接体的生成。PROTAC-INVENT [[66](#bib.bib66)] 可以联合采样目标蛋白质口袋内的二维分子图和三维连接体结构。
- en: 'DiffLinker [[121](#bib.bib121)] designs a conditional diffusion-based model
    that generates molecular linkers conditioned on input fragments and the target
    protein structure (optional). In the generation process (Figure [7](#S3.F7 "Figure
    7 ‣ 3.3.6 Limitations and Future Directions ‣ 3.3 De Novo Ligand Generation ‣
    3 Structure-based Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based
    Drug Design: A Survey")), the probabilities of linker sizes are first computed
    for the input fragments. Next, linker atoms are sampled and denoised using a conditioned
    equivariant diffusion model. Results show that considering the target protein
    structure improves the binding affinity of the resulting PROTAC molecules.'
  id: totrans-268
  prefs: []
  type: TYPE_NORMAL
  zh: 'DiffLinker [[121](#bib.bib121)] 设计了一种条件扩散模型，生成基于输入片段和目标蛋白质结构（可选）的分子连接体。在生成过程中（图
    [7](#S3.F7 "Figure 7 ‣ 3.3.6 Limitations and Future Directions ‣ 3.3 De Novo Ligand
    Generation ‣ 3 Structure-based Drug Design Tasks ‣ Geometric Deep Learning for
    Structure-Based Drug Design: A Survey")），首先计算输入片段的连接体尺寸的概率。接着，使用条件等变扩散模型对连接体原子进行采样和去噪。结果表明，考虑目标蛋白质结构可以提高生成的
    PROTAC 分子的结合亲和力。'
- en: 3.4.3 Datasets
  id: totrans-269
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.4.3 数据集
- en: 'Zinc [[162](#bib.bib162)] is a free database of commercially-available compounds
    for virtual screening. A subset of 250,000 molecules randomly selected by [[163](#bib.bib163)]
    is used for linker design. The dataset is preprocessed as follows: firstly, 3D
    conformers are generated using RDKit [[148](#bib.bib148)], and a reference 3D
    structure with the lowest energy conformation is selected for each molecule. Then,
    these molecules are fragmented by enumerating all double cuts of acyclic single
    bonds outside functional groups. The results are further filtered by the number
    of atoms in the linker and fragments, synthetic accessibility [[164](#bib.bib164)],
    ring aromaticity, and pan-assay interference compounds (PAINS) [[165](#bib.bib165)]
    criteria. As a result, a single molecule may yield different combinations of two
    fragments separated by a linker. The Zinc dataset is randomly split into train,
    validation, and test sets (438,610/400/400 examples).'
  id: totrans-270
  prefs: []
  type: TYPE_NORMAL
  zh: Zinc [[162](#bib.bib162)] 是一个免费提供商业化化合物的数据库，用于虚拟筛选。[[163](#bib.bib163)] 随机选择的
    250,000 个分子子集用于连接体设计。数据集的预处理如下：首先，使用 RDKit [[148](#bib.bib148)] 生成三维构象，并为每个分子选择最低能量构象的参考三维结构。然后，通过枚举功能基团外的非环状单键的所有双重切割来对这些分子进行碎片化。结果根据连接体和碎片中的原子数量、合成可及性
    [[164](#bib.bib164)]、环芳香性以及全测定干扰化合物（PAINS） [[165](#bib.bib165)] 标准进一步筛选。因此，一个分子可能产生不同的两个碎片由连接体分隔的组合。Zinc
    数据集随机拆分为训练集、验证集和测试集（438,610/400/400 个样本）。
- en: CASF [[166](#bib.bib166)] includes experimentally verified 3D conformations.
    The preprocessing procedure is the same as Zinc.
  id: totrans-271
  prefs: []
  type: TYPE_NORMAL
  zh: CASF [[166](#bib.bib166)] 包含经过实验验证的三维构象。预处理过程与 Zinc 相同。
- en: GEOM [[167](#bib.bib167)] is considered for real-world applications that require
    connecting more than two fragments with one or more linkers. The molecules are
    decomposed into three or more fragments with one or two linkers with an MMPA-based
    algorithm [[168](#bib.bib168)] and BRICS [[169](#bib.bib169)].
  id: totrans-272
  prefs: []
  type: TYPE_NORMAL
  zh: GEOM [[167](#bib.bib167)] 被考虑用于需要将多个片段通过一个或多个连接体连接起来的实际应用。这些分子被分解成三个或更多的片段，通过一个或两个连接体，使用基于
    MMPA 的算法 [[168](#bib.bib168)] 和 BRICS [[169](#bib.bib169)] 进行处理。
- en: Binding MOAD [[152](#bib.bib152)] contains experimentally determined complexed
    protein-ligand structures. DiffLinker [[121](#bib.bib121)] uses Binding MOAD to
    assess further the ability to generate valid linkers given additional information
    about protein pockets. The authors extract amino acids with at least one atom
    closer than 6 Å to any ligand atom as the pockets. The molecules are preprocessed
    into fragments using RDKit’s implementation of MMPA-based algorithm [[168](#bib.bib168)].
    The resulting dataset is split based on the proteins’ Enzyme Commission (EC) numbers.
  id: totrans-273
  prefs: []
  type: TYPE_NORMAL
  zh: Binding MOAD [[152](#bib.bib152)] 包含实验确定的复合蛋白质-配体结构。DiffLinker [[121](#bib.bib121)]
    使用 Binding MOAD 进一步评估在获得关于蛋白质口袋的额外信息的情况下生成有效连接体的能力。作者提取了与任何配体原子距离小于 6 Å 的氨基酸作为口袋。使用
    RDKit 的 MMPA 基于算法 [[168](#bib.bib168)] 对分子进行预处理。得到的数据集根据蛋白质的酶委员会 (EC) 编号进行划分。
- en: 3.4.4 Evaluation Metrics
  id: totrans-274
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.4.4 评估指标
- en: 'The following metrics are widely used to evaluate linker design methods: (1)
    Validity is the percentage of chemically valid molecules among all generated molecules.
    (2) Quantitative Estimation of Drug-likeness (QED) measures how likely a molecule
    is a potential drug candidate. (3) Synthetic Accessibility (SA) indicates the
    difficulty of drug synthesis. (4) Rings is the average number of rings in the
    linker. (5) Uniqueness measures the percentage of non-duplicate generated molecules.
    (6) Novelty calculates the ratio of generated molecules not in the training set.
    (7) Recovery records the percentage of the original molecules recovered by the
    generation process. (8) Root Mean Squared Deviation (RMSD) is calculated between
    the generated and real linker coordinates in the cases where true molecules are
    recovered. (9) $\rm RD_{scit}$ [[170](#bib.bib170)] evaluates the geometric and
    chemical similarity between the ground truth and generated molecules.'
  id: totrans-275
  prefs: []
  type: TYPE_NORMAL
  zh: 以下指标被广泛用于评估连接体设计方法：（1）有效性是所有生成的分子中化学有效分子的百分比。（2）药物相似性定量估计 (QED) 测量一个分子作为潜在药物候选者的可能性。（3）合成可及性
    (SA) 表示药物合成的难度。（4）环的数量是连接体中环的平均数量。（5）独特性测量生成的分子中非重复分子的百分比。（6）新颖性计算生成的分子不在训练集中的比例。（7）恢复率记录生成过程中恢复的原始分子的百分比。（8）均方根偏差
    (RMSD) 是在恢复真实分子的情况下，计算生成的和真实连接体坐标之间的偏差。（9）$\rm RD_{scit}$ [[170](#bib.bib170)]
    评估真实值和生成分子之间的几何和化学相似性。
- en: 3.4.5 Benchmark Performance
  id: totrans-276
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.4.5 基准性能
- en: 'We benchmark representative linker design methods on the Zinc dataset in Table [VII](#S3.T7
    "Table VII ‣ 3.4.1 Problem Formulation ‣ 3.4 Linker Design ‣ 3 Structure-based
    Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based Drug Design: A
    Survey"). In the default setting, all the methods generate the linker the same
    size as the ground truth. DiffLinker [[121](#bib.bib121)] as the state-of-the-art
    method achieves the best results on molecule drug-likeliness and synthesizability.
    We also note that sampling the linker size can significantly improve novelty and
    uniqueness of the generated linkers without much degradation of the other important
    metrics.'
  id: totrans-277
  prefs: []
  type: TYPE_NORMAL
  zh: '我们在表 [VII](#S3.T7 "Table VII ‣ 3.4.1 Problem Formulation ‣ 3.4 Linker Design
    ‣ 3 Structure-based Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based
    Drug Design: A Survey") 上对 Zinc 数据集中的代表性连接体设计方法进行了基准测试。在默认设置下，所有方法生成的连接体与真实值的大小相同。作为最先进方法的
    DiffLinker [[121](#bib.bib121)] 在分子药物相似性和可合成性上取得了最佳结果。我们还注意到，采样连接体大小可以显著提高生成连接体的独特性和新颖性，而不会对其他重要指标造成太大退化。'
- en: 3.4.6 Limitations and Future Directions
  id: totrans-278
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.4.6 局限性和未来方向
- en: Although impressive progress has been obtained for linker design with geometric
    deep learning, there remain open questions. Firstly, most existing methods fail
    to consider the protein pocket context. The generated molecules may have steric
    clashes or inferior binding affinities with the target protein. We are glad to
    see some recent methods, such as DiffLinker [[121](#bib.bib121)], manage to design
    linkers conditioned on the pocket and expect to see more progress in this direction.
    Secondly, existing models for linker design assume that the relative positions
    of the fragments are known, which may not be practical in real scenarios. Generative
    models that co-design both fragment poses and linkers are more favorable.
  id: totrans-279
  prefs: []
  type: TYPE_NORMAL
  zh: 尽管几何深度学习在连接体设计方面取得了令人印象深刻的进展，但仍然存在一些未解的问题。首先，大多数现有方法未能考虑蛋白质口袋的上下文。生成的分子可能会与目标蛋白质发生空间冲突或具有较差的结合亲和力。我们很高兴看到一些近期的方法，例如
    DiffLinker [[121](#bib.bib121)]，能够在口袋条件下设计连接体，并期待在这方面有更多进展。其次，现有的连接体设计模型假设片段的相对位置是已知的，但在实际情况中可能并不实用。共同设计片段姿势和连接体的生成模型更具优势。
- en: 3.5 Binding Affinity Prediction
  id: totrans-280
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 3.5 结合亲和力预测
- en: 3.5.1 Problem Formulation
  id: totrans-281
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.5.1 问题表述
- en: Protein-ligand binding affinity is a measurement of interaction strength. Accurate
    affinity prediction helps design effective drug molecules and plays a vital role
    in SBDD. Formally, denoted the bound protein structure as $\mathcal{P}$, the bound
    ligand as $\mathcal{L}$, and the binding affinity as $y$, our target is to train
    a model $f(\mathcal{P},\mathcal{L})=y$ for binding affinity prediction.
  id: totrans-282
  prefs: []
  type: TYPE_NORMAL
  zh: 蛋白质-配体结合亲和力是衡量相互作用强度的指标。准确的亲和力预测有助于设计有效的药物分子，并在结构基础药物设计（SBDD）中发挥重要作用。形式上，将结合蛋白质结构记作
    $\mathcal{P}$，结合配体记作 $\mathcal{L}$，结合亲和力记作 $y$，我们的目标是训练一个模型 $f(\mathcal{P},\mathcal{L})=y$
    以进行结合亲和力预测。
- en: 3.5.2 Representative Methods
  id: totrans-283
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.5.2 代表性方法
- en: 'The exploration of binding affinity prediction methods has a long-standing
    history. Early studies focused on utilizing empirical formulas [[171](#bib.bib171)]
    or designing handcrafted features coupled with traditional machine learning algorithms
    for binding affinity prediction [[172](#bib.bib172)]. Despite some advancements,
    these methods have limited prediction accuracy and require considerable feature
    engineering to perform well. Recent research has highlighted the application of
    geometric deep learning methods, representing the protein-ligand complex structure
    as 3D grids or 3D graphs for processing and prediction. These approaches directly
    model the relationship between the complex’s 3D structure and binding affinity
    using CNNs or GNNs. For example, given a complex structure, Pafnucy [[96](#bib.bib96)]
    extracts a 20 Å cubic box focused on the geometric center of the ligand and discretizes
    it into a $21\times 21\times 21\times 19$ grid with 1 Å resolution. A 3D-CNN is
    then employed to process the grid, treating it as a multi-channel 3D image. SIGN [[21](#bib.bib21)]
    converts the complex structure into a complex 3D graph and designs a structure-aware
    interactive graph neural network to capture 3D spatial information and global
    long-range interactions using polar-inspired graph attention layers in a semi-supervised
    manner. PIGNet [[86](#bib.bib86)] introduces a novel physics-informed graph neural
    network, which can predict accurate binding affinity based on four physics energy
    components – van der Waals (vdW) interaction, hydrogen bond, metal-ligand interaction,
    and hydrophobic interaction (Figure [8](#S3.F8 "Figure 8 ‣ 3.5.2 Representative
    Methods ‣ 3.5 Binding Affinity Prediction ‣ 3 Structure-based Drug Design Tasks
    ‣ Geometric Deep Learning for Structure-Based Drug Design: A Survey")). Fusion [[101](#bib.bib101)]
    simultaneously utilizes the complex 3D grid representation and 3D graph to capture
    different characteristics of interactions. HOLOPROT [[87](#bib.bib87)] considers
    both complex structures and complex surfaces. MBP [[95](#bib.bib95)] introduces
    the first affinity pre-training framework, which involves training the model to
    predict the ranking of samples from the same bioassay. This pre-training uses
    a self-constructed ChEMBL-Dock dataset containing over 300,000 experimental affinity
    labels and about 2.8M docking-generated complex structures. The geometric deep
    learning-based methods effectively capture the 3D structural information and show
    superior prediction accuracy.'
  id: totrans-284
  prefs: []
  type: TYPE_NORMAL
  zh: 绑定亲和力预测方法的探索有着悠久的历史。早期研究集中于利用经验公式[[171](#bib.bib171)]或设计手工特征，并结合传统的机器学习算法进行绑定亲和力预测[[172](#bib.bib172)]。尽管取得了一些进展，这些方法的预测准确性仍有限，并且需要大量的特征工程以获得良好的性能。近期研究强调了几何深度学习方法的应用，将蛋白质-配体复合物结构表示为3D网格或3D图进行处理和预测。这些方法直接使用CNN或GNN建模复合物的3D结构与绑定亲和力之间的关系。例如，给定一个复合物结构，Pafnucy
    [[96](#bib.bib96)] 提取了一个聚焦于配体几何中心的20 Å立方体，并将其离散化为一个$21\times 21\times 21\times
    19$的网格，分辨率为1 Å。然后，使用3D-CNN处理这个网格，将其视为一个多通道的3D图像。SIGN [[21](#bib.bib21)] 将复合物结构转换为复杂的3D图，并设计了一个结构感知的交互式图神经网络，以捕获3D空间信息和全球长距离交互，采用极坐标启发的图注意力层进行半监督学习。PIGNet
    [[86](#bib.bib86)] 引入了一种新型的物理信息图神经网络，能够基于四种物理能量组件——范德华（vdW）相互作用、氢键、金属-配体相互作用和疏水相互作用（图[8](#S3.F8
    "图8 ‣ 3.5.2 代表性方法 ‣ 3.5 绑定亲和力预测 ‣ 3 基于结构的药物设计任务 ‣ 基于结构的药物设计的几何深度学习：综述")）预测准确的绑定亲和力。Fusion
    [[101](#bib.bib101)] 同时利用复杂的3D网格表示和3D图，以捕捉交互的不同特征。HOLOPROT [[87](#bib.bib87)]
    考虑了复合物结构和复合物表面。MBP [[95](#bib.bib95)] 引入了第一个亲和力预训练框架，该框架涉及训练模型以预测来自同一生物测定的样本的排名。这种预训练使用了自构建的ChEMBL-Dock数据集，其中包含超过300,000个实验亲和力标签和大约2.8M个对接生成的复合物结构。基于几何深度学习的方法有效捕捉了3D结构信息，并显示出优越的预测准确性。
- en: '![Refer to caption](img/5482040c0ac22c1d9e428f97801f043d.png)'
  id: totrans-285
  prefs: []
  type: TYPE_IMG
  zh: '![参见标题](img/5482040c0ac22c1d9e428f97801f043d.png)'
- en: 'Figure 8: Overview of PIGNet [[86](#bib.bib86)] for binding affinity prediction.
    A protein-ligand complex is represented in a graph, and adjacency matrices are
    assigned from the binding structure of the complex. Each node feature is updated
    through neural networks to carry the information of covalent bonds and intermolecular
    interactions. Given each atom pair’s distance and final node features, four energy
    components are calculated from the physics-informed parameterized equations. The
    total binding affinity is obtained as a sum of pairwise binding affinities, a
    sum of the four energy components divided by an entropy term.'
  id: totrans-286
  prefs: []
  type: TYPE_NORMAL
  zh: 图8：PIGNet [[86](#bib.bib86)] 的绑定亲和力预测概述。一个蛋白质-配体复合物以图的形式表示，并从复合物的结合结构中分配邻接矩阵。每个节点特征通过神经网络更新，以携带共价键和分子间相互作用的信息。给定每对原子的距离和最终的节点特征后，从物理信息化的参数化方程中计算出四个能量成分。总的绑定亲和力作为成对绑定亲和力之和以及四个能量成分之和除以熵项获得。
- en: 3.5.3 Datasets
  id: totrans-287
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.5.3 数据集
- en: 'PDBBind [[132](#bib.bib132)] is the most commonly used dataset for binding
    affinity prediction. As previously mentioned, the latest version of the dataset
    consists of 19,443 complexes. Specifically, the dataset comprises three overlapping
    subsets: the general set (14,127 3D protein-ligand complexes), the refined set
    (5,316 complexes selected from the general set with higher quality), and the core
    set (290 complexes selected as the highest quality benchmark for testing). It
    is customary to train and validate models on either the general or refined sets
    and evaluate them on the core set. The PDBbind v2016 core set is also known as
    the CASF-2016 dataset.'
  id: totrans-288
  prefs: []
  type: TYPE_NORMAL
  zh: PDBBind [[132](#bib.bib132)] 是用于绑定亲和力预测的最常用数据集。如前所述，该数据集的最新版本包含19,443个复合物。具体而言，该数据集包括三个重叠的子集：通用集（14,127个3D蛋白质-配体复合物）、精炼集（5,316个从通用集中挑选出的高质量复合物）和核心集（290个选作最高质量基准用于测试的复合物）。通常在通用集或精炼集上训练和验证模型，并在核心集上进行评估。PDBbind
    v2016核心集也称为CASF-2016数据集。
- en: CSAR-HiQ [[173](#bib.bib173)] is another commonly used dataset, consisting of
    two subsets containing 176 and 167 complexes, respectively. This dataset is often
    used as the independent dataset in generalizability benchmarks.
  id: totrans-289
  prefs: []
  type: TYPE_NORMAL
  zh: CSAR-HiQ [[173](#bib.bib173)] 是另一个常用的数据集，由两个子集组成，分别包含176和167个复合物。该数据集通常用作通用性基准中的独立数据集。
- en: 3.5.4 Evaluation Metrics
  id: totrans-290
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.5.4 评估指标
- en: Root Mean Square Error (RMSE) and Mean Absolute Error (MAE) are widely used
    to quantify the errors between the predicted values and the ground-truth values
    [[174](#bib.bib174)]. These two metrics are the most direct evaluation metrics
    for prediction errors.
  id: totrans-291
  prefs: []
  type: TYPE_NORMAL
  zh: 均方根误差（RMSE）和平均绝对误差（MAE）被广泛用于量化预测值与真实值之间的误差 [[174](#bib.bib174)]。这两个指标是评估预测误差的最直接指标。
- en: Pearson’s Correlation Coefficient (PCC) [[175](#bib.bib175)] quantifies the
    linear correlation between the predicted values and the ground-truth values. This
    metric serves as a means to evaluate prediction accuracy. Unlike RMSE and MAE,
    PCC is a normalized value ranging from -1 to 1, allowing for a standardized assessment
    of prediction accuracy.
  id: totrans-292
  prefs: []
  type: TYPE_NORMAL
  zh: 皮尔逊相关系数（PCC） [[175](#bib.bib175)] 量化了预测值与真实值之间的线性相关性。该指标用于评估预测的准确性。与RMSE和MAE不同，PCC是一个标准化值，范围从-1到1，允许对预测准确性进行标准化评估。
- en: Spearman’s Correlation Coefficient (SCC) [[176](#bib.bib176)] quantifies the
    ranking correlation between predicted values and experimental values. It is calculated
    as the PCC between the rank values of the two variables. This metric is relevant,
    as affinity prediction is frequently employed to identify molecules with the highest
    rankings in virtual screening.
  id: totrans-293
  prefs: []
  type: TYPE_NORMAL
  zh: 斯皮尔曼相关系数（SCC） [[176](#bib.bib176)] 量化了预测值与实验值之间的排名相关性。它被计算为两个变量排名值之间的PCC。该指标相关，因为亲和力预测常用于识别虚拟筛选中排名最高的分子。
- en: 3.5.5 Benchmark Performance
  id: totrans-294
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.5.5 基准性能
- en: 'The field of affinity prediction methods has a rich history, characterized
    by various methodologies and the utilization of diverse datasets. Consequently,
    conducting a fair and comprehensive comparison of all these methods presents a
    formidable challenge. In Table [V](#S3.T5 "Table V ‣ 3.2.6 Limitations and Future
    Directions ‣ 3.2 Binding Pose Prediction ‣ 3 Structure-based Drug Design Tasks
    ‣ Geometric Deep Learning for Structure-Based Drug Design: A Survey"), we present
    statistics on training and testing settings and the performance of these binding
    affinity prediction models. As shown in the table, although the testing settings
    of these methods are generally the same, their training settings vary significantly.
    Larger training datasets generally lead to better results. For future research
    in binding affinity prediction, it is essential to carefully select suitable settings
    for training and testing.'
  id: totrans-295
  prefs: []
  type: TYPE_NORMAL
  zh: '亲和力预测方法领域拥有丰富的历史，特点是各种方法论和多样化的数据集。因此，对所有这些方法进行公平而全面的比较是一个艰巨的挑战。在表格 [V](#S3.T5
    "Table V ‣ 3.2.6 Limitations and Future Directions ‣ 3.2 Binding Pose Prediction
    ‣ 3 Structure-based Drug Design Tasks ‣ Geometric Deep Learning for Structure-Based
    Drug Design: A Survey") 中，我们展示了关于这些结合亲和力预测模型的训练和测试设置以及性能的统计数据。如表中所示，尽管这些方法的测试设置通常相同，但它们的训练设置差异显著。更大的训练数据集通常会导致更好的结果。对于未来的结合亲和力预测研究，精心选择适当的训练和测试设置至关重要。'
- en: 3.5.6 Limitations and Future Directions
  id: totrans-296
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 3.5.6 限制与未来方向
- en: While recent advancements in geometric deep learning for affinity prediction
    have significantly improved accuracy, several critical limitations remain to be
    addressed. Firstly, the current geometric deep learning methods are predominantly
    trained on co-crystal complex structures where all the data are positive, making
    it challenging for these methods to effectively screen out true active ligands
    from a large pool of decoys. As exemplified by PIGNet, previous research has aimed
    to enhance both the scoring power and the screening power of affinity prediction
    models. Nevertheless, their results suggest that improving screening power often
    results in a trade-off with reduced scoring power, underscoring the difficulty
    of simultaneously achieving high performance in both aspects. It is essential
    to develop robust models capable of excelling in scoring and screening, expanding
    their practical applications.
  id: totrans-297
  prefs: []
  type: TYPE_NORMAL
  zh: 尽管几何深度学习在亲和力预测方面的近期进展显著提高了准确性，但仍然存在几个关键的限制需要解决。首先，目前的几何深度学习方法主要在共晶复合物结构上进行训练，其中所有数据都是正样本，这使得这些方法在从大量伪配体中有效筛选出真正的活性配体时面临挑战。如PIGNet所示，先前的研究旨在增强亲和力预测模型的评分能力和筛选能力。然而，他们的结果表明，提高筛选能力通常会导致评分能力的下降，突显了在两个方面同时取得高性能的困难。开发能够在评分和筛选方面都表现出色的强大模型，扩展其实用应用至关重要。
- en: Furthermore, generalization to protein structures beyond those encountered during
    training is crucial. One potential solution to this challenge involves creating
    additional high-quality training datasets. Currently, there are approximately
    5,000 high-quality protein-ligand complexes with experimentally verified affinities,
    as the PDBBind refined set exemplifies. However, this limited dataset often constrains
    the full training of deep learning models. Additionally, integrating prior physical
    knowledge into deep learning models, such as physics-informed deep learning [[177](#bib.bib177)],
    represents a promising avenue for enhancing generalization capabilities.
  id: totrans-298
  prefs: []
  type: TYPE_NORMAL
  zh: 此外，对超出训练过程中遇到的蛋白质结构的泛化能力至关重要。解决这一挑战的一个潜在方案是创建额外的高质量训练数据集。目前，大约有5,000个具有实验验证亲和力的高质量蛋白质-配体复合物，如PDBBind精炼集所示。然而，这一有限的数据集常常限制了深度学习模型的全面训练。此外，将先验物理知识融入深度学习模型中，例如物理知识驱动的深度学习
    [[177](#bib.bib177)]，代表了提升泛化能力的一个有前途的方向。
- en: 4 Challenges and Opportunities
  id: totrans-299
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 4 挑战与机遇
- en: We discuss challenges and opportunities in SBDD across various dimensions, including
    algorithmic innovation, practical considerations concerning model and output evaluation,
    and integration with experimental systems.
  id: totrans-300
  prefs: []
  type: TYPE_NORMAL
  zh: 我们讨论了结构基础药物设计（SBDD）在各个维度上的挑战和机遇，包括算法创新、关于模型和输出评估的实际考虑，以及与实验系统的整合。
- en: 4.1 Challenges
  id: totrans-301
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 4.1 挑战
- en: •
  id: totrans-302
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: 'Oversimplified Problem Formulation: In structure-based drug design (SBDD),
    problem formulations must align with real-world applications and adhere to established
    physical and chemical principles. For instance, numerous studies on binding pose
    generation and *de novo* ligand generation operate under the assumption that the
    target protein structure remains static. In reality, protein structures exhibit
    flexibility and can experience intrinsic or induced conformational alterations
    [[127](#bib.bib127)]. This discrepancy underscores a gap between SBDD models and
    their practical applications.'
  id: totrans-303
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 简化问题的公式化：在基于结构的药物设计（SBDD）中，问题公式必须与现实应用对齐，并遵循既定的物理和化学原理。例如，许多关于结合位点生成和*de novo*
    配体生成的研究都假设目标蛋白质结构保持静态。实际上，蛋白质结构具有灵活性，可能会经历固有或诱导的构象变化[[127](#bib.bib127)]。这种差异突显了SBDD模型与实际应用之间的差距。
- en: •
  id: totrans-304
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: 'Out-of-distribution Generalization: Most existing studies do not sufficiently
    address the out-of-distribution challenge. Given the constraints posed by dataset
    sizes and, occasionally, inappropriate dataset splits, certain studies might overestimate
    the efficacy of model predictions. For instance, during the COVID-19 pandemic,
    generative models need to produce ligand molecules for novel protein targets,
    such as the main protease of SARS-CoV-2\. Consequently, the need for generalizable
    geometric deep learning models becomes evident, especially for real-world applications.'
  id: totrans-305
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 分布外泛化：大多数现有研究没有充分解决分布外挑战。鉴于数据集规模的限制和有时不适当的数据集分割，一些研究可能高估了模型预测的效果。例如，在COVID-19大流行期间，生成模型需要为新的蛋白质靶点（如SARS-CoV-2的主要蛋白酶）生成配体分子。因此，通用几何深度学习模型的需求变得显而易见，尤其是在现实世界应用中。
- en: •
  id: totrans-306
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: 'The Need for Reliable Evaluation Metrics: Establishing robust criteria to define
    an optimal drug candidate remains challenging. Even though various evaluation
    metrics have been proposed, they often fall short in their applicability. Some
    models exploit shortcuts [[178](#bib.bib178)] in these metrics, resulting in the
    generation of molecules with limited real-world utility.'
  id: totrans-307
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 可靠评估指标的需求：建立定义最佳药物候选者的稳健标准仍然具有挑战性。尽管已提出各种评估指标，但它们往往在适用性上存在不足。一些模型利用这些指标的快捷方式[[178](#bib.bib178)]，导致生成的分子在现实世界中的实用性有限。
- en: •
  id: totrans-308
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: 'Lack of Large-scale Benchmarks: While datasets and evaluation splits are available
    for diverse SBDD tasks, there remains a dearth of large-scale, reliable benchmarks
    with high-quality data. For example, the refined dataset from PDBbind [[132](#bib.bib132)]
    used in training affinity prediction models encompasses merely 5,000 complexes.
    The CrossDocked dataset [[150](#bib.bib150)], used to benchmark *de novo* ligand
    design methods, comprises only 2,922 distinct proteins and 13,780 unique ligand
    molecules. These datasets pale compared to the size of chemical space and protein
    universe, underscoring the need for expansive, high-quality benchmarks.'
  id: totrans-309
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 大规模基准的缺乏：虽然有用于各种SBDD任务的数据集和评估分割，但仍缺乏大规模、可靠的高质量基准。例如，用于训练亲和力预测模型的PDBbind [[132](#bib.bib132)]精炼数据集仅包含5,000个复合物。用于评估*de
    novo* 配体设计方法的CrossDocked数据集[[150](#bib.bib150)]仅包含2,922种不同的蛋白质和13,780种独特的配体分子。这些数据集与化学空间和蛋白质宇宙的规模相比显得微不足道，突显了对广泛、高质量基准的需求。
- en: •
  id: totrans-310
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: 'The Need for Experimental Verification: Computationally evaluating generated
    drug candidates using a set of metrics, while valuable, is not sufficient. Experimental
    verification using *in vivo* or *in vitro* tests is crucial to validate a candidate’s
    effectiveness. These experimental outcomes can be harnessed to refine the models,
    facilitating an integrative loop between computational simulations and empirical
    experiments.'
  id: totrans-311
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 实验验证的需求：使用一组指标对生成的药物候选者进行计算评估虽然有价值，但并不足够。使用*in vivo* 或*in vitro* 测试进行实验验证对于验证候选者的有效性至关重要。这些实验结果可以用于优化模型，促进计算模拟与实证实验之间的整合循环。
- en: •
  id: totrans-312
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: 'Lack of Interpretability: Achieving interpretability is a paramount yet formidable
    task for deep learning models, often perceived as black boxes. Within SBDD, researchers
    often seek insights into rationales behind predicted protein-ligand affinities
    or factors that can explain why a specific protein surface region represents a
    viable binding site. While the interpretability of SBDD models aids in debugging
    and model enhancement, current efforts in this direction, such as those outlined
    in [[72](#bib.bib72), [179](#bib.bib179), [180](#bib.bib180)], remain in their
    infancy and warrant further exploration.'
  id: totrans-313
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 缺乏可解释性：实现可解释性是深度学习模型的一个至关重要但艰巨的任务，这些模型常被视为黑箱。在 SBDD 中，研究人员通常寻求对预测的蛋白质-配体亲和力背后的理由或解释为何特定的蛋白质表面区域是有效的结合位点的见解。虽然
    SBDD 模型的可解释性有助于调试和模型优化，但目前在此方向上的努力，如 [[72](#bib.bib72), [179](#bib.bib179), [180](#bib.bib180)]
    所述，仍处于起步阶段，需要进一步探索。
- en: 4.2 Opportunities
  id: totrans-314
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 4.2 机会
- en: •
  id: totrans-315
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: 'Leverage Multimodal Datasets: High-quality protein structure data remains limited;
    for example, CrossDocked and PDBBind datasets contain fewer than 10 thousand unique
    protein structures. In contrast, UniRef [[181](#bib.bib181)] boasts over 260 million
    protein sequences. As such, the incorporation of protein language models [[182](#bib.bib182),
    [183](#bib.bib183), [184](#bib.bib184)] trained on protein sequence data into
    structure-based drug design holds promise [[185](#bib.bib185)]. Additionally,
    textual data describing protein functions [[186](#bib.bib186)] and proteomics
    [[187](#bib.bib187)] can be integrated into SBDD models.'
  id: totrans-316
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 利用多模态数据集：高质量的蛋白质结构数据仍然有限。例如，CrossDocked 和 PDBBind 数据集包含的独特蛋白质结构少于 1 万个。相比之下，UniRef
    [[181](#bib.bib181)] 拥有超过 2.6 亿个蛋白质序列。因此，将基于蛋白质序列数据训练的蛋白质语言模型 [[182](#bib.bib182),
    [183](#bib.bib183), [184](#bib.bib184)] 融入结构基础药物设计中具有前景 [[185](#bib.bib185)]。此外，描述蛋白质功能的文本数据
    [[186](#bib.bib186)] 和蛋白质组学 [[187](#bib.bib187)] 可以整合到 SBDD 模型中。
- en: •
  id: totrans-317
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: 'Incorporate Biological and Chemical Knowledge: Integrating chemical and biomedical
    knowledge into model development has proven effective across various tasks. For
    instance, geometric symmetry is incorporated in equivariant neural networks, while
    molecular fragments are utilized to generate more realistic and valid molecules.
    Geometric deep learning stands to gain from the further infusion of domain knowledge.'
  id: totrans-318
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 融入生物学和化学知识：将化学和生物医学知识整合到模型开发中在各种任务中已被证明有效。例如，几何对称性被纳入等变神经网络，而分子片段被用来生成更现实和有效的分子。几何深度学习有望通过进一步注入领域知识而受益。
- en: •
  id: totrans-319
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: 'Build Comprehensive Benchmarks: Standardized benchmarks offer dataset splits
    and evaluation tools, facilitating straightforward and robust comparison of SBDD
    models within a consistent framework [[188](#bib.bib188), [189](#bib.bib189)].'
  id: totrans-320
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 建立全面的基准测试：标准化基准提供数据集拆分和评估工具，便于在一致的框架内对 SBDD 模型进行直观且稳健的比较 [[188](#bib.bib188),
    [189](#bib.bib189)]。
- en: •
  id: totrans-321
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: 'Design Criteria Based on Clinical Endpoints: Structure-based drug design is
    considered during the early stages of drug discovery and development. However,
    a palpable chasm exists between early-phase drug discovery and pre-clinical and
    clinical drug development [[190](#bib.bib190), [191](#bib.bib191)]. This can result
    in drug candidates faltering in clinical trials. Consequently, leveraging feedback
    from late drug development and using it to design novel design criteria to guide
    SBDD may increase therapeutic yield.'
  id: totrans-322
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 基于临床终点的设计标准：结构基础药物设计通常在药物发现和开发的早期阶段考虑。然而，早期药物发现与临床前和临床药物开发之间存在明显的鸿沟 [[190](#bib.bib190),
    [191](#bib.bib191)]。这可能导致药物候选者在临床试验中失败。因此，利用来自晚期药物开发的反馈，并将其用于设计新的设计标准以指导 SBDD
    可能会提高治疗效果。
- en: •
  id: totrans-323
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: 'Establish Foundation Models for SBDD: Contemporary research on geometric deep
    learning methods for SBDD predominantly revolves around single-task models. However,
    with the emergence of general-purpose pre-trained models[[192](#bib.bib192), [193](#bib.bib193),
    [194](#bib.bib194), [195](#bib.bib195)], there is potential to develop unified
    foundation models that are compatible with a variety of data formats and tasks
    in SBDD.'
  id: totrans-324
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 为 SBDD 建立基础模型：当代对 SBDD 的几何深度学习方法的研究主要集中在单任务模型上。然而，随着通用预训练模型的出现 [[192](#bib.bib192),
    [193](#bib.bib193), [194](#bib.bib194), [195](#bib.bib195)]，有可能开发出与 SBDD 中各种数据格式和任务兼容的统一基础模型。
- en: •
  id: totrans-325
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: 'Consider a Broad Range of Design Tasks: This survey examines geometric deep
    learning methods tailored for SBDD tasks, emphasizing small molecule drugs. Many
    methods are broadly applicable and can be adapted to other areas, such as antibody
    design [[196](#bib.bib196)], protein pocket design [[197](#bib.bib197)], and crystal
    material generation [[198](#bib.bib198)].'
  id: totrans-326
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 考虑广泛的设计任务：这项综述审查了针对SBDD任务的几何深度学习方法，重点关注小分子药物。许多方法具有广泛的适用性，可以适应其他领域，例如抗体设计[[196](#bib.bib196)]，蛋白质口袋设计[[197](#bib.bib197)]，以及晶体材料生成[[198](#bib.bib198)]。
- en: 5 Conclusion
  id: totrans-327
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 5 结论
- en: We systematically review geometric deep learning methods and applications for
    structure-based drug design. Our methodology involves categorizing existing research
    into five distinct categories based on the tasks they address. We present a comprehensive
    problem formulation for each task, summarizing noteworthy methods and delineating
    datasets and evaluation metrics. Considering both challenges and prospects for
    the field, we anticipate that this survey will facilitate a rapid comprehension
    of existing methodology and lay the groundwork for future structure-based drug
    design using geometric deep learning.
  id: totrans-328
  prefs: []
  type: TYPE_NORMAL
  zh: 我们系统地回顾了几何深度学习方法及其在基于结构的药物设计中的应用。我们的方法包括将现有研究根据所解决的任务分类为五个不同的类别。我们为每个任务提出了全面的问题定义，总结了值得注意的方法，并描述了数据集和评估指标。考虑到该领域的挑战和前景，我们预期这项综述将有助于快速理解现有的方法，并为未来使用几何深度学习的基于结构的药物设计奠定基础。
- en: References
  id: totrans-329
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 参考文献
- en: '[1] A. Schneuing, Y. Du, C. Harris, A. Jamasb, I. Igashov, W. Du, T. Blundell,
    P. Lió, C. Gomes, M. Welling, M. Bronstein, and B. Correia, “Structure-based drug
    design with equivariant diffusion models,” *arXiv preprint arXiv:2210.13695*,
    2022.'
  id: totrans-330
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[1] A. Schneuing, Y. Du, C. Harris, A. Jamasb, I. Igashov, W. Du, T. Blundell,
    P. Lió, C. Gomes, M. Welling, M. Bronstein, 和 B. Correia，“使用等变扩散模型进行基于结构的药物设计，”*arXiv
    预印本 arXiv:2210.13695*，2022年。'
- en: '[2] S. Luo, J. Guan, J. Ma, and J. Peng, “A 3D generative model for structure-based
    drug design,” in *NeurIPS*, 2021.'
  id: totrans-331
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[2] S. Luo, J. Guan, J. Ma, 和 J. Peng，“用于基于结构的药物设计的3D生成模型，”在*NeurIPS*，2021年。'
- en: '[3] C. Isert, K. Atz, and G. Schneider, “Structure-based drug design with geometric
    deep learning,” *Current Opinion in Structural Biology*, vol. 79, p. 102548, 2023.'
  id: totrans-332
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[3] C. Isert, K. Atz, 和 G. Schneider，“利用几何深度学习进行基于结构的药物设计，”*结构生物学的当前观点*，第79卷，第102548页，2023年。'
- en: '[4] J. Drenth, *Principles of protein X-ray crystallography*.   Springer Science
    & Business Media, 2007.'
  id: totrans-333
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[4] J. Drenth，*蛋白质X射线晶体学原理*。Springer 科学与商业媒体，2007年。'
- en: '[5] J. Mitchell, J. B. W. Webber, and J. H. Strange, “Nuclear magnetic resonance
    cryoporometry,” *Physics Reports*, vol. 461, no. 1, pp. 1–36, 2008.'
  id: totrans-334
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[5] J. Mitchell, J. B. W. Webber, 和 J. H. Strange，“核磁共振冷冻孔径测量法，”*物理学报告*，第461卷，第1期，第1–36页，2008年。'
- en: '[6] R. Danev, H. Yanagisawa, and M. Kikkawa, “Cryo-electron microscopy methodology:
    current aspects and future directions,” *Trends in biochemical sciences*, vol. 44,
    no. 10, pp. 837–848, 2019.'
  id: totrans-335
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[6] R. Danev, H. Yanagisawa, 和 M. Kikkawa，“冷冻电子显微镜方法学：当前方面及未来方向，”*生化科学趋势*，第44卷，第10期，第837–848页，2019年。'
- en: '[7] J. Jumper, R. Evans, A. Pritzel, T. Green, M. Figurnov, O. Ronneberger,
    K. Tunyasuvunakool, R. Bates, A. Žídek, A. Potapenko *et al.*, “Highly accurate
    protein structure prediction with alphafold,” *Nature*, vol. 596, no. 7873, pp.
    583–589, 2021.'
  id: totrans-336
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[7] J. Jumper, R. Evans, A. Pritzel, T. Green, M. Figurnov, O. Ronneberger,
    K. Tunyasuvunakool, R. Bates, A. Žídek, A. Potapenko *等*，“使用alphafold进行高精度蛋白质结构预测，”*自然*，第596卷，第7873期，第583–589页，2021年。'
- en: '[8] Z. Lin, H. Akin, R. Rao, B. Hie, Z. Zhu, W. Lu, N. Smetanin, R. Verkuil,
    O. Kabeli, Y. Shmueli *et al.*, “Evolutionary-scale prediction of atomic-level
    protein structure with a language model,” *Science*, vol. 379, no. 6637, pp. 1123–1130,
    2023.'
  id: totrans-337
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[8] Z. Lin, H. Akin, R. Rao, B. Hie, Z. Zhu, W. Lu, N. Smetanin, R. Verkuil,
    O. Kabeli, Y. Shmueli *等*，“利用语言模型对原子级蛋白质结构进行进化尺度预测，”*科学*，第379卷，第6637期，第1123–1130页，2023年。'
- en: '[9] A. Wlodawer and J. Vondrasek, “Inhibitors of hiv-1 protease: a major success
    of structure-assisted drug design,” *Annual review of biophysics and biomolecular
    structure*, vol. 27, no. 1, pp. 249–284, 1998.'
  id: totrans-338
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[9] A. Wlodawer 和 J. Vondrasek，“HIV-1 蛋白酶抑制剂：结构辅助药物设计的重大成功，”*生物物理学和生物分子结构年评*，第27卷，第1期，第249–284页，1998年。'
- en: '[10] A. C. Anderson, “The process of structure-based drug design,” *Chemistry
    & biology*, vol. 10, no. 9, pp. 787–797, 2003.'
  id: totrans-339
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[10] A. C. Anderson，“基于结构的药物设计过程，”*化学与生物学*，第10卷，第9期，第787–797页，2003年。'
- en: '[11] E. E. Rutenber and R. M. Stroud, “Binding of the anticancer drug zd1694
    to e. coli thymidylate synthase: assessing specificity and affinity,” *Structure*,
    vol. 4, no. 11, pp. 1317–1324, 1996.'
  id: totrans-340
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[11] E. E. Rutenber 和 R. M. Stroud，“抗癌药物 zd1694 与大肠杆菌胸苷酸合成酶的结合：评估特异性和亲和力，”
    *Structure*，第4卷，第11期，第1317–1324页，1996年。'
- en: '[12] K. Atz, F. Grisoni, and G. Schneider, “Geometric deep learning on molecular
    representations,” *Nature Machine Intelligence*, pp. 1–10, 2021.'
  id: totrans-341
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[12] K. Atz, F. Grisoni 和 G. Schneider，“分子表征中的几何深度学习，” *Nature Machine Intelligence*，第1–10页，2021年。'
- en: '[13] M. M. Li, K. Huang, and M. Zitnik, “Graph representation learning in biomedicine
    and healthcare,” *Nature Biomedical Engineering*, vol. 6, no. 12, pp. 1353–1369,
    2022.'
  id: totrans-342
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[13] M. M. Li, K. Huang 和 M. Zitnik，“生物医学和医疗中的图表示学习，” *Nature Biomedical Engineering*，第6卷，第12期，第1353–1369页，2022年。'
- en: '[14] N. Thomas, T. Smidt, S. Kearnes, L. Yang, L. Li, K. Kohlhoff, and P. Riley,
    “Tensor field networks: Rotation-and translation-equivariant neural networks for
    3d point clouds,” *arXiv preprint arXiv:1802.08219*, 2018.'
  id: totrans-343
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[14] N. Thomas, T. Smidt, S. Kearnes, L. Yang, L. Li, K. Kohlhoff 和 P. Riley，“张量场网络：用于
    3d 点云的旋转和位移等变神经网络，” *arXiv 预印本 arXiv:1802.08219*，2018年。'
- en: '[15] V. G. Satorras, E. Hoogeboom, and M. Welling, “E(n) equivariant graph
    neural networks,” *ICML*, vol. 139, pp. 9323–9332, 2021.'
  id: totrans-344
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[15] V. G. Satorras, E. Hoogeboom 和 M. Welling，“E(n) 等变图神经网络，” *ICML*，第139卷，第9323–9332页，2021年。'
- en: '[16] W. Huang, J. Han, Y. Rong, T. Xu, F. Sun, and J. Huang, “Equivariant graph
    mechanics networks with constraints,” *arXiv preprint arXiv:2203.06442*, 2022.'
  id: totrans-345
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[16] W. Huang, J. Han, Y. Rong, T. Xu, F. Sun 和 J. Huang，“具有约束的等变图力学网络，” *arXiv
    预印本 arXiv:2203.06442*，2022年。'
- en: '[17] P. Gainza, F. Sverrisson, F. Monti, E. Rodola, D. Boscaini, M. Bronstein,
    and B. Correia, “Deciphering interaction fingerprints from protein molecular surfaces
    using geometric deep learning,” *Nature Methods*, vol. 17, no. 2, pp. 184–192,
    2020.'
  id: totrans-346
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[17] P. Gainza, F. Sverrisson, F. Monti, E. Rodola, D. Boscaini, M. Bronstein
    和 B. Correia，“通过几何深度学习解读蛋白质分子表面的相互作用指纹，” *Nature Methods*，第17卷，第2期，第184–192页，2020年。'
- en: '[18] G. Corso, H. Stärk, B. Jing, R. Barzilay, and T. Jaakkola, “Diffdock:
    Diffusion steps, twists, and turns for molecular docking,” *ICLR*, 2023.'
  id: totrans-347
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[18] G. Corso, H. Stärk, B. Jing, R. Barzilay 和 T. Jaakkola，“Diffdock：用于分子对接的扩散步骤、扭曲和旋转，”
    *ICLR*，2023年。'
- en: '[19] X. Peng, S. Luo, J. Guan, Q. Xie, J. Peng, and J. Ma, “Pocket2mol: Efficient
    molecular sampling based on 3d protein pockets,” in *ICML*.   PMLR, 2022, pp.
    17 644–17 655.'
  id: totrans-348
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[19] X. Peng, S. Luo, J. Guan, Q. Xie, J. Peng 和 J. Ma，“Pocket2mol：基于 3d 蛋白质口袋的高效分子采样，”
    收录于 *ICML*。   PMLR，2022年，第17 644–17 655页。'
- en: '[20] Y. Huang, X. Peng, J. Ma, and M. Zhang, “3dlinker: An e (3) equivariant
    variational autoencoder for molecular linker design,” *ICML*, 2022.'
  id: totrans-349
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[20] Y. Huang, X. Peng, J. Ma 和 M. Zhang，“3dlinker：一种用于分子链接设计的 e (3) 等变变分自编码器，”
    *ICML*，2022年。'
- en: '[21] Y. Li, J. Pei, and L. Lai, “Structure-based de novo drug design using
    3d deep generative models,” *Chemical science*, vol. 12, no. 41, pp. 13 664–13 675,
    2021.'
  id: totrans-350
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[21] Y. Li, J. Pei 和 L. Lai，“基于结构的全新药物设计使用 3d 深度生成模型，” *Chemical Science*，第12卷，第41期，第13 664–13 675页，2021年。'
- en: '[22] J. Dauparas, I. Anishchenko, N. Bennett, H. Bai, R. J. Ragotte, L. F.
    Milles, B. I. Wicky, A. Courbet, R. J. de Haas, N. Bethel *et al.*, “Robust deep
    learning–based protein sequence design using proteinmpnn,” *Science*, vol. 378,
    no. 6615, pp. 49–56, 2022.'
  id: totrans-351
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[22] J. Dauparas, I. Anishchenko, N. Bennett, H. Bai, R. J. Ragotte, L. F.
    Milles, B. I. Wicky, A. Courbet, R. J. de Haas, N. Bethel *等*，“基于深度学习的鲁棒蛋白质序列设计使用
    proteinmpnn，” *Science*，第378卷，第6615期，第49–56页，2022年。'
- en: '[23] J. L. Watson, D. Juergens, N. R. Bennett, B. L. Trippe, J. Yim, H. E.
    Eisenach, W. Ahern, A. J. Borst, R. J. Ragotte, L. F. Milles *et al.*, “De novo
    design of protein structure and function with rfdiffusion,” *Nature*, vol. 620,
    no. 7976, pp. 1089–1100, 2023.'
  id: totrans-352
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[23] J. L. Watson, D. Juergens, N. R. Bennett, B. L. Trippe, J. Yim, H. E.
    Eisenach, W. Ahern, A. J. Borst, R. J. Ragotte, L. F. Milles *等*，“使用 rfdiffusion
    进行蛋白质结构和功能的全新设计，” *Nature*，第620卷，第7976期，第1089–1100页，2023年。'
- en: '[24] S. Li, J. Zhou, T. Xu, L. Huang, F. Wang, H. Xiong, W. Huang, D. Dou,
    and H. Xiong, “Structure-aware interactive graph neural networks for the prediction
    of protein-ligand binding affinity,” ser. KDD ’21.   New York, NY, USA: Association
    for Computing Machinery, 2021.'
  id: totrans-353
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[24] S. Li, J. Zhou, T. Xu, L. Huang, F. Wang, H. Xiong, W. Huang, D. Dou 和
    H. Xiong，“基于结构的交互式图神经网络预测蛋白质-配体结合亲和力，” 会议录 KDD ’21。   纽约, NY, USA：计算机协会，2021年。'
- en: '[25] H. Wang, T. Fu, Y. Du, W. Gao, K. Huang, Z. Liu, P. Chandak, S. Liu, P. Van Katwyk,
    A. Deac *et al.*, “Scientific discovery in the age of artificial intelligence,”
    *Nature*, vol. 620, no. 7972, pp. 47–60, 2023.'
  id: totrans-354
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[25] H. Wang, T. Fu, Y. Du, W. Gao, K. Huang, Z. Liu, P. Chandak, S. Liu, P.
    Van Katwyk, A. Deac *等*，“人工智能时代的科学发现，” *Nature*，第620卷，第7972期，第47–60页，2023年。'
- en: '[26] X. Zhang, L. Wang, J. Helwig, Y. Luo, C. Fu, Y. Xie, M. Liu, Y. Lin, Z. Xu,
    K. Yan *et al.*, “Artificial intelligence for science in quantum, atomistic, and
    continuum systems,” *arXiv preprint arXiv:2307.08423*, 2023.'
  id: totrans-355
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[26] X. Zhang, L. Wang, J. Helwig, Y. Luo, C. Fu, Y. Xie, M. Liu, Y. Lin, Z.
    Xu, K. Yan *等*, “量子、原子和连续系统中的人工智能科学,” *arXiv 预印本 arXiv:2307.08423*, 2023.'
- en: '[27] C. L. Verlinde and W. G. Hol, “Structure-based drug design: progress,
    results and challenges,” *Structure*, vol. 2, no. 7, pp. 577–587, 1994.'
  id: totrans-356
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[27] C. L. Verlinde 和 W. G. Hol, “基于结构的药物设计: 进展、结果和挑战,” *结构*, vol. 2, no. 7,
    pp. 577–587, 1994.'
- en: '[28] P. M. Colman, “Structure-based drug design,” *Current opinion in structural
    biology*, vol. 4, no. 6, pp. 868–874, 1994.'
  id: totrans-357
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[28] P. M. Colman, “基于结构的药物设计,” *结构生物学当前观点*, vol. 4, no. 6, pp. 868–874, 1994.'
- en: '[29] T. L. Blundell, “Structure-based drug design.” *Nature*, vol. 384, no.
    6604 Suppl, pp. 23–26, 1996.'
  id: totrans-358
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[29] T. L. Blundell, “基于结构的药物设计.” *自然*, vol. 384, no. 6604 Suppl, pp. 23–26,
    1996.'
- en: '[30] G. Klebe, “Recent developments in structure-based drug design,” *Journal
    of molecular medicine*, vol. 78, pp. 269–281, 2000.'
  id: totrans-359
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[30] G. Klebe, “基于结构的药物设计的最新进展,” *分子医学杂志*, vol. 78, pp. 269–281, 2000.'
- en: '[31] L. G. Ferreira, R. N. Dos Santos, G. Oliva, and A. D. Andricopulo, “Molecular
    docking and structure-based drug design strategies,” *Molecules*, vol. 20, no. 7,
    pp. 13 384–13 421, 2015.'
  id: totrans-360
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[31] L. G. Ferreira, R. N. Dos Santos, G. Oliva, 和 A. D. Andricopulo, “分子对接和基于结构的药物设计策略,”
    *分子*, vol. 20, no. 7, pp. 13 384–13 421, 2015.'
- en: '[32] R. Özçelik, D. van Tilborg, J. Jiménez-Luna, and F. Grisoni, “Structure-based
    drug discovery with deep learning,” *ChemBioChem*, p. e202200776, 2022.'
  id: totrans-361
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[32] R. Özçelik, D. van Tilborg, J. Jiménez-Luna, 和 F. Grisoni, “基于结构的药物发现与深度学习,”
    *ChemBioChem*, p. e202200776, 2022.'
- en: '[33] D. Benedetto Tiz, L. Bagnoli, O. Rosati, F. Marini, C. Santi, and L. Sancineto,
    “Fda-approved small molecules in 2022: Clinical uses and their synthesis,” *Pharmaceutics*,
    vol. 14, no. 11, p. 2538, 2022.'
  id: totrans-362
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[33] D. Benedetto Tiz, L. Bagnoli, O. Rosati, F. Marini, C. Santi, 和 L. Sancineto,
    “2022 年 FDA 批准的小分子: 临床用途及其合成,” *药物剂型*, vol. 14, no. 11, p. 2538, 2022.'
- en: '[34] M. Batool, B. Ahmad, and S. Choi, “A structure-based drug discovery paradigm,”
    *International journal of molecular sciences*, vol. 20, no. 11, p. 2783, 2019.'
  id: totrans-363
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[34] M. Batool, B. Ahmad, 和 S. Choi, “基于结构的药物发现范式,” *国际分子科学杂志*, vol. 20, no.
    11, p. 2783, 2019.'
- en: '[35] H. Stärk, O.-E. Ganea, L. Pattanaik, R. Barzilay, and T. Jaakkola, “EquiBind:
    Geometric deep learning for drug binding structure prediction,” *arXiv preprint
    arXiv:2202.05146*, 2022.'
  id: totrans-364
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[35] H. Stärk, O.-E. Ganea, L. Pattanaik, R. Barzilay, 和 T. Jaakkola, “EquiBind:
    药物结合结构预测的几何深度学习,” *arXiv 预印本 arXiv:2202.05146*, 2022.'
- en: '[36] B. Jing, S. Eismann, P. Suriana, R. J. L. Townshend, and R. Dror, “Learning
    from protein structure with geometric vector perceptrons,” in *ICLR*, 2021.'
  id: totrans-365
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[36] B. Jing, S. Eismann, P. Suriana, R. J. L. Townshend, 和 R. Dror, “利用几何向量感知器从蛋白质结构中学习,”
    in *ICLR*, 2021.'
- en: '[37] D. Weininger, “SMILES, a chemical language and information system. 1\.
    introduction to methodology and encoding rules,” *Journal of chemical information
    and computer sciences*, vol. 28, no. 1, pp. 31–36, 1988.'
  id: totrans-366
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[37] D. Weininger, “SMILES, 一种化学语言和信息系统。1. 方法学和编码规则介绍,” *化学信息与计算科学杂志*, vol.
    28, no. 1, pp. 31–36, 1988.'
- en: '[38] Y. Du, T. Fu, J. Sun, and S. Liu, “Molgensurvey: A systematic survey in
    machine learning models for molecule design,” *arXiv preprint arXiv:2203.14500*,
    2022.'
  id: totrans-367
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[38] Y. Du, T. Fu, J. Sun, 和 S. Liu, “Molgensurvey: 分子设计中机器学习模型的系统调查,” *arXiv
    预印本 arXiv:2203.14500*, 2022.'
- en: '[39] M. M. Bronstein, J. Bruna, Y. LeCun, A. Szlam, and P. Vandergheynst, “Geometric
    deep learning: going beyond euclidean data,” *IEEE Signal Processing Magazine*,
    vol. 34, no. 4, pp. 18–42, 2017.'
  id: totrans-368
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[39] M. M. Bronstein, J. Bruna, Y. LeCun, A. Szlam, 和 P. Vandergheynst, “几何深度学习:
    超越欧几里得数据,” *IEEE 信号处理杂志*, vol. 34, no. 4, pp. 18–42, 2017.'
- en: '[40] K. Adams, L. Pattanaik, and C. W. Coley, “Learning 3d representations
    of molecular chirality with invariance to bond rotations,” *ICLR*, 2022.'
  id: totrans-369
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[40] K. Adams, L. Pattanaik, 和 C. W. Coley, “学习分子手性的 3d 表示，具有对键旋转的不变性,” *ICLR*,
    2022.'
- en: '[41] J. Jiménez, S. Doerr, G. Martínez-Rosell, A. S. Rose, and G. De Fabritiis,
    “Deepsite: protein-binding site predictor using 3d-convolutional neural networks,”
    *Bioinformatics*, vol. 33, no. 19, pp. 3036–3042, 2017.'
  id: totrans-370
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[41] J. Jiménez, S. Doerr, G. Martínez-Rosell, A. S. Rose, 和 G. De Fabritiis,
    “Deepsite: 使用 3d 卷积神经网络预测蛋白质结合位点,” *生物信息学*, vol. 33, no. 19, pp. 3036–3042, 2017.'
- en: '[42] J. Kandel, H. Tayara, and K. T. Chong, “Puresnet: prediction of protein-ligand
    binding sites using deep residual neural network,” *Journal of cheminformatics*,
    vol. 13, no. 1, pp. 1–14, 2021.'
  id: totrans-371
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[42] J. Kandel, H. Tayara, 和 K. T. Chong, “Puresnet: 使用深度残差神经网络预测蛋白质-配体结合位点,”
    *化学信息学杂志*, vol. 13, no. 1, pp. 1–14, 2021.'
- en: '[43] J. Han, Y. Rong, T. Xu, and W. Huang, “Geometrically equivariant graph
    neural networks: A survey,” *arXiv preprint arXiv:2202.07230*, 2022.'
  id: totrans-372
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[43] J. Han, Y. Rong, T. Xu, 和 W. Huang，“几何等变图神经网络：综述，” *arXiv预印本 arXiv:2202.07230*，2022年。'
- en: '[44] K. T. Schütt, H. E. Sauceda, P.-J. Kindermans, A. Tkatchenko, and K.-R.
    Müller, “Schnet–a deep learning architecture for molecules and materials,” *The
    Journal of Chemical Physics*, vol. 148, no. 24, p. 241722, 2018.'
  id: totrans-373
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[44] K. T. Schütt, H. E. Sauceda, P.-J. Kindermans, A. Tkatchenko, 和 K.-R.
    Müller，“Schnet——一种用于分子和材料的深度学习架构，” *化学物理学杂志*，第148卷，第24期，p. 241722，2018年。'
- en: '[45] B. Jing, S. Eismann, P. Suriana, R. J. Townshend, and R. Dror, “Learning
    from protein structure with geometric vector perceptrons,” *arXiv preprint arXiv:2009.01411*,
    2020.'
  id: totrans-374
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[45] B. Jing, S. Eismann, P. Suriana, R. J. Townshend, 和 R. Dror，“利用几何向量感知器学习蛋白质结构，”
    *arXiv预印本 arXiv:2009.01411*，2020年。'
- en: '[46] J. Klicpera, J. Groß, and S. Günnemann, “Directional message passing for
    molecular graphs,” *arXiv preprint arXiv:2003.03123*, 2020.'
  id: totrans-375
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[46] J. Klicpera, J. Groß, 和 S. Günnemann，“用于分子图的方向消息传递，” *arXiv预印本 arXiv:2003.03123*，2020年。'
- en: '[47] J. Klicpera, S. Giri, J. T. Margraf, and S. Günnemann, “Fast and uncertainty-aware
    directional message passing for non-equilibrium molecules,” *arXiv preprint arXiv:2011.14115*,
    2020.'
  id: totrans-376
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[47] J. Klicpera, S. Giri, J. T. Margraf, 和 S. Günnemann，“快速且具不确定性感知的方向消息传递用于非平衡分子，”
    *arXiv预印本 arXiv:2011.14115*，2020年。'
- en: '[48] Y. Liu, L. Wang, M. Liu, X. Zhang, B. Oztekin, and S. Ji, “Spherical message
    passing for 3d graph networks,” *arXiv preprint arXiv:2102.05013*, 2021.'
  id: totrans-377
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[48] Y. Liu, L. Wang, M. Liu, X. Zhang, B. Oztekin, 和 S. Ji，“用于3d图网络的球形消息传递，”
    *arXiv预印本 arXiv:2102.05013*，2021年。'
- en: '[49] L. Wang, Y. Liu, Y. Lin, H. Liu, and S. Ji, “Comenet: Towards complete
    and efficient message passing for 3d molecular graphs,” *arXiv preprint arXiv:2206.08515*,
    2022.'
  id: totrans-378
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[49] L. Wang, Y. Liu, Y. Lin, H. Liu, 和 S. Ji，“Comenet：面向3d分子图的完整高效消息传递，” *arXiv预印本
    arXiv:2206.08515*，2022年。'
- en: '[50] J. Devlin, M. Chang, K. Lee, and K. Toutanova, “BERT: pre-training of
    deep bidirectional transformers for language understanding,” in *Proceedings of
    the 2019 Conference of the North American Chapter of the Association for Computational
    Linguistics: Human Language Technologies, NAACL-HLT 2019.*   Association for Computational
    Linguistics, 2019, pp. 4171–4186.'
  id: totrans-379
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[50] J. Devlin, M. Chang, K. Lee, 和 K. Toutanova，“BERT：用于语言理解的深度双向变换器预训练，”
    收录于 *2019年北美计算语言学协会：人类语言技术会议论文集，NAACL-HLT 2019*，计算语言学协会，2019年，pp. 4171–4186。'
- en: '[51] C. Ying, T. Cai, S. Luo, S. Zheng, G. Ke, D. He, Y. Shen, and T.-Y. Liu,
    “Do transformers really perform badly for graph representation?” *NeurIPS*, vol. 34,
    2021.'
  id: totrans-380
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[51] C. Ying, T. Cai, S. Luo, S. Zheng, G. Ke, D. He, Y. Shen, 和 T.-Y. Liu，“变换器在图表示中的表现真的很差吗？”
    *NeurIPS*，第34卷，2021年。'
- en: '[52] Y. Li, J. Pei, and L. Lai, “Synthesis-driven design of 3d molecules for
    structure-based drug discovery using geometric transformers,” *arXiv preprint
    arXiv:2301.00167*, 2022.'
  id: totrans-381
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[52] Y. Li, J. Pei, 和 L. Lai，“基于几何变换器的3d分子合成驱动药物发现设计，” *arXiv预印本 arXiv:2301.00167*，2022年。'
- en: '[53] Y. Rong, Y. Bian, T. Xu, W. Xie, Y. Wei, W. Huang, and J. Huang, “Self-supervised
    graph transformer on large-scale molecular data,” in *NeurIPS*, 2020.'
  id: totrans-382
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[53] Y. Rong, Y. Bian, T. Xu, W. Xie, Y. Wei, W. Huang, 和 J. Huang，“大规模分子数据上的自监督图变换器，”
    收录于 *NeurIPS*，2020年。'
- en: '[54] Y.-L. Liao and T. Smidt, “Equiformer: Equivariant graph attention transformer
    for 3d atomistic graphs,” *arXiv preprint arXiv:2206.11990*, 2022.'
  id: totrans-383
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[54] Y.-L. Liao 和 T. Smidt，“Equiformer：用于3d原子图的等变图注意力变换器，” *arXiv预印本 arXiv:2206.11990*，2022年。'
- en: '[55] S. Luo, T. Chen, Y. Xu, S. Zheng, T.-Y. Liu, L. Wang, and D. He, “One
    transformer can understand both 2d & 3d molecular data,” *arXiv preprint arXiv:2210.01765*,
    2022.'
  id: totrans-384
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[55] S. Luo, T. Chen, Y. Xu, S. Zheng, T.-Y. Liu, L. Wang, 和 D. He，“一个变换器可以理解2d和3d分子数据，”
    *arXiv预印本 arXiv:2210.01765*，2022年。'
- en: '[56] K. He, X. Zhang, S. Ren, and J. Sun, “Deep residual learning for image
    recognition,” in *Proceedings of the IEEE conference on computer vision and pattern
    recognition*, 2016, pp. 770–778.'
  id: totrans-385
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[56] K. He, X. Zhang, S. Ren, 和 J. Sun，“深度残差学习用于图像识别，” 收录于 *IEEE计算机视觉与模式识别会议论文集*，2016年，pp.
    770–778。'
- en: '[57] Z. Zhang, Q. Liu, Q. Hu, and C.-K. Lee, “Hierarchical graph transformer
    with adaptive node sampling,” *NeurIPS*, vol. 35, pp. 21 171–21 183, 2022.'
  id: totrans-386
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[57] Z. Zhang, Q. Liu, Q. Hu, 和 C.-K. Lee，“具有自适应节点采样的层次图变换器，” *NeurIPS*，第35卷，pp.
    21 171–21 183，2022年。'
- en: '[58] D. Kreuzer, D. Beaini, W. Hamilton, V. Létourneau, and P. Tossou, “Rethinking
    graph transformers with spectral attention,” *NeurIPS*, vol. 34, pp. 21 618–21 629,
    2021.'
  id: totrans-387
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[58] D. Kreuzer, D. Beaini, W. Hamilton, V. Létourneau, 和 P. Tossou，“重新思考图变换器的谱注意力，”
    *NeurIPS*，第34卷，pp. 21 618–21 629，2021年。'
- en: '[59] B. Scholkopf, K.-K. Sung, C. J. Burges, F. Girosi, P. Niyogi, T. Poggio,
    and V. Vapnik, “Comparing support vector machines with gaussian kernels to radial
    basis function classifiers,” *IEEE transactions on Signal Processing*, vol. 45,
    no. 11, pp. 2758–2765, 1997.'
  id: totrans-388
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[59] B. Scholkopf, K.-K. Sung, C. J. Burges, F. Girosi, P. Niyogi, T. Poggio,
    和 V. Vapnik, “比较支持向量机与高斯核和径向基函数分类器，” *IEEE Transactions on Signal Processing*，第
    45 卷，第 11 期，第 2758–2765 页，1997 年。'
- en: '[60] L. Dinh, D. Krueger, and Y. Bengio, “NICE: Non-linear independent components
    estimation,” *ICLR (Workshop)*, 2015.'
  id: totrans-389
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[60] L. Dinh, D. Krueger, 和 Y. Bengio, “NICE: 非线性独立成分估计，” *ICLR (Workshop)*，2015
    年。'
- en: '[61] L. Dinh, J. Sohl-Dickstein, and S. Bengio, “Density estimation using real
    NVP,” *arXiv preprint arXiv:1605.08803*, 2016.'
  id: totrans-390
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[61] L. Dinh, J. Sohl-Dickstein, 和 S. Bengio, “使用真实 NVP 进行密度估计，” *arXiv 预印本
    arXiv:1605.08803*，2016 年。'
- en: '[62] D. P. Kingma and M. Welling, “Auto-encoding variational bayes,” *ICLR*,
    2013.'
  id: totrans-391
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[62] D. P. Kingma 和 M. Welling, “自动编码变分贝叶斯，” *ICLR*，2013 年。'
- en: '[63] J. Sohl-Dickstein, E. Weiss, N. Maheswaranathan, and S. Ganguli, “Deep
    unsupervised learning using nonequilibrium thermodynamics,” in *ICML*.   PMLR,
    2015, pp. 2256–2265.'
  id: totrans-392
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[63] J. Sohl-Dickstein, E. Weiss, N. Maheswaranathan, 和 S. Ganguli, “利用非平衡热力学进行深度无监督学习，”
    收录于 *ICML*，PMLR，2015 年，第 2256–2265 页。'
- en: '[64] J. Ho, A. Jain, and P. Abbeel, “Denoising diffusion probabilistic models,”
    *arXiv preprint arXiv:2006.11239*, 2020.'
  id: totrans-393
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[64] J. Ho, A. Jain, 和 P. Abbeel, “去噪扩散概率模型，” *arXiv 预印本 arXiv:2006.11239*，2020
    年。'
- en: '[65] L. Weng, “What are diffusion models?” *lilianweng.github.io/lil-log*,
    2021\. [Online]. Available: [https://lilianweng.github.io/lil-log/2021/07/11/diffusion-models.html](https://lilianweng.github.io/lil-log/2021/07/11/diffusion-models.html)'
  id: totrans-394
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[65] L. Weng, “什么是扩散模型？” *lilianweng.github.io/lil-log*，2021\. [在线]. 可用： [https://lilianweng.github.io/lil-log/2021/07/11/diffusion-models.html](https://lilianweng.github.io/lil-log/2021/07/11/diffusion-models.html)'
- en: '[66] H. Chen and B. Li, “3d based generative protac linker design with reinforcement
    learning,” 2023.'
  id: totrans-395
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[66] H. Chen 和 B. Li, “基于 3D 的生成性 ProTac 连接子设计与强化学习，” 2023 年。'
- en: '[67] T. Fu, W. Gao, C. Coley, and J. Sun, “Reinforced genetic algorithm for
    structure-based drug design,” *NeurIPS*, vol. 35, pp. 12 325–12 338, 2022.'
  id: totrans-396
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[67] T. Fu, W. Gao, C. Coley, 和 J. Sun, “基于结构的药物设计的强化遗传算法，” *NeurIPS*，第 35
    卷，第 12 325–12 338 页，2022 年。'
- en: '[68] S. Lu, L. Yao, X. Chen, H. Zheng, and G. Ke, “3d molecular generation
    by virtual dynamics,” 2023.'
  id: totrans-397
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[68] S. Lu, L. Yao, X. Chen, H. Zheng, 和 G. Ke, “通过虚拟动态生成 3D 分子，” 2023 年。'
- en: '[69] Z. Zhang, Y. Min, S. Zheng, and Q. Liu, “Molecule generation for target
    protein binding with structural motifs,” in *The Eleventh ICLR*, 2023.'
  id: totrans-398
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[69] Z. Zhang, Y. Min, S. Zheng, 和 Q. Liu, “用于目标蛋白质结合的分子生成与结构基序，” 收录于 *The
    Eleventh ICLR*，2023 年。'
- en: '[70] F. Sverrisson, J. Feydy, B. E. Correia, and M. M. Bronstein, “Fast end-to-end
    learning on protein surfaces,” in *Proceedings of the IEEE/CVF Conference on Computer
    Vision and Pattern Recognition*, 2021, pp. 15 272–15 281.'
  id: totrans-399
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[70] F. Sverrisson, J. Feydy, B. E. Correia, 和 M. M. Bronstein, “在蛋白质表面进行快速端到端学习，”
    收录于 *Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition*，2021
    年，第 15 272–15 281 页。'
- en: '[71] L. F. Krapp, L. A. Abriata, F. Cortés Rodriguez, and M. Dal Peraro, “Pesto:
    parameter-free geometric deep learning for accurate prediction of protein binding
    interfaces,” *Nature Communications*, vol. 14, no. 1, p. 2175, 2023.'
  id: totrans-400
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[71] L. F. Krapp, L. A. Abriata, F. Cortés Rodriguez, 和 M. Dal Peraro, “Pesto:
    无需参数的几何深度学习以准确预测蛋白质结合界面，” *Nature Communications*，第 14 卷，第 1 期，第 2175 页，2023 年。'
- en: '[72] J. Tubiana, D. Schneidman-Duhovny, and H. J. Wolfson, “Scannet: an interpretable
    geometric deep learning model for structure-based protein binding site prediction,”
    *Nature Methods*, vol. 19, no. 6, pp. 730–739, 2022.'
  id: totrans-401
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[72] J. Tubiana, D. Schneidman-Duhovny, 和 H. J. Wolfson, “Scannet: 一种可解释的几何深度学习模型用于基于结构的蛋白质结合位点预测，”
    *Nature Methods*，第 19 卷，第 6 期，第 730–739 页，2022 年。'
- en: '[73] A. Meller, M. D. Ward, J. H. Borowsky, J. M. Lotthammer, M. Kshirsagar,
    F. Oviedo, J. L. Ferres, and G. Bowman, “Predicting the locations of cryptic pockets
    from single protein structures using the pocketminer graph neural network,” *Nature
    Communications*, 2023.'
  id: totrans-402
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[73] A. Meller, M. D. Ward, J. H. Borowsky, J. M. Lotthammer, M. Kshirsagar,
    F. Oviedo, J. L. Ferres, 和 G. Bowman, “使用 PocketMiner 图神经网络预测隐秘口袋的位置，” *Nature
    Communications*，2023 年。'
- en: '[74] A. Fout, J. Byrd, B. Shariat, and A. Ben-Hur, “Protein interface prediction
    using graph convolutional networks,” *NeurIPS*, vol. 30, 2017.'
  id: totrans-403
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[74] A. Fout, J. Byrd, B. Shariat, 和 A. Ben-Hur, “使用图卷积网络进行蛋白质界面预测，” *NeurIPS*，第
    30 卷，2017 年。'
- en: '[75] Y. Zhang, W. Huang, Z. Wei, Y. Yuan, and Z. Ding, “Equipocket: an e (3)-equivariant
    geometric graph neural network for ligand binding site prediction,” *arXiv preprint
    arXiv:2302.12177*, 2023.'
  id: totrans-404
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[75] Y. Zhang, W. Huang, Z. Wei, Y. Yuan, 和 Z. Ding, “Equipocket: 一种 e (3)-等变几何图神经网络用于配体结合位点预测，”
    *arXiv 预印本 arXiv:2302.12177*，2023 年。'
- en: '[76] N. Abdollahi, S. A. M. Tonekaboni, J. Huang, B. Wang, and S. MacKinnon,
    “Nodecoder: a graph-based machine learning platform to predict active sites of
    modeled protein structures,” *arXiv preprint arXiv:2302.03590*, 2023.'
  id: totrans-405
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[76] N. Abdollahi, S. A. M. Tonekaboni, J. Huang, B. Wang, 和 S. MacKinnon，“Nodecoder:
    一个基于图的机器学习平台，用于预测建模蛋白质结构的活性位点，” *arXiv 预印本 arXiv:2302.03590*，2023年。'
- en: '[77] O. Méndez-Lucio, M. Ahmad, E. A. del Rio-Chanona, and J. K. Wegner, “A
    geometric deep learning approach to predict binding conformations of bioactive
    molecules,” *Nature Machine Intelligence*, vol. 3, no. 12, pp. 1033–1039, 2021.'
  id: totrans-406
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[77] O. Méndez-Lucio, M. Ahmad, E. A. del Rio-Chanona, 和 J. K. Wegner，“一种几何深度学习方法，用于预测生物活性分子的结合构象，”
    *Nature Machine Intelligence*，第3卷，第12期，页码1033–1039，2021年。'
- en: '[78] W. Lu, Q. Wu, J. Zhang, J. Rao, C. Li, and S. Zheng, “Tankbind: Trigonometry-aware
    neural networks for drug-protein binding structure prediction,” *NeurIPS*, pp.
    2022–06, 2022.'
  id: totrans-407
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[78] W. Lu, Q. Wu, J. Zhang, J. Rao, C. Li, 和 S. Zheng，“Tankbind: 针对药物-蛋白质结合结构预测的三角学感知神经网络，”
    *NeurIPS*，页码2022–06，2022年。'
- en: '[79] M. R. Masters, A. H. Mahmoud, Y. Wei, and M. A. Lill, “Deep learning model
    for efficient protein–ligand docking with implicit side-chain flexibility,” *Journal
    of Chemical Information and Modeling*, vol. 63, no. 6, pp. 1695–1707, 2023.'
  id: totrans-408
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[79] M. R. Masters, A. H. Mahmoud, Y. Wei, 和 M. A. Lill，“一种用于高效蛋白质-配体对接的深度学习模型，具有隐式侧链灵活性，”
    *Journal of Chemical Information and Modeling*，第63卷，第6期，页码1695–1707，2023年。'
- en: '[80] P. Nakata, Y. Mori, and S. Tanaka, “End-to-end protein-ligand complex
    structure generation with diffusion-based generative models,” *https://doi.org/10.1101/2022.12.20.521309*,
    2022.'
  id: totrans-409
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[80] P. Nakata, Y. Mori, 和 S. Tanaka，“基于扩散生成模型的端到端蛋白质-配体复合物结构生成，” *https://doi.org/10.1101/2022.12.20.521309*，2022年。'
- en: '[81] Z. Qiao, W. Nie, A. Vahdat, T. F. M. III, and A. Anandkumar, “State-specific
    protein-ligand complex structure prediction with a multi-scale deep generative
    model,” *arXiv preprint arXiv:2209.15171*, 2021.'
  id: totrans-410
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[81] Z. Qiao, W. Nie, A. Vahdat, T. F. M. III, 和 A. Anandkumar，“基于多尺度深度生成模型的状态特异性蛋白质-配体复合物结构预测，”
    *arXiv 预印本 arXiv:2209.15171*，2021年。'
- en: '[82] W. Lu, J.-X. Zhang, W. Huang, Z. Zhang, X. Jia, Z. Wang, L. Shi, C. Li,
    P. Wolynes, and S. Zheng, “Dynamicbind: Predicting ligand-specific protein-ligand
    complex structure with a deep equivariant generative model,” 2023.'
  id: totrans-411
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[82] W. Lu, J.-X. Zhang, W. Huang, Z. Zhang, X. Jia, Z. Wang, L. Shi, C. Li,
    P. Wolynes, 和 S. Zheng，“Dynamicbind: 利用深度等变生成模型预测配体特异性蛋白质-配体复合物结构，” 2023年。'
- en: '[83] Y. Zhang, H. Cai, C. Shi, B. Zhong, and J. Tang, “E3bind: An end-to-end
    equivariant network for protein-ligand docking,” *ICLR*, 2023.'
  id: totrans-412
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[83] Y. Zhang, H. Cai, C. Shi, B. Zhong, 和 J. Tang，“E3bind: 一种用于蛋白质-配体对接的端到端等变网络，”
    *ICLR*，2023年。'
- en: '[84] Z. Wang, L. Zheng, S. Wang, M. Lin, Z. Wang, A. W.-K. Kong, Y. Mu, Y. Wei,
    and W. Li, “A fully differentiable ligand pose optimization framework guided by
    deep learning and a traditional scoring function,” *Briefings in Bioinformatics*,
    vol. 24, no. 1, p. bbac520, 2023.'
  id: totrans-413
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[84] Z. Wang, L. Zheng, S. Wang, M. Lin, Z. Wang, A. W.-K. Kong, Y. Mu, Y.
    Wei, 和 W. Li，“一个完全可微分的配体姿态优化框架，由深度学习和传统评分函数指导，” *Briefings in Bioinformatics*，第24卷，第1期，页码bbac520，2023年。'
- en: '[85] J. P. Mailoa, Z. Ye, J. Qiu, C.-Y. Hsieh, and S. Zhang, “Protein-ligand
    complex generator & drug screening via tiered tensor transform,” *arXiv preprint
    arXiv:2301.00984*, 2023.'
  id: totrans-414
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[85] J. P. Mailoa, Z. Ye, J. Qiu, C.-Y. Hsieh, 和 S. Zhang，“蛋白质-配体复合物生成器与药物筛选，通过分级张量变换，”
    *arXiv 预印本 arXiv:2301.00984*，2023年。'
- en: '[86] S. Moon, W. Zhung, S. Yang, J. Lim, and W. Y. Kim, “Pignet: a physics-informed
    deep learning model toward generalized drug–target interaction predictions,” *Chemical
    Science*, vol. 13, no. 13, pp. 3661–3673, 2022.'
  id: totrans-415
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[86] S. Moon, W. Zhung, S. Yang, J. Lim, 和 W. Y. Kim，“Pignet: 一个基于物理信息的深度学习模型，用于通用药物-靶标相互作用预测，”
    *Chemical Science*，第13卷，第13期，页码3661–3673，2022年。'
- en: '[87] V. R. Somnath, C. Bunne, and A. Krause, “Multi-scale representation learning
    on proteins,” *NeurIPS*, vol. 34, pp. 25 244–25 255, 2021.'
  id: totrans-416
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[87] V. R. Somnath, C. Bunne, 和 A. Krause，“蛋白质的多尺度表示学习，” *NeurIPS*，第34卷，页码25 244–25 255，2021年。'
- en: '[88] M. A. Moesser, D. Klein, F. Boyles, C. M. Deane, A. Baxter, and G. M.
    Morris, “Protein-ligand interaction graphs: Learning from ligand-shaped 3d interaction
    graphs to improve binding affinity prediction,” *bioRxiv*, pp. 2022–03, 2022.'
  id: totrans-417
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[88] M. A. Moesser, D. Klein, F. Boyles, C. M. Deane, A. Baxter, 和 G. M. Morris，“蛋白质-配体相互作用图：从配体形状的3D相互作用图中学习，以提高结合亲和力预测，”
    *bioRxiv*，页码2022–03，2022年。'
- en: '[89] S. Zhang, Y. Liu, and L. Xie, “Efficient and accurate physics-aware multiplex
    graph neural networks for 3d small molecules and macromolecule complexes,” *arXiv
    preprint arXiv:2206.02789*, 2022.'
  id: totrans-418
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[89] S. Zhang, Y. Liu, 和 L. Xie，“高效准确的物理感知多重图神经网络，用于3D小分子和大分子复合物，” *arXiv 预印本
    arXiv:2206.02789*，2022年。'
- en: '[90] D. Jiang, C.-Y. Hsieh, Z. Wu, Y. Kang, J. Wang, E. Wang, B. Liao, C. Shen,
    L. Xu, J. Wu *et al.*, “Interactiongraphnet: A novel and efficient deep graph
    representation learning framework for accurate protein–ligand interaction predictions,”
    *Journal of medicinal chemistry*, vol. 64, no. 24, pp. 18 209–18 232, 2021.'
  id: totrans-419
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[90] D. Jiang、C.-Y. Hsieh、Z. Wu、Y. Kang、J. Wang、E. Wang、B. Liao、C. Shen、L.
    Xu、J. Wu *等*，“Interactiongraphnet：一种新颖且高效的深度图表示学习框架，用于准确的蛋白质-配体相互作用预测，” *医学化学期刊*，第
    64 卷，第 24 期，第 18 209–18 232 页，2021 年。'
- en: '[91] Z. Yang, W. Zhong, Q. Lv, T. Dong, and C. Yu-Chian Chen, “Geometric interaction
    graph neural network for predicting protein–ligand binding affinities from 3d
    structures (gign),” *The Journal of Physical Chemistry Letters*, vol. 14, no. 8,
    pp. 2020–2033, 2023.'
  id: totrans-420
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[91] Z. Yang、W. Zhong、Q. Lv、T. Dong 和 C. Yu-Chian Chen，“几何交互图神经网络用于从 3D 结构预测蛋白质-配体结合亲和力（gign），”
    *物理化学学报快报*，第 14 卷，第 8 期，第 2020–2033 页，2023 年。'
- en: '[92] K. Wang, R. Zhou, J. Tang, and M. Li, “Graphscoredta: optimized graph
    neural network for protein–ligand binding affinity prediction,” *Bioinformatics*,
    vol. 39, 2023\. [Online]. Available: [https://api.semanticscholar.org/CorpusID:258889283](https://api.semanticscholar.org/CorpusID:258889283)'
  id: totrans-421
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[92] K. Wang、R. Zhou、J. Tang 和 M. Li，“Graphscoredta：优化的图神经网络用于蛋白质-配体结合亲和力预测，”
    *生物信息学*，第 39 卷，2023 年。 [在线]. 可用：[https://api.semanticscholar.org/CorpusID:258889283](https://api.semanticscholar.org/CorpusID:258889283)'
- en: '[93] X. jun Zhang, H. Gao, H. Wang, Z. Chen, Z. Zhang, X. Chen, Y. Li, Y. Qi,
    and R. Wang, “Planet: A multi-objective graph neural network model for protein–ligand
    binding affinity prediction,” *bioRxiv*, 2023\. [Online]. Available: [https://api.semanticscholar.org/CorpusID:256617516](https://api.semanticscholar.org/CorpusID:256617516)'
  id: totrans-422
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[93] X. jun Zhang、H. Gao、H. Wang、Z. Chen、Z. Zhang、X. Chen、Y. Li、Y. Qi 和 R.
    Wang，“Planet：一种用于蛋白质-配体结合亲和力预测的多目标图神经网络模型，” *bioRxiv*，2023 年。 [在线]. 可用：[https://api.semanticscholar.org/CorpusID:256617516](https://api.semanticscholar.org/CorpusID:256617516)'
- en: '[94] J. Liu, J. Wan, Y. Ren, X. Shao, X. Xu, and L. Rao, “Dox_bdw: Incorporating
    solvation and desolvation effects of cavity water into nonfitting protein-ligand
    binding affinity prediction,” *Journal of chemical information and modeling*,
    2023\. [Online]. Available: [https://api.semanticscholar.org/CorpusID:260485936](https://api.semanticscholar.org/CorpusID:260485936)'
  id: totrans-423
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[94] J. Liu、J. Wan、Y. Ren、X. Shao、X. Xu 和 L. Rao，“Dox_bdw：将腔水的溶剂化和去溶剂化效应纳入不适合的蛋白质-配体结合亲和力预测，”
    *化学信息与建模期刊*，2023 年。 [在线]. 可用：[https://api.semanticscholar.org/CorpusID:260485936](https://api.semanticscholar.org/CorpusID:260485936)'
- en: '[95] J. Yan, Z. Ye, Z. Yang, C. Lu, S. Zhang, Q. Liu, and J. Qiu, “Multi-task
    bioassay pre-training for protein-ligand binding affinity prediction,” *arXiv
    preprint arXiv:2306.04886*, 2023.'
  id: totrans-424
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[95] J. Yan、Z. Ye、Z. Yang、C. Lu、S. Zhang、Q. Liu 和 J. Qiu，“用于蛋白质-配体结合亲和力预测的多任务生物测定预训练，”
    *arXiv 预印本 arXiv:2306.04886*，2023 年。'
- en: '[96] M. M. Stepniewska-Dziubinska, P. Zielenkiewicz, and P. Siedlecki, “Development
    and evaluation of a deep learning model for protein–ligand binding affinity prediction,”
    *Bioinformatics*, vol. 34, pp. 3666 – 3674, 2018.'
  id: totrans-425
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[96] M. M. Stepniewska-Dziubinska、P. Zielenkiewicz 和 P. Siedlecki，“开发和评估用于蛋白质-配体结合亲和力预测的深度学习模型，”
    *生物信息学*，第 34 卷，第 3666 – 3674 页，2018 年。'
- en: '[97] Y. Li, M. A. Rezaei, C. Li, X. Li, and D. O. Wu, “Deepatom: A framework
    for protein-ligand binding affinity prediction,” *2019 IEEE International Conference
    on Bioinformatics and Biomedicine (BIBM)*, pp. 303–310, 2019.'
  id: totrans-426
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[97] Y. Li、M. A. Rezaei、C. Li、X. Li 和 D. O. Wu，“Deepatom：用于蛋白质-配体结合亲和力预测的框架，”
    *2019 IEEE 国际生物信息学与生物医学会议 (BIBM)*，第 303–310 页，2019 年。'
- en: '[98] H. Hassan-Harrirou, C. Zhang, and T. Lemmin, “Rosenet: Improving binding
    affinity prediction by leveraging molecular mechanics energies with an ensemble
    of 3d convolutional neural networks,” *Journal of chemical information and modeling*,
    2020.'
  id: totrans-427
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[98] H. Hassan-Harrirou、C. Zhang 和 T. Lemmin，“Rosenet：通过利用分子力学能量和 3D 卷积神经网络集成来改进结合亲和力预测，”
    *化学信息与建模期刊*，2020 年。'
- en: '[99] P. Hermosilla, M. Schäfer, M. Lang, G. Fackelmann, P. P. Vázquez, B. Kozlíková,
    M. Krone, T. Ritschel, and T. Ropinski, “Intrinsic-extrinsic convolution and pooling
    for learning on 3d protein structures,” *arXiv preprint arXiv:2007.06252*, 2020.'
  id: totrans-428
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[99] P. Hermosilla、M. Schäfer、M. Lang、G. Fackelmann、P. P. Vázquez、B. Kozlíková、M.
    Krone、T. Ritschel 和 T. Ropinski，“用于学习 3D 蛋白质结构的内在-外在卷积和池化，” *arXiv 预印本 arXiv:2007.06252*，2020
    年。'
- en: '[100] R. Lu, J. Wang, P. Li, Y. Li, S. Tan, Y. Pan, H. Liu, P. Gao, G. Xie,
    and X. Yao, “Improving drug-target affinity prediction via feature fusion and
    knowledge distillation,” *Briefings in Bioinformatics*, vol. 24, no. 3, p. bbad145,
    2023.'
  id: totrans-429
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[100] R. Lu、J. Wang、P. Li、Y. Li、S. Tan、Y. Pan、H. Liu、P. Gao、G. Xie 和 X. Yao，“通过特征融合和知识蒸馏改进药物靶点亲和力预测，”
    *生物信息学简报*，第 24 卷，第 3 期，第 bbad145 页，2023 年。'
- en: '[101] D. Jones, H. Kim, X. Zhang, A. T. Zemla, G. Stevenson, W. F. D. Bennett,
    D. A. Kirshner, S. E. Wong, F. C. Lightstone, and J. E. Allen, “Improved protein-ligand
    binding affinity prediction with structure-based deep fusion inference,” *Journal
    of chemical information and modeling*, 2020.'
  id: totrans-430
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[101] D. Jones, H. Kim, X. Zhang, A. T. Zemla, G. Stevenson, W. F. D. Bennett,
    D. A. Kirshner, S. E. Wong, F. C. Lightstone 和 J. E. Allen， “通过基于结构的深度融合推理改进蛋白质-配体结合亲和力预测，”
    *化学信息与建模杂志*，2020。'
- en: '[102] J. O. Spiegel and J. D. Durrant, “Autogrow4: an open-source genetic algorithm
    for de novo drug design and lead optimization,” *Journal of cheminformatics*,
    vol. 12, no. 1, pp. 1–16, 2020.'
  id: totrans-431
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[102] J. O. Spiegel 和 J. D. Durrant， “Autogrow4: 一种开源遗传算法用于新药设计和领先优化，” *化学信息学杂志*，第12卷，第1期，页码1–16，2020。'
- en: '[103] T. Masuda, M. Ragoza, and D. R. Koes, “Generating 3d molecular structures
    conditional on a receptor binding site with deep generative models,” *arXiv preprint
    arXiv:2010.14442*, 2020.'
  id: totrans-432
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[103] T. Masuda, M. Ragoza 和 D. R. Koes， “生成基于受体结合位点的3D分子结构的深度生成模型，” *arXiv
    预印本 arXiv:2010.14442*，2020。'
- en: '[104] M. Wang, C.-Y. Hsieh, J. Wang, D. Wang, G. Weng, C. Shen, X. Yao, Z. Bing,
    H. Li, D. Cao *et al.*, “Relation: A deep generative model for structure-based
    de novo drug design,” *Journal of Medicinal Chemistry*, vol. 65, no. 13, pp. 9478–9492,
    2022.'
  id: totrans-433
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[104] M. Wang, C.-Y. Hsieh, J. Wang, D. Wang, G. Weng, C. Shen, X. Yao, Z.
    Bing, H. Li, D. Cao *等*， “Relation: 一种基于结构的深度生成模型用于新药设计，” *药物化学杂志*，第65卷，第13期，页码9478–9492，2022。'
- en: '[105] K. Adams and C. W. Coley, “Equivariant shape-conditioned generation of
    3d molecules for ligand-based drug design,” *ICLR*, 2023.'
  id: totrans-434
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[105] K. Adams 和 C. W. Coley， “基于形状条件的等变3D分子生成用于配体基础的药物设计，” *ICLR*，2023。'
- en: '[106] S. Long, Y. Zhou, X. Dai, and H. Zhou, “Zero-shot 3d drug design by sketching
    and generating,” *arXiv preprint arXiv:2209.13865*, 2022.'
  id: totrans-435
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[106] S. Long, Y. Zhou, X. Dai 和 H. Zhou， “通过草图和生成实现零样本3D药物设计，” *arXiv 预印本
    arXiv:2209.13865*，2022。'
- en: '[107] Z. Gao, Y. Hu, C. Tan, and S. Z. Li, “Prefixmol: Target-and chemistry-aware
    molecule design via prefix embedding,” *arXiv preprint arXiv:2302.07120*, 2023.'
  id: totrans-436
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[107] Z. Gao, Y. Hu, C. Tan 和 S. Z. Li， “Prefixmol: 基于前缀嵌入的靶向和化学感知分子设计，” *arXiv
    预印本 arXiv:2302.07120*，2023。'
- en: '[108] Z. Zhang and Q. Liu, “Learning subpocket prototypes for generalizable
    structure-based drug design,” in *ICML*, 2023.'
  id: totrans-437
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[108] Z. Zhang 和 Q. Liu， “学习子口袋原型用于通用的基于结构的药物设计，” 在 *ICML*，2023。'
- en: '[109] L. Wang, Z. Lin, Y. Zhu, R. Bai, W. Feng, H. Wang, J. Zhou, W. Peng,
    B. Huang, and W. Zhou, “Lingo3dmol: Generation of a pocket-based 3d molecule using
    a language model,” *arXiv preprint arXiv:2305.10133*, 2023.'
  id: totrans-438
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[109] L. Wang, Z. Lin, Y. Zhu, R. Bai, W. Feng, H. Wang, J. Zhou, W. Peng,
    B. Huang 和 W. Zhou， “Lingo3dmol: 使用语言模型生成基于口袋的3D分子，” *arXiv 预印本 arXiv:2305.10133*，2023。'
- en: '[110] M. Liu, Y. Luo, K. Uchino, K. Maruhashi, and S. Ji, “Generating 3d molecules
    for target protein binding,” in *ICML*, 2022.'
  id: totrans-439
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[110] M. Liu, Y. Luo, K. Uchino, K. Maruhashi 和 S. Ji， “生成用于靶蛋白结合的3D分子，” 在
    *ICML*，2022。'
- en: '[111] Z. Zhang, Q. Liu, C.-K. Lee, C.-Y. Kim, and E. Chen, “An equivariant
    generative framework for molecular graph-structure co-design,” *bioRxiv*, pp.
    2023–04, 2023.'
  id: totrans-440
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[111] Z. Zhang, Q. Liu, C.-K. Lee, C.-Y. Kim 和 E. Chen， “一种等变生成框架用于分子图结构共同设计，”
    *bioRxiv*，第2023–04期，2023。'
- en: '[112] F. Sun, Z. Zhan, H. Guo, M. Zhang, and J. Tang, “Graphvf: Controllable
    protein-specific 3d molecule generation with variational flow,” *arXiv preprint
    arXiv:2304.12825*, 2023.'
  id: totrans-441
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[112] F. Sun, Z. Zhan, H. Guo, M. Zhang 和 J. Tang， “Graphvf: 具有变分流的可控蛋白特异性3D分子生成，”
    *arXiv 预印本 arXiv:2304.12825*，2023。'
- en: '[113] E. Rozenberg, E. Rivlin, and D. Freedman, “Structure-based drug design
    via semi-equivariant conditional normalizing flows,” in *ICLR 2023 - Machine Learning
    for Drug Discovery workshop*, 2023.'
  id: totrans-442
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[113] E. Rozenberg, E. Rivlin 和 D. Freedman， “通过半等变条件归一化流进行基于结构的药物设计，” 在 *ICLR
    2023 - 药物发现机器学习研讨会*，2023。'
- en: '[114] J. Guan, W. W. Qian, X. Peng, Y. Su, J. Peng, and J. Ma, “3d equivariant
    diffusion for target-aware molecule generation and affinity prediction,” in *ICLR*,
    2023.'
  id: totrans-443
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[114] J. Guan, W. W. Qian, X. Peng, Y. Su, J. Peng 和 J. Ma， “用于靶点感知分子生成和亲和力预测的3D等变扩散，”
    在 *ICLR*，2023。'
- en: '[115] H. Lin, Y. Huang, M. Liu, X. Li, S. Ji, and S. Z. Li, “Diffbp: Generative
    diffusion of 3d molecules for target protein binding,” *arXiv preprint arXiv:2211.11214*,
    2022.'
  id: totrans-444
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[115] H. Lin, Y. Huang, M. Liu, X. Li, S. Ji 和 S. Z. Li， “Diffbp: 生成扩散的3D分子用于靶蛋白结合，”
    *arXiv 预印本 arXiv:2211.11214*，2022。'
- en: '[116] J. Guan, X. Zhou, Y. Yang, Y. Bao, J. Peng, J. Ma, Q. Liu, L. Wang, and
    Q. Gu, “Decompdiff: Diffusion models with decomposed priors for structure-based
    drug design,” *ICML*, 2023.'
  id: totrans-445
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[116] J. Guan, X. Zhou, Y. Yang, Y. Bao, J. Peng, J. Ma, Q. Liu, L. Wang 和
    Q. Gu， “Decompdiff: 具有分解先验的扩散模型用于基于结构的药物设计，” *ICML*，2023。'
- en: '[117] Z. Chen, B. Peng, S. Parthasarathy, and X. Ning, “Shape-conditioned 3d
    molecule generation via equivariant diffusion models,” *arXiv preprint arXiv:2308.11890*,
    2023.'
  id: totrans-446
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[117] Z. Chen, B. Peng, S. Parthasarathy, 和 X. Ning，“形状条件的 3d 分子生成通过等变扩散模型，”
    *arXiv 预印本 arXiv:2308.11890*，2023年。'
- en: '[118] F. Imrie, A. R. Bradley, M. van der Schaar, and C. M. Deane, “Deep generative
    models for 3d linker design,” *Journal of chemical information and modeling*,
    vol. 60, no. 4, pp. 1983–1995, 2020.'
  id: totrans-447
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[118] F. Imrie, A. R. Bradley, M. van der Schaar, 和 C. M. Deane，“用于 3d 连接器设计的深度生成模型，”
    *化学信息与建模杂志*，第 60 卷，第 4 期，页码 1983–1995，2020年。'
- en: '[119] F. Imrie, T. E. Hadfield, A. R. Bradley, and C. M. Deane, “Deep generative
    design with 3d pharmacophoric constraints,” *Chemical science*, vol. 12, no. 43,
    pp. 14 577–14 589, 2021.'
  id: totrans-448
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[119] F. Imrie, T. E. Hadfield, A. R. Bradley, 和 C. M. Deane，“带有 3d 药效基团约束的深度生成设计，”
    *化学科学*，第 12 卷，第 43 期，页码 14 577–14 589，2021年。'
- en: '[120] J. Guo, F. Knuth, C. Margreitter, J. P. Janet, K. Papadopoulos, O. Engkvist,
    and A. Patronov, “Link-invent: generative linker design with reinforcement learning,”
    *Digital Discovery*, vol. 2, no. 2, pp. 392–408, 2023.'
  id: totrans-449
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[120] J. Guo, F. Knuth, C. Margreitter, J. P. Janet, K. Papadopoulos, O. Engkvist,
    和 A. Patronov，“Link-invent：使用强化学习的生成型连接器设计，” *数字发现*，第 2 卷，第 2 期，页码 392–408，2023年。'
- en: '[121] I. Igashov, H. Stärk, C. Vignac, V. G. Satorras, P. Frossard, M. Welling,
    M. Bronstein, and B. Correia, “Equivariant 3d-conditional diffusion models for
    molecular linker design,” *arXiv preprint arXiv:2210.05274*, 2022.'
  id: totrans-450
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[121] I. Igashov, H. Stark, C. Vignac, V. G. Satorras, P. Frossard, M. Welling,
    M. Bronstein, 和 B. Correia，“用于分子连接器设计的等变 3d 条件扩散模型，” *arXiv 预印本 arXiv:2210.05274*，2022年。'
- en: '[122] H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig,
    I. N. Shindyalov, and P. E. Bourne, “The protein data bank,” *Nucleic acids research*,
    vol. 28, no. 1, pp. 235–242, 2000.'
  id: totrans-451
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[122] H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig,
    I. N. Shindyalov, 和 P. E. Bourne，“蛋白质数据银行，” *核酸研究*，第 28 卷，第 1 期，页码 235–242，2000年。'
- en: '[123] P. J. Kundrotas, I. Anishchenko, T. Dauzhenka, I. Kotthoff, D. Mnevets,
    M. M. Copeland, and I. A. Vakser, “Dockground: a comprehensive data resource for
    modeling of protein complexes,” *Protein Science*, vol. 27, no. 1, pp. 172–181,
    2018.'
  id: totrans-452
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[123] P. J. Kundrotas, I. Anishchenko, T. Dauzhenka, I. Kotthoff, D. Mnevets,
    M. M. Copeland, 和 I. A. Vakser，“Dockground：一个用于蛋白质复合体建模的综合数据资源，” *蛋白质科学*，第 27
    卷，第 1 期，页码 172–181，2018年。'
- en: '[124] R. E. Amaro, “Will the real cryptic pocket please stand out?” *Biophysical
    Journal*, vol. 116, no. 5, pp. 753–754, 2019.'
  id: totrans-453
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[124] R. E. Amaro，“真正的隐蔽口袋会显现吗？” *生物物理学杂志*，第 116 卷，第 5 期，页码 753–754，2019年。'
- en: '[125] C. R. Knoverek, G. K. Amarasinghe, and G. R. Bowman, “Advanced methods
    for accessing protein shape-shifting present new therapeutic opportunities,” *Trends
    in biochemical sciences*, vol. 44, no. 4, pp. 351–364, 2019.'
  id: totrans-454
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[125] C. R. Knoverek, G. K. Amarasinghe, 和 G. R. Bowman，“获取蛋白质形状变化的先进方法带来了新的治疗机会，”
    *生化科学趋势*，第 44 卷，第 4 期，页码 351–364，2019年。'
- en: '[126] O. Trott and A. J. Olson, “Autodock vina: Improving the speed and accuracy
    of docking with a new scoring function, efficient optimization, and multithreading,”
    *Journal of Computational Chemistry*, vol. 31, 2010.'
  id: totrans-455
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[126] O. Trott 和 A. J. Olson，“Autodock vina：通过新的评分函数、高效优化和多线程提高对接的速度和准确性，”
    *计算化学杂志*，第 31 卷，2010年。'
- en: '[127] D. E. Koshland Jr, “The key–lock theory and the induced fit theory,”
    *Angewandte Chemie International Edition in English*, vol. 33, no. 23-24, pp.
    2375–2378, 1995.'
  id: totrans-456
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[127] D. E. Koshland Jr，“钥匙-锁理论和诱导契合理论，” *应用化学国际版（英文）*，第 33 卷，第 23-24 期，页码
    2375–2378，1995年。'
- en: '[128] N. Hassan, A. Alhossary, Y. Mu, and C. Kwoh, “Protein-ligand blind docking
    using quickvina-w with inter-process spatio-temporal integration,” *Scientific
    Reports*, vol. 7, 2017.'
  id: totrans-457
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[128] N. Hassan, A. Alhossary, Y. Mu, 和 C. Kwoh，“使用 quickvina-w 进行蛋白质-配体盲对接，结合进程间时空整合，”
    *科学报告*，第 7 卷，2017年。'
- en: '[129] A. T. McNutt, P. G. Francoeur, R. Aggarwal, T. Masuda, R. Meli, M. Ragoza,
    J. Sunseri, and D. R. Koes, “Gnina 1.0: molecular docking with deep learning,”
    *Journal of Cheminformatics*, vol. 13, 2021.'
  id: totrans-458
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[129] A. T. McNutt, P. G. Francoeur, R. Aggarwal, T. Masuda, R. Meli, M. Ragoza,
    J. Sunseri, 和 D. R. Koes，“Gnina 1.0：使用深度学习的分子对接，” *化学信息学杂志*，第 13 卷，2021年。'
- en: '[130] D. R. Koes, M. P. Baumgartner, and C. J. Camacho, “Lessons learned in
    empirical scoring with smina from the csar 2011 benchmarking exercise,” *Journal
    of chemical information and modeling*, vol. 53 8, pp. 1893–904, 2013.'
  id: totrans-459
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[130] D. R. Koes, M. P. Baumgartner, 和 C. J. Camacho，“在 CSAR 2011 基准测试中的经验评分所学到的经验，”
    *化学信息与建模杂志*，第 53 卷第 8 期，页码 1893–1904，2013年。'
- en: '[131] R. A. Friesner, J. L. Banks, R. B. Murphy, T. A. Halgren, J. Klicic,
    D. T. Mainz, M. P. Repasky, E. H. Knoll, M. Shelley, J. K. Perry, D. E. Shaw,
    P. Francis, and P. S. Shenkin, “Glide: a new approach for rapid, accurate docking
    and scoring. 1\. method and assessment of docking accuracy.” *Journal of medicinal
    chemistry*, vol. 47 7, pp. 1739–49, 2004.'
  id: totrans-460
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[131] R. A. Friesner, J. L. Banks, R. B. Murphy, T. A. Halgren, J. Klicic,
    D. T. Mainz, M. P. Repasky, E. H. Knoll, M. Shelley, J. K. Perry, D. E. Shaw,
    P. Francis 和 P. S. Shenkin，"Glide: 一种用于快速、准确对接和打分的新方法。1. 方法和对接准确性评估。" *医学化学杂志*，第
    47 卷，第 7 期，页 1739–1749，2004 年。'
- en: '[132] Z. Liu, M. Su, L. Han, J. Liu, Q. Yang, Y. Li, and R. Wang, “Forging
    the basis for developing protein–ligand interaction scoring functions,” *Accounts
    of chemical research*, vol. 50, no. 2, pp. 302–309, 2017.'
  id: totrans-461
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[132] Z. Liu, M. Su, L. Han, J. Liu, Q. Yang, Y. Li 和 R. Wang，"为开发蛋白质-配体相互作用打分函数奠定基础"，*化学研究汇报*，第
    50 卷，第 2 期，页 302–309，2017 年。'
- en: '[133] H. M. Berman, J. D. Westbrook, Z. Feng, G. L. Gilliland, T. N. Bhat,
    H. Weissig, I. N. Shindyalov, and P. E. Bourne, “The protein data bank,” *Acta
    crystallographica. Section D, Biological crystallography*, vol. 58 Pt 6 No 1,
    pp. 899–907, 2000.'
  id: totrans-462
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[133] H. M. Berman, J. D. Westbrook, Z. Feng, G. L. Gilliland, T. N. Bhat,
    H. Weissig, I. N. Shindyalov 和 P. E. Bourne，"蛋白质数据银行"，*晶体学学报 D 部，生物晶体学*，第 58 卷，第
    6 期，第 1 部分，页 899–907，2000 年。'
- en: '[134] M. Buttenschoen, G. M. Morris, and C. M. Deane, “Posebusters: Ai-based
    docking methods fail to generate physically valid poses or generalise to novel
    sequences,” 2023\. [Online]. Available: [https://api.semanticscholar.org/CorpusID:260865809](https://api.semanticscholar.org/CorpusID:260865809)'
  id: totrans-463
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[134] M. Buttenschoen, G. M. Morris 和 C. M. Deane，"Posebusters: 基于 AI 的对接方法无法生成物理有效的姿势或对新序列进行推广"，2023
    年。 [在线]. 可用: [https://api.semanticscholar.org/CorpusID:260865809](https://api.semanticscholar.org/CorpusID:260865809)'
- en: '[135] J. Ding, S. xiong Tang, Z. Mei, L. Wang, Q. Huang, H. Hu, M. Ling, and
    J. Wu, “Vina-gpu 2.0: Further accelerating autodock vina and its derivatives with
    graphics processing units,” *Journal of chemical information and modeling*, 2023\.
    [Online]. Available: [https://api.semanticscholar.org/CorpusID:257639425](https://api.semanticscholar.org/CorpusID:257639425)'
  id: totrans-464
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[135] J. Ding, S. xiong Tang, Z. Mei, L. Wang, Q. Huang, H. Hu, M. Ling 和 J.
    Wu，"Vina-gpu 2.0: 进一步通过图形处理单元加速 AutoDock Vina 及其衍生物"，*化学信息与建模杂志*，2023 年。 [在线].
    可用: [https://api.semanticscholar.org/CorpusID:257639425](https://api.semanticscholar.org/CorpusID:257639425)'
- en: '[136] Y. Huang, H. Zhang, S. Jiang, D. Yue, X. Lin, J. Zhang, and Y. Q. Gao,
    “Dsdp: A blind docking strategy accelerated by gpus,” *Journal of chemical information
    and modeling*, 2023\. [Online]. Available: [https://api.semanticscholar.org/CorpusID:257622863](https://api.semanticscholar.org/CorpusID:257622863)'
  id: totrans-465
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[136] Y. Huang, H. Zhang, S. Jiang, D. Yue, X. Lin, J. Zhang 和 Y. Q. Gao，"Dsdp:
    一种通过 GPU 加速的盲对接策略"，*化学信息与建模杂志*，2023 年。 [在线]. 可用: [https://api.semanticscholar.org/CorpusID:257622863](https://api.semanticscholar.org/CorpusID:257622863)'
- en: '[137] O. Trott and A. J. Olson, “AutoDock Vina: improving the speed and accuracy
    of docking with a new scoring function, efficient optimization, and multithreading,”
    *Journal of computational chemistry*, vol. 31, no. 2, pp. 455–461, 2010.'
  id: totrans-466
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[137] O. Trott 和 A. J. Olson，"AutoDock Vina: 提高对接速度和准确性的全新打分函数、有效的优化和多线程"，*计算化学杂志*，第
    31 卷，第 2 期，页 455–461，2010 年。'
- en: '[138] L. Zheng, J. Fan, and Y. Mu, “Onionnet: a multiple-layer intermolecular-contact-based
    convolutional neural network for protein–ligand binding affinity prediction,”
    *ACS Omega*, vol. 4, pp. 15 956 – 15 965, 2019.'
  id: totrans-467
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[138] L. Zheng, J. Fan 和 Y. Mu，"Onionnet: 一种基于多层分子接触的卷积神经网络，用于蛋白质-配体结合亲和力预测"，*ACS
    Omega*，第 4 卷，页 15 956 – 15 965，2019 年。'
- en: '[139] Z. Wang, L. Zheng, Y. Liu, Y. Qu, Y. Li, M. Zhao, Y. Mu, and W. Li, “Onionnet-2:
    A convolutional neural network model for predicting protein-ligand binding affinity
    based on residue-atom contacting shells,” *Frontiers in Chemistry*, vol. 9, 2021.'
  id: totrans-468
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[139] Z. Wang, L. Zheng, Y. Liu, Y. Qu, Y. Li, M. Zhao, Y. Mu 和 W. Li，"Onionnet-2:
    基于残基-原子接触壳的卷积神经网络模型，用于预测蛋白质-配体结合亲和力"，*化学前沿*，第 9 卷，2021 年。'
- en: '[140] Y. Zhang, G. Zhou, Z. Wei, and H. Xu, “Predicting protein-ligand binding
    affinity via joint global-local interaction modeling,” *2022 IEEE International
    Conference on Data Mining (ICDM)*, pp. 1323–1328, 2022\. [Online]. Available:
    [https://api.semanticscholar.org/CorpusID:252544919](https://api.semanticscholar.org/CorpusID:252544919)'
  id: totrans-469
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[140] Y. Zhang, G. Zhou, Z. Wei 和 H. Xu，"通过联合全局-局部交互建模预测蛋白质-配体结合亲和力"，*2022
    IEEE 国际数据挖掘大会 (ICDM)*，页 1323–1328，2022 年。 [在线]. 可用: [https://api.semanticscholar.org/CorpusID:252544919](https://api.semanticscholar.org/CorpusID:252544919)'
- en: '[141] M. Ragoza, T. Masuda, and D. R. Koes, “Generating 3d molecules conditional
    on receptor binding sites with deep generative models,” *Chemical science*, vol. 13,
    no. 9, pp. 2701–2713, 2022.'
  id: totrans-470
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[141] M. Ragoza, T. Masuda, 和 D. R. Koes，“Generating 3d molecules conditional
    on receptor binding sites with deep generative models,” *Chemical science*, vol. 13,
    no. 9, pp. 2701–2713, 2022.'
- en: '[142] Y. Luo and S. Ji, “An autoregressive flow model for 3d molecular geometry
    generation from scratch,” in *ICLR*, 2021.'
  id: totrans-471
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[142] Y. Luo 和 S. Ji，“An autoregressive flow model for 3d molecular geometry
    generation from scratch,” in *ICLR*, 2021.'
- en: '[143] K. Schütt, P.-J. Kindermans, H. E. Sauceda Felix, S. Chmiela, A. Tkatchenko,
    and K.-R. Müller, “Schnet: A continuous-filter convolutional neural network for
    modeling quantum interactions,” *NeurIPS*, vol. 30, 2017.'
  id: totrans-472
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[143] K. Schütt, P.-J. Kindermans, H. E. Sauceda Felix, S. Chmiela, A. Tkatchenko,
    和 K.-R. Müller，“Schnet: A continuous-filter convolutional neural network for modeling
    quantum interactions,” *NeurIPS*, vol. 30, 2017.'
- en: '[144] M. Liu, Y. Luo, K. Uchino, K. Maruhashi, and S. Ji, “Generating 3d molecules
    for target protein binding,” *ICML*, 2022.'
  id: totrans-473
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[144] M. Liu, Y. Luo, K. Uchino, K. Maruhashi, 和 S. Ji，“Generating 3d molecules
    for target protein binding,” *ICML*, 2022.'
- en: '[145] D. Rezende and S. Mohamed, “Variational inference with normalizing flows,”
    in *ICML*.   PMLR, 2015, pp. 1530–1538.'
  id: totrans-474
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[145] D. Rezende 和 S. Mohamed，“Variational inference with normalizing flows,”
    in *ICML*，PMLR，2015, pp. 1530–1538.'
- en: '[146] B. Jing, S. Eismann, P. N. Soni, and R. O. Dror, “Equivariant graph neural
    networks for 3d macromolecular structure,” *ICML*, 2021.'
  id: totrans-475
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[146] B. Jing, S. Eismann, P. N. Soni, 和 R. O. Dror，“Equivariant graph neural
    networks for 3d macromolecular structure,” *ICML*, 2021.'
- en: '[147] C. Deng, O. Litany, Y. Duan, A. Poulenard, A. Tagliasacchi, and L. J.
    Guibas, “Vector neurons: A general framework for so (3)-equivariant networks,”
    in *CVPR*, 2021, pp. 12 200–12 209.'
  id: totrans-476
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[147] C. Deng, O. Litany, Y. Duan, A. Poulenard, A. Tagliasacchi, 和 L. J. Guibas，“Vector
    neurons: A general framework for so (3)-equivariant networks,” in *CVPR*, 2021,
    pp. 12 200–12 209.'
- en: '[148] A. P. Bento, A. Hersey, E. Félix, G. Landrum, A. Gaulton, F. Atkinson,
    L. J. Bellis, M. De Veij, and A. R. Leach, “An open source chemical structure
    curation pipeline using rdkit,” *Journal of Cheminformatics*, vol. 12, no. 1,
    pp. 1–16, 2020.'
  id: totrans-477
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[148] A. P. Bento, A. Hersey, E. Félix, G. Landrum, A. Gaulton, F. Atkinson,
    L. J. Bellis, M. De Veij, 和 A. R. Leach，“An open source chemical structure curation
    pipeline using rdkit,” *Journal of Cheminformatics*, vol. 12, no. 1, pp. 1–16,
    2020.'
- en: '[149] T. Kalliokoski, T. S. Olsson, and A. Vulpetti, “Subpocket analysis method
    for fragment-based drug discovery,” *Journal of chemical information and modeling*,
    vol. 53, no. 1, pp. 131–141, 2013.'
  id: totrans-478
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[149] T. Kalliokoski, T. S. Olsson, 和 A. Vulpetti，“Subpocket analysis method
    for fragment-based drug discovery,” *Journal of chemical information and modeling*,
    vol. 53, no. 1, pp. 131–141, 2013.'
- en: '[150] P. G. Francoeur, T. Masuda, J. Sunseri, A. Jia, R. B. Iovanisci, I. Snyder,
    and D. R. Koes, “Three-dimensional convolutional neural networks and a cross-docked
    data set for structure-based drug design,” *Journal of Chemical Information and
    Modeling*, vol. 60, no. 9, pp. 4200–4215, 2020.'
  id: totrans-479
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[150] P. G. Francoeur, T. Masuda, J. Sunseri, A. Jia, R. B. Iovanisci, I. Snyder,
    和 D. R. Koes，“Three-dimensional convolutional neural networks and a cross-docked
    data set for structure-based drug design,” *Journal of Chemical Information and
    Modeling*, vol. 60, no. 9, pp. 4200–4215, 2020.'
- en: '[151] M. Steinegger and J. Söding, “Mmseqs2 enables sensitive protein sequence
    searching for the analysis of massive data sets,” *Nature biotechnology*, vol. 35,
    no. 11, pp. 1026–1028, 2017.'
  id: totrans-480
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[151] M. Steinegger 和 J. Söding，“Mmseqs2 enables sensitive protein sequence
    searching for the analysis of massive data sets,” *Nature biotechnology*, vol. 35,
    no. 11, pp. 1026–1028, 2017.'
- en: '[152] L. Hu, M. L. Benson, R. D. Smith, M. G. Lerner, and H. A. Carlson, “Binding
    moad (mother of all databases),” *Proteins: Structure, Function, and Bioinformatics*,
    vol. 60, no. 3, pp. 333–340, 2005.'
  id: totrans-481
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[152] L. Hu, M. L. Benson, R. D. Smith, M. G. Lerner, 和 H. A. Carlson，“Binding
    moad (mother of all databases),” *Proteins: Structure, Function, and Bioinformatics*,
    vol. 60, no. 3, pp. 333–340, 2005.'
- en: '[153] A. Bairoch, “The enzyme data bank,” *Nucleic acids research*, vol. 22,
    no. 17, pp. 3626–3627, 1994.'
  id: totrans-482
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[153] A. Bairoch，“The enzyme data bank,” *Nucleic acids research*, vol. 22,
    no. 17, pp. 3626–3627, 1994.'
- en: '[154] A. Alhossary, S. D. Handoko, Y. Mu, and C.-K. Kwoh, “Fast, accurate,
    and reliable molecular docking with quickvina 2,” *Bioinformatics*, vol. 31, no. 13,
    pp. 2214–2216, 2015.'
  id: totrans-483
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[154] A. Alhossary, S. D. Handoko, Y. Mu, 和 C.-K. Kwoh，“Fast, accurate, and
    reliable molecular docking with quickvina 2,” *Bioinformatics*, vol. 31, no. 13,
    pp. 2214–2216, 2015.'
- en: '[155] M. Ragoza, J. Hochuli, E. Idrobo, J. Sunseri, and D. R. Koes, “Protein–ligand
    scoring with convolutional neural networks,” *Journal of chemical information
    and modeling*, vol. 57, no. 4, pp. 942–957, 2017.'
  id: totrans-484
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[155] M. Ragoza, J. Hochuli, E. Idrobo, J. Sunseri, 和 D. R. Koes，“Protein–ligand
    scoring with convolutional neural networks,” *Journal of chemical information
    and modeling*, vol. 57, no. 4, pp. 942–957, 2017.'
- en: '[156] A. K. Rappé, C. J. Casewit, K. Colwell, W. A. Goddard III, and W. M.
    Skiff, “Uff, a full periodic table force field for molecular mechanics and molecular
    dynamics simulations,” *Journal of the American chemical society*, vol. 114, no. 25,
    pp. 10 024–10 035, 1992.'
  id: totrans-485
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[156] A. K. Rappé, C. J. Casewit, K. Colwell, W. A. Goddard III, 和 W. M. Skiff，“UFF，一个用于分子力学和分子动力学模拟的完整周期表力场，”
    *Journal of the American Chemical Society*，第 114 卷，第 25 期，页码 10 024–10 035，1992。'
- en: '[157] A. K. Ghose, V. N. Viswanadhan, and J. J. Wendoloski, “A knowledge-based
    approach in designing combinatorial or medicinal chemistry libraries for drug
    discovery. 1\. a qualitative and quantitative characterization of known drug databases,”
    *Journal of combinatorial chemistry*, vol. 1, no. 1, pp. 55–68, 1999.'
  id: totrans-486
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[157] A. K. Ghose, V. N. Viswanadhan, 和 J. J. Wendoloski，“在药物发现中设计组合或药物化学库的知识驱动方法。1.
    对已知药物数据库的定性和定量特征描述，” *Journal of Combinatorial Chemistry*，第 1 卷，第 1 期，页码 55–68，1999。'
- en: '[158] C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, “Experimental
    and computational approaches to estimate solubility and permeability in drug discovery
    and development settings,” *Advanced drug delivery reviews*, vol. 64, pp. 4–17,
    2012.'
  id: totrans-487
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[158] C. A. Lipinski, F. Lombardo, B. W. Dominy, 和 P. J. Feeney，“在药物发现和开发环境中估计溶解度和渗透性的实验和计算方法，”
    *Advanced Drug Delivery Reviews*，第 64 卷，页码 4–17，2012。'
- en: '[159] D. Bajusz, A. Rácz, and K. Héberger, “Why is tanimoto index an appropriate
    choice for fingerprint-based similarity calculations?” *Journal of cheminformatics*,
    vol. 7, no. 1, pp. 1–13, 2015.'
  id: totrans-488
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[159] D. Bajusz, A. Rácz, 和 K. Héberger，“为什么 Tanimoto 指数是基于指纹的相似性计算的合适选择？”
    *Journal of Cheminformatics*，第 7 卷，第 1 期，页码 1–13，2015。'
- en: '[160] C. Harris, K. Didi, A. R. Jamasb, C. K. Joshi, S. V. Mathis, P. Lio,
    and T. Blundell, “Benchmarking generated poses: How rational is structure-based
    drug design with generative models?” *arXiv preprint arXiv:2308.07413*, 2023.'
  id: totrans-489
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[160] C. Harris, K. Didi, A. R. Jamasb, C. K. Joshi, S. V. Mathis, P. Lio,
    和 T. Blundell，“生成的姿势基准测试：基于结构的药物设计使用生成模型有多合理？” *arXiv 预印本 arXiv:2308.07413*，2023。'
- en: '[161] T. Blaschke, J. Arús-Pous, H. Chen, C. Margreitter, C. Tyrchan, O. Engkvist,
    K. Papadopoulos, and A. Patronov, “REINVENT 2.0: an ai tool for de novo drug design,”
    *Journal of Chemical Information and Modeling*, vol. 60, no. 12, pp. 5918–5922,
    2020.'
  id: totrans-490
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[161] T. Blaschke, J. Arús-Pous, H. Chen, C. Margreitter, C. Tyrchan, O. Engkvist,
    K. Papadopoulos, 和 A. Patronov，“REINVENT 2.0：用于新药设计的 AI 工具，” *Journal of Chemical
    Information and Modeling*，第 60 卷，第 12 期，页码 5918–5922，2020。'
- en: '[162] T. Sterling and J. J. Irwin, “ZINC 15–ligand discovery for everyone,”
    *Journal of chemical information and modeling*, vol. 55, no. 11, pp. 2324–2337,
    2015.'
  id: totrans-491
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[162] T. Sterling 和 J. J. Irwin，“ZINC 15–人人都可以发现配体，” *Journal of Chemical Information
    and Modeling*，第 55 卷，第 11 期，页码 2324–2337，2015。'
- en: '[163] R. Gómez-Bombarelli, J. N. Wei, D. Duvenaud, J. M. Hernández-Lobato,
    B. Sánchez-Lengeling, D. Sheberla, J. Aguilera-Iparraguirre, T. D. Hirzel, R. P.
    Adams, and A. Aspuru-Guzik, “Automatic chemical design using a data-driven continuous
    representation of molecules,” *ACS central science*, 2018.'
  id: totrans-492
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[163] R. Gómez-Bombarelli, J. N. Wei, D. Duvenaud, J. M. Hernández-Lobato,
    B. Sánchez-Lengeling, D. Sheberla, J. Aguilera-Iparraguirre, T. D. Hirzel, R. P.
    Adams, 和 A. Aspuru-Guzik，“使用数据驱动的分子连续表示进行自动化化学设计，” *ACS Central Science*，2018。'
- en: '[164] P. Ertl and A. Schuffenhauer, “Estimation of synthetic accessibility
    score of drug-like molecules based on molecular complexity and fragment contributions,”
    *Journal of cheminformatics*, vol. 1, no. 1, p. 8, 2009.'
  id: totrans-493
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[164] P. Ertl 和 A. Schuffenhauer，“基于分子复杂性和片段贡献估计药物样分子的合成可达性评分，” *Journal of
    Cheminformatics*，第 1 卷，第 1 期，页码 8，2009。'
- en: '[165] J. B. Baell and G. A. Holloway, “New substructure filters for removal
    of pan assay interference compounds (pains) from screening libraries and for their
    exclusion in bioassays,” *Journal of medicinal chemistry*, vol. 53, no. 7, pp.
    2719–2740, 2010.'
  id: totrans-494
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[165] J. B. Baell 和 G. A. Holloway，“用于从筛选库中去除全试验干扰化合物（PAINS）和在生物测定中排除这些化合物的新子结构筛选器，”
    *Journal of Medicinal Chemistry*，第 53 卷，第 7 期，页码 2719–2740，2010。'
- en: '[166] M. Su, Q. Yang, Y. Du, G. Feng, Z. Liu, Y. Li, and R. Wang, “Comparative
    assessment of scoring functions: the casf-2016 update,” *Journal of chemical information
    and modeling*, vol. 59, no. 2, pp. 895–913, 2018.'
  id: totrans-495
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[166] M. Su, Q. Yang, Y. Du, G. Feng, Z. Liu, Y. Li, 和 R. Wang，“评分函数的比较评估：CASF-2016
    更新，” *Journal of Chemical Information and Modeling*，第 59 卷，第 2 期，页码 895–913，2018。'
- en: '[167] S. Axelrod and R. Gomez-Bombarelli, “Geom, energy-annotated molecular
    conformations for property prediction and molecular generation,” *Scientific Data*,
    vol. 9, no. 1, p. 185, 2022.'
  id: totrans-496
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[167] S. Axelrod 和 R. Gomez-Bombarelli，“Geom，为属性预测和分子生成注释的分子构象，” *Scientific
    Data*，第 9 卷，第 1 期，页码 185，2022。'
- en: '[168] A. G. Dossetter, E. J. Griffen, and A. G. Leach, “Matched molecular pair
    analysis in drug discovery,” *Drug Discovery Today*, vol. 18, no. 15-16, pp. 724–731,
    2013.'
  id: totrans-497
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[168] A. G. Dossetter, E. J. Griffen 和 A. G. Leach, “药物发现中的匹配分子对分析，” *Drug
    Discovery Today*, 第18卷，第15-16期，第724–731页, 2013年。'
- en: '[169] J. Degen, C. Wegscheid-Gerlach, A. Zaliani, and M. Rarey, “On the art
    of compiling and using’drug-like’chemical fragment spaces,” *ChemMedChem: Chemistry
    Enabling Drug Discovery*, vol. 3, no. 10, pp. 1503–1507, 2008.'
  id: totrans-498
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[169] J. Degen, C. Wegscheid-Gerlach, A. Zaliani 和 M. Rarey, “编制和使用‘药物样’化学片段空间的艺术，”
    *ChemMedChem: Chemistry Enabling Drug Discovery*, 第3卷，第10期，第1503–1507页, 2008年。'
- en: '[170] S. Putta, G. A. Landrum, and J. E. Penzotti, “Conformation mining: an
    algorithm for finding biologically relevant conformations,” *Journal of medicinal
    chemistry*, vol. 48, no. 9, pp. 3313–3318, 2005.'
  id: totrans-499
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[170] S. Putta, G. A. Landrum 和 J. E. Penzotti, “构象挖掘：寻找生物学相关构象的算法，” *Journal
    of Medicinal Chemistry*, 第48卷，第9期，第3313–3318页, 2005年。'
- en: '[171] I. A. Guedes, F. S. S. Pereira, and L. E. Dardenne, “Empirical scoring
    functions for structure-based virtual screening: Applications, critical aspects,
    and challenges,” *Frontiers in Pharmacology*, vol. 9, 2018.'
  id: totrans-500
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[171] I. A. Guedes, F. S. S. Pereira 和 L. E. Dardenne, “基于结构的虚拟筛选的经验评分函数：应用、关键方面和挑战，”
    *Frontiers in Pharmacology*, 第9卷, 2018年。'
- en: '[172] G. Bitencourt-Ferreira, C. Rizzotto, and W. F. de Azevedo Junior, “Machine
    learning-based scoring functions. development and applications with sandres.”
    *Current medicinal chemistry*, 2020.'
  id: totrans-501
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[172] G. Bitencourt-Ferreira, C. Rizzotto 和 W. F. de Azevedo Junior, “基于机器学习的评分函数。开发与Sandres的应用，”
    *Current Medicinal Chemistry*, 2020年。'
- en: '[173] J. B. Dunbar, R. D. Smith, K. L. Damm-Ganamet, A. Ahmed, E. X. Esposito,
    J. Delproposto, K. Chinnaswamy, Y.-N. Kang, G. Kubish, J. E. Gestwicki, J. A.
    Stuckey, and H. A. Carlson, “Csar data set release 2012: Ligands, affinities,
    complexes, and docking decoys,” *Journal of Chemical Information and Modeling*,
    vol. 53, pp. 1842 – 1852, 2013.'
  id: totrans-502
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[173] J. B. Dunbar, R. D. Smith, K. L. Damm-Ganamet, A. Ahmed, E. X. Esposito,
    J. Delproposto, K. Chinnaswamy, Y.-N. Kang, G. Kubish, J. E. Gestwicki, J. A.
    Stuckey 和 H. A. Carlson, “CSAR数据集发布2012：配体、亲和力、复合物和对接假像，” *Journal of Chemical
    Information and Modeling*, 第53卷，第1842–1852页, 2013年。'
- en: '[174] J. D. Durrant, S. Lindert, and J. A. McCammon, “Autogrow 3.0: an improved
    algorithm for chemically tractable, semi-automated protein inhibitor design,”
    *Journal of Molecular Graphics and Modelling*, vol. 44, pp. 104–112, 2013.'
  id: totrans-503
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[174] J. D. Durrant, S. Lindert 和 J. A. McCammon, “AutoGrow 3.0：一种改进的化学可处理、半自动化的蛋白质抑制剂设计算法，”
    *Journal of Molecular Graphics and Modelling*, 第44卷，第104–112页, 2013年。'
- en: '[175] K. Yeager, “Spss tutorials: Pearson correlation,” *University Libraries:
    Geneva, Switzerland*, 2019.'
  id: totrans-504
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[175] K. Yeager, “SPSS教程：皮尔逊相关性，” *University Libraries: Geneva, Switzerland*,
    2019年。'
- en: '[176] P. Sedgwick, “Spearman’s rank correlation coefficient,” *Bmj*, vol. 349,
    2014.'
  id: totrans-505
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[176] P. Sedgwick, “斯皮尔曼等级相关系数，” *BMJ*, 第349卷, 2014年。'
- en: '[177] N. Wahlström, A. G. Wills, J. N. Hendriks, A. Gregg, C. M. Wensrich,
    A. Solin, and S. Särkkä, “Physics-informed machine learning,” 2021\. [Online].
    Available: [https://api.semanticscholar.org/CorpusID:235703044](https://api.semanticscholar.org/CorpusID:235703044)'
  id: totrans-506
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[177] N. Wahlström, A. G. Wills, J. N. Hendriks, A. Gregg, C. M. Wensrich,
    A. Solin 和 S. Särkkä, “物理信息驱动的机器学习，” 2021年。[在线]. 可用链接: [https://api.semanticscholar.org/CorpusID:235703044](https://api.semanticscholar.org/CorpusID:235703044)'
- en: '[178] R. Geirhos, J.-H. Jacobsen, C. Michaelis, R. Zemel, W. Brendel, M. Bethge,
    and F. A. Wichmann, “Shortcut learning in deep neural networks,” *Nature Machine
    Intelligence*, vol. 2, no. 11, pp. 665–673, 2020.'
  id: totrans-507
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[178] R. Geirhos, J.-H. Jacobsen, C. Michaelis, R. Zemel, W. Brendel, M. Bethge
    和 F. A. Wichmann, “深度神经网络中的捷径学习，” *Nature Machine Intelligence*, 第2卷，第11期，第665–673页,
    2020年。'
- en: '[179] H. He, G. Chen, and C. Y.-C. Chen, “Nhgnn-dta: A node-adaptive hybrid
    graph neural network for interpretable drug-target binding affinity prediction,”
    *Bioinformatics*, p. btad355, 2023.'
  id: totrans-508
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[179] H. He, G. Chen 和 C. Y.-C. Chen, “NHGNN-DTA：一种节点自适应混合图神经网络用于可解释的药物-靶标结合亲和力预测，”
    *Bioinformatics*, 第btad355页, 2023年。'
- en: '[180] H. T. Rube, C. Rastogi, S. Feng, J. F. Kribelbauer, A. Li, B. Becerra,
    L. A. Melo, B. V. Do, X. Li, H. H. Adam *et al.*, “Prediction of protein–ligand
    binding affinity from sequencing data with interpretable machine learning,” *Nature
    Biotechnology*, vol. 40, no. 10, pp. 1520–1527, 2022.'
  id: totrans-509
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[180] H. T. Rube, C. Rastogi, S. Feng, J. F. Kribelbauer, A. Li, B. Becerra,
    L. A. Melo, B. V. Do, X. Li, H. H. Adam *等*, “基于序列数据的蛋白质-配体结合亲和力预测及可解释的机器学习，”
    *Nature Biotechnology*, 第40卷，第10期，第1520–1527页, 2022年。'
- en: '[181] B. E. Suzek, H. Huang, P. McGarvey, R. Mazumder, and C. H. Wu, “Uniref:
    comprehensive and non-redundant uniprot reference clusters,” *Bioinformatics*,
    vol. 23, no. 10, pp. 1282–1288, 2007.'
  id: totrans-510
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[181] B. E. Suzek, H. Huang, P. McGarvey, R. Mazumder 和 C. H. Wu, “UniRef：全面且无冗余的UniProt参考簇，”
    *Bioinformatics*, 第23卷，第10期，第1282–1288页, 2007年。'
- en: '[182] N. Ferruz, S. Schmidt, and B. Höcker, “Protgpt2 is a deep unsupervised
    language model for protein design,” *Nature communications*, vol. 13, no. 1, p.
    4348, 2022.'
  id: totrans-511
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[182] N. Ferruz, S. Schmidt, 和 B. Höcker, “Protgpt2 是用于蛋白质设计的深度无监督语言模型,” *Nature
    communications*, 第 13 卷，第 1 期，第 4348 页, 2022.'
- en: '[183] Z. Lin, H. Akin, R. Rao, B. Hie, Z. Zhu, W. Lu, N. Smetanin, A. dos Santos Costa,
    M. Fazel-Zarandi, T. Sercu, S. Candido *et al.*, “Language models of protein sequences
    at the scale of evolution enable accurate structure prediction,” *bioRxiv*, 2022.'
  id: totrans-512
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[183] Z. Lin, H. Akin, R. Rao, B. Hie, Z. Zhu, W. Lu, N. Smetanin, A. dos Santos
    Costa, M. Fazel-Zarandi, T. Sercu, S. Candido *等*, “在进化规模下的蛋白质序列语言模型实现准确的结构预测,”
    *bioRxiv*, 2022.'
- en: '[184] A. Madani, B. McCann, N. Naik, N. S. Keskar, N. Anand, R. R. Eguchi,
    P.-S. Huang, and R. Socher, “Progen: Language modeling for protein generation,”
    *arXiv preprint arXiv:2004.03497*, 2020.'
  id: totrans-513
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[184] A. Madani, B. McCann, N. Naik, N. S. Keskar, N. Anand, R. R. Eguchi,
    P.-S. Huang, 和 R. Socher, “Progen: 蛋白质生成的语言建模,” *arXiv preprint arXiv:2004.03497*,
    2020.'
- en: '[185] Y. Ektefaie, G. Dasoulas, A. Noori, M. Farhat, and M. Zitnik, “Multimodal
    learning with graphs,” *Nature Machine Intelligence*, vol. 5, no. 4, pp. 340–350,
    2023.'
  id: totrans-514
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[185] Y. Ektefaie, G. Dasoulas, A. Noori, M. Farhat, 和 M. Zitnik, “图的多模态学习,”
    *Nature Machine Intelligence*, 第 5 卷，第 4 期，第 340–350 页, 2023.'
- en: '[186] M. Xu, X. Yuan, S. Miret, and J. Tang, “Protst: Multi-modality learning
    of protein sequences and biomedical texts,” *arXiv preprint arXiv:2301.12040*,
    2023.'
  id: totrans-515
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[186] M. Xu, X. Yuan, S. Miret, 和 J. Tang, “Protst: 蛋白质序列和生物医学文本的多模态学习,” *arXiv
    preprint arXiv:2301.12040*, 2023.'
- en: '[187] B. Aslam, M. Basit, M. A. Nisar, M. Khurshid, and M. H. Rasool, “Proteomics:
    technologies and their applications,” *Journal of chromatographic science*, pp.
    1–15, 2016.'
  id: totrans-516
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[187] B. Aslam, M. Basit, M. A. Nisar, M. Khurshid, 和 M. H. Rasool, “蛋白质组学：技术及其应用,”
    *Journal of chromatographic science*, 第 1–15 页, 2016.'
- en: '[188] K. Huang, T. Fu, W. Gao, Y. Zhao, Y. Roohani, J. Leskovec, C. W. Coley,
    C. Xiao, J. Sun, and M. Zitnik, “Therapeutics data commons: machine learning datasets
    and tasks for therapeutics,” *NeurIPS Track Datasets and Benchmarks*, 2021.'
  id: totrans-517
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[188] K. Huang, T. Fu, W. Gao, Y. Zhao, Y. Roohani, J. Leskovec, C. W. Coley,
    C. Xiao, J. Sun, 和 M. Zitnik, “Therapeutics data commons: machine learning datasets
    and tasks for therapeutics,” *NeurIPS Track Datasets and Benchmarks*, 2021.'
- en: '[189] ——, “Artificial intelligence foundation for therapeutic science,” *Nature
    chemical biology*, vol. 18, no. 10, pp. 1033–1036, 2022.'
  id: totrans-518
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[189] ——, “治疗科学的人工智能基础,” *Nature chemical biology*, 第 18 卷，第 10 期，第 1033–1036
    页, 2022.'
- en: '[190] T. Fu, K. Huang, C. Xiao, L. M. Glass, and J. Sun, “HINT: Hierarchical
    interaction network for clinical-trial-outcome predictions,” *Cell Patterns*,
    p. 100445, 2022.'
  id: totrans-519
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[190] T. Fu, K. Huang, C. Xiao, L. M. Glass, 和 J. Sun, “HINT: Hierarchical
    interaction network for clinical-trial-outcome predictions,” *Cell Patterns*,
    第 100445 页, 2022.'
- en: '[191] T. Fu, C. Xiao, C. Qian, L. M. Glass, and J. Sun, “Probabilistic and
    dynamic molecule-disease interaction modeling for drug discovery,” in *SIGKDD*,
    2021, pp. 404–414.'
  id: totrans-520
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[191] T. Fu, C. Xiao, C. Qian, L. M. Glass, 和 J. Sun, “用于药物发现的概率和动态分子-疾病互动建模,”
    在 *SIGKDD*, 2021, 第 404–414 页.'
- en: '[192] C. Zhou, Q. Li, C. Li, J. Yu, Y. Liu, G. Wang, K. Zhang, C. Ji, Q. Yan,
    L. He *et al.*, “A comprehensive survey on pretrained foundation models: A history
    from bert to chatgpt,” *arXiv preprint arXiv:2302.09419*, 2023.'
  id: totrans-521
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[192] C. Zhou, Q. Li, C. Li, J. Yu, Y. Liu, G. Wang, K. Zhang, C. Ji, Q. Yan,
    L. He *等*, “关于预训练基础模型的综合调查：从 BERT 到 ChatGPT 的历史,” *arXiv preprint arXiv:2302.09419*,
    2023.'
- en: '[193] K. Huang, P. Chandak, Q. Wang, S. Havaldar, A. Vaid, J. Leskovec, G. Nadkarni,
    B. S. Glicksberg, N. Gehlenborg, and M. Zitnik, “Zero-shot prediction of therapeutic
    use with geometric deep learning and clinician centered design,” *medRxiv*, pp.
    2023–03, 2023.'
  id: totrans-522
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[193] K. Huang, P. Chandak, Q. Wang, S. Havaldar, A. Vaid, J. Leskovec, G.
    Nadkarni, B. S. Glicksberg, N. Gehlenborg, 和 M. Zitnik, “使用几何深度学习和以临床医生为中心的设计进行的零样本治疗用途预测,”
    *medRxiv*, 第 2023–03 页, 2023.'
- en: '[194] M. B. McDermott, B. Yap, P. Szolovits, and M. Zitnik, “Structure-inducing
    pre-training,” *Nature Machine Intelligence*, pp. 1–10, 2023.'
  id: totrans-523
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[194] M. B. McDermott, B. Yap, P. Szolovits, 和 M. Zitnik, “结构诱导预训练,” *Nature
    Machine Intelligence*, 第 1–10 页, 2023.'
- en: '[195] R. Krishna, J. Wang, W. Ahern, P. Sturmfels, P. Venkatesh, I. Kalvet,
    G. R. Lee, F. S. Morey-Burrows, I. Anishchenko, I. R. Humphreys *et al.*, “Generalized
    biomolecular modeling and design with rosettafold all-atom,” *bioRxiv*, pp. 2023–10,
    2023.'
  id: totrans-524
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[195] R. Krishna, J. Wang, W. Ahern, P. Sturmfels, P. Venkatesh, I. Kalvet,
    G. R. Lee, F. S. Morey-Burrows, I. Anishchenko, I. R. Humphreys *等*, “使用 rosettafold
    全原子模型进行的广义生物分子建模和设计,” *bioRxiv*, 第 2023–10 页, 2023.'
- en: '[196] X. Kong, W. Huang, and Y. Liu, “Conditional antibody design as 3d equivariant
    graph translation,” *arXiv preprint arXiv:2208.06073*, 2022.'
  id: totrans-525
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[196] X. Kong, W. Huang, 和 Y. Liu, “条件抗体设计作为 3D 等变图转换,” *arXiv preprint arXiv:2208.06073*,
    2022.'
- en: '[197] Z. Zhang, Z. Lu, Z. Hao, M. Zitnik, and Q. Liu, “Full-atom protein pocket
    design via iterative refinement,” *NeurIPS*, 2023.'
  id: totrans-526
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[197] Z. Zhang, Z. Lu, Z. Hao, M. Zitnik, and Q. Liu, “通过迭代优化设计全原子蛋白质口袋，” *NeurIPS*,
    2023.'
- en: '[198] T. Xie, X. Fu, O.-E. Ganea, R. Barzilay, and T. Jaakkola, “Crystal diffusion
    variational autoencoder for periodic material generation,” *arXiv preprint arXiv:2110.06197*,
    2021.'
  id: totrans-527
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[198] T. Xie, X. Fu, O.-E. Ganea, R. Barzilay, and T. Jaakkola, “用于周期性材料生成的晶体扩散变分自编码器，”
    *arXiv预印本 arXiv:2110.06197*, 2021.'
- en: '| ![[Uncaptioned image]](img/88ca7b9bd0a1d31fc9b8cb2041c19f58.png) | Zaixi
    Zhang received the BS degree from the Department of Gifted Young, University of
    Science and Technology of China (USTC), China, in 2019\. He is currently working
    toward a Ph.D. degree in the School of Computer Science and Technology at USTC.
    His main research interests include graph representation learning and AI for Drug
    Discovery. He has published papers in referred conferences and journals, such
    as ICML, NeurIPS, CVPR, ICLR, and TKDE. |'
  id: totrans-528
  prefs: []
  type: TYPE_TB
  zh: '| ![[未标注的图片]](img/88ca7b9bd0a1d31fc9b8cb2041c19f58.png) | 张在希于2019年获得中国科学技术大学（USTC）天才少年学院的学士学位。他目前在USTC计算机科学与技术学院攻读博士学位。他的主要研究兴趣包括图表示学习和药物发现中的人工智能。他在ICML、NeurIPS、CVPR、ICLR和TKDE等会议和期刊上发表过论文。
    |'
- en: '| ![[Uncaptioned image]](img/6b52956ff3fdccc8c33bd46ca75208c7.png) | Jiaxian
    Yan is a master’s student at School of Data Science, University of Science and
    Technology of China (USTC). His research interests include data mining and AI-driven
    drug design. |'
  id: totrans-529
  prefs: []
  type: TYPE_TB
  zh: '| ![[未标注的图片]](img/6b52956ff3fdccc8c33bd46ca75208c7.png) | 闫家贤是中国科学技术大学（USTC）数据科学学院的硕士研究生。他的研究兴趣包括数据挖掘和基于人工智能的药物设计。
    |'
- en: '| ![[Uncaptioned image]](img/6e680a91e80231d7e84b6d1b3a89d08d.png) | Qi Liu
    received the Ph.D. degree from University of Science and Technology of China (USTC),
    Hefei, China, in 2013\. He is currently a Professor in the School of Computer
    Science and Technology at USTC. His general area of research is data mining and
    knowledge discovery. He has published prolifically in refereed journals and conference
    proceedings (e.g., TKDE, TOIS, KDD). He is an Associate Editor of IEEE TBD and
    Neurocomputing. He was the recipient of KDD’ 18 Best Student Paper Award and ICDM’ 11
    Best Research Paper Award. He is a member of the Alibaba DAMO Academy Young Fellow.
    He was also the recipient of China Outstanding Youth Science Foundation in 2019.
    |'
  id: totrans-530
  prefs: []
  type: TYPE_TB
  zh: '| ![[未标注的图片]](img/6e680a91e80231d7e84b6d1b3a89d08d.png) | 刘琪于2013年获得中国科学技术大学（USTC）的博士学位。他目前是USTC计算机科学与技术学院的教授。他的研究领域是数据挖掘和知识发现。他在TKDE、TOIS、KDD等期刊和会议论文集中发表了大量论文。他是IEEE
    TBD和Neurocomputing的副编辑。他曾获得KDD’ 18最佳学生论文奖和ICDM’ 11最佳研究论文奖。他是阿里巴巴DAMO学院的青年学者成员。2019年，他还获得了中国杰出青年科学基金。'
- en: '| ![[Uncaptioned image]](img/4e503e86a0823ed2188d10114daae2b7.png) | Enhong
    Chen (SM’07) is a professor and vice dean of the School of Computer Science at
    University of Science and Technology of China (USTC). He received the Ph.D. degree
    from USTC. His general area of research includes data mining and machine learning,
    social network analysis and recommender systems. He has published more than 100
    papers in refereed conferences and journals, including IEEE Trans. KDE, IEEE Trans.
    MC, KDD, ICDM, NIPS, and CIKM. He was on program committees of numerous conferences
    including KDD, ICDM, SDM. He received the Best Application Paper Award on KDD-2008,
    the Best Student Paper Award on KDD-2018 (Research), the Best Research Paper Award
    on ICDM-2011 and Best of SDM-2015\. His research is supported by the National
    Science Foundation for Distinguished Young Scholars of China. He is a senior member
    of the IEEE. |'
  id: totrans-531
  prefs: []
  type: TYPE_TB
  zh: '| ![[未标注的图片]](img/4e503e86a0823ed2188d10114daae2b7.png) | 陈恩宏（SM’07）是中国科学技术大学（USTC）计算机科学学院的教授和副院长。他获得了USTC的博士学位。他的研究领域包括数据挖掘和机器学习、社交网络分析和推荐系统。他在IEEE
    Trans. KDE、IEEE Trans. MC、KDD、ICDM、NIPS和CIKM等会议和期刊上发表了100多篇论文。他曾担任KDD、ICDM、SDM等多个会议的程序委员会成员。他曾获得KDD-2008最佳应用论文奖、KDD-2018最佳学生论文奖（研究）、ICDM-2011最佳研究论文奖以及SDM-2015最佳论文奖。他的研究得到了中国国家自然科学基金杰出青年基金的资助。他是IEEE的高级会员。
    |'
- en: '| ![[Uncaptioned image]](img/2c392b546845f8a08917d74f3f3ae1bb.png) | Marinka
    Zitnik is an Assistant Professor of Biomedical Informatics at Harvard University
    with additional appointments at the Kempner Institute for the Study of Natural
    and Artificial Intelligence, Broad Institute of MIT and Harvard, and Harvard Data
    Science. Zitnik investigates the foundations of AI to enhance scientific discovery
    and realize individualized diagnosis and treatment. The mission of her lab is
    to lay the foundations for AI to enhance the understanding of medicine, eventually
    enabling AI to learn and innovate on its own. Her research won several best paper
    and research awards, including the Kavli Fellowship of the National Academy of
    Sciences, awards from the International Society for Computational Biology, International
    Conference in Machine Learning, Bayer Early Excellence in Science, Amazon Faculty
    Research, Google Faculty Research, and Roche Alliance with Distinguished Scientists.
    Zitnik founded Therapeutics Data Commons, a global open-science initiative to
    access and evaluate AI across stages of development and therapeutic modalities,
    and she is also the faculty lead of the International AI4Science initiative. |'
  id: totrans-532
  prefs: []
  type: TYPE_TB
  zh: '| ![[未标注的图片]](img/2c392b546845f8a08917d74f3f3ae1bb.png) | Marinka Zitnik 是哈佛大学生物医学信息学的助理教授，同时还担任
    Kempner 人工智能研究所、麻省理工学院与哈佛大学 Broad Institute 以及哈佛数据科学中心的职务。Zitnik 研究 AI 的基础，以促进科学发现并实现个性化诊断和治疗。她实验室的使命是为
    AI 提升医学理解奠定基础，最终使 AI 能够自主学习和创新。她的研究获得了多个最佳论文和研究奖项，包括国家科学院的 Kavli 奖学金、国际计算生物学学会奖、国际机器学习会议奖、拜耳早期科学卓越奖、亚马逊教师研究奖、谷歌教师研究奖以及罗氏与杰出科学家联盟奖。Zitnik
    创立了 Therapeutics Data Commons，这是一个全球开放科学倡议，旨在访问和评估各阶段开发和治疗方式中的 AI，并且她还是国际 AI4Science
    计划的教师负责人。'
